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Abstract 
Liver surgery is an advancing specialty with improved outcomes in recent years(1). Liver 
resection is used with curative intent for both primary and metastatic cancer(2)(3)(4). 
Despite the rapid improvements and increasing range of surgical options, there remains 
a significant risk of developing Post-Hepatectomy Liver Failure (PHLF) – caused by 
inadequate remnant liver function after surgery(5)(6). This is a condition with high 
mortality and morbidity(7) and currently there are no specific treatments for it once it has 
developed(8). Its pathogenesis is complex and multifactorial(9)(10), and some risk 
factors, particularly ageing are uncertain as to their contributing significance. This thesis 
aimed to investigate risk factors for PHLF development and a imaging based 
measurement of liver function after major liver resection. This study identified patients 
over-75 years have a significantly increased risk of PHLF.  
Development of a method to predict post-operative function is needed to aid patient 
selection and reduce complications for those who undergo resection. Currently, 
volumetry is performed but this has proven inadequate, with some patients still 
developing PHLF despite adequate remnant volume(11). Other options such as 
Indocyanine Green(12) and Technetium-99m labelled Mebrofenin(13) are not readily 
available.  One potential solution is Dynamic Gadoxetate Enhanced (DGE) MRI of the 
Liver, which has been developed to investigate liver function, with promising results for 
demonstrating liver heterogenicity in patients with parenchymal liver diseases(14). 
Oncological staging of the liver involves MRI to plan surgical resection, and DGE-MRI 
can be integrated into the diagnostic protocol easily with no additional burden to the 
patient. This thesis aimed to demonstrate if DGE-MRI functional estimates can predict 
post-operative liver function after resection of colorectal liver metastases. This study 
demonstrated that there was good correlation of DGE-MRI-function tests with post-
operative hyperbilirubinaemia, a measure of hepatic dysfunction. This could be utilised 
in surgical planning to improve patient selection and outcomes. 
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Chapter 1 – Introduction, Aims and Hypotheses 
Liver surgery is a rapidly advancing specialty with significant improvements in patient 
outcomes in recent years(1). Liver resection is used with curative intent for both primary 
and metastatic cancer(2). It is possible for up to 75% of the liver to be to be resected with 
improving outcome for the patient, both in terms of cure, and recovery from surgery(3)(4). 
Despite such improvements, and an increasing range of surgical options, there remains 
a significant risk of developing a major complication known as post-hepatectomy liver 
failure (PHLF). This is caused by inadequate remnant liver function after surgery(5)(6). 
This is a condition with high mortality and morbidity(7) and currently there are no specific 
treatments for it once it has developed(8). Its pathogenesis is complex and 
multifactorial(9) and it is essential to understand what increases risk. Current methods 
of predicting PHLF are inadequate, as such, new approaches are required(10). 
Prevention is critical to PHLF management(8). This thesis aims to investigate risk 
factors for PHLF development after liver surgery and to assess investigations aiming 
to optimise the patient’s pre-operative condition to reduce risk of developing 
complications.  
Development of a method to predict post-operative function is needed to inform patient 
selection and prevent PHLF for those who undergo resection. Volumetry is currently 
performed but this has proven inadequate, with some patients still developing PHLF 
despite adequate remnant volume(11). One potential solution is Dynamic Gadoxetate 
Enhanced (DGE-MRI) of the Liver, which has been developed to investigate liver 
function, with promising results for demonstrating liver heterogenicity in patients with 
parenchymal liver diseases(14). Oncological staging involves MRI to plan surgical 
resection, and DGE-MRI can be integrated into the diagnostic protocol easily with no 
additional burden to the patient. This thesis tested if DGE-MRI estimates of function can 
predict post-operative liver function after resection of colorectal liver metastasis, the 
commonest indication for resection. 
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1.1 Aims and Hypothesis 
Chapter 2 provides a background to current surgical practice, describing the history and 
development of liver surgery. This retrospective overview current evidence and needs 
for future developments. It describes the current indications for liver resection, along with 
current pre-operative assessments of fitness to ensure that patients are suitable for 
surgery, along with the pitfalls of current practice. The role of MRI in current practice is 
discussed, and the development of DGE-MRI is described, with a summary of published 
reports on the measurement of liver function with DGE-MRI that led to the hypothesis 
that it could be used to assess surgical patients. 
Chapter 3 describes a retrospective cohort study designed to investigate known risk 
factors for PHLF in a population of patients having major liver resection, with age as a 
primary independent variable, and its impact on PHLF development. The impact of 
ageing on liver function and surgical outcomes was uncertain prior to this study, and this 
chapter aimed to investigate outcomes with the following hypothesis that there is an 
association between increasing age and the incidence of development of PHLF in 
patients undergoing major resection. The population, intervention, comparison & 
outcome (PICO) study design is described in table 1. 
Table 1: PICO for study of PHLF risk factors 
Population Patients undergoing curative right hepatectomy  
Intervention Older patients 
Comparison Younger patients 
Outcome Incidence of PHLF development 
 
Secondary outcome hypotheses were to investigate the extent of association between  
other known risk factors for PHLF development(6): preoperative eGFR levels <90 (CKD 
grade 2(15), Pre-operative neo-adjuvant chemotherapy, diabetes status, ASA grade, 
background liver disease, steatosis if present, operation time (>4h) and intraoperative 
transfusion. 
16 
 
 
 
In addition, a cost-effectiveness analysis between development of PHLF and normal 
post-operative clinical course was conducted and a discussion of a potential cost-benefit 
in reducing it PHLF incidence with hypertrophic procedures such as Portal Vein 
Embolisation (PVE).  
This study identified that age is an independent risk factor for PHLF development after 
right hepatectomy when all other known risk factors are accounted for. Older patients 
are at risk of PHLF should therefore have their Future Liver Remnant (FLR) pre-
operatively assessed and optimised to prevent a poorer outcome in this at-risk 
population. 
Chapter 4 describes a study on the technical aspects of DGE-MRI acquisition. DGE-
MRI is a relatively new technological innovation and the best methods of acquisition and 
how to analyse the data is not yet defined. After an initial analysis of 3 different acquisition 
models to assess which was the most suitable in a clinically pragmatic manner, a 3D 
spoiled gradient echo sequence with a temporal resolution of 2.4 seconds was selected 
as it provided better quality images than other acquisitions and could be analysed easily. 
Following this, a comparison of different methods of post-processing the results of key 
perfusion and function parameters was performed to ascertain which model gives the 
most precise and accurate output values, principally looking at single and dual input 
models with and without an arterial delay. This demonstrated that the dual input model 
with arterial delay provided results that were in keeping with previously reported 
literature values and was selected for future analysis of liver function. 
Chapter 5 describes a prospective hypothesis-generating study examining if DGE-MRI 
measurements of function have any role in predicting post-operative function following 
resection surgery. Patients with Colorectal Liver Metastasis (CRLM) were examined and 
bilirubin was chosen as the primary dependant variable. Secondary outcomes were 
correlations of clinical and biochemical risk factors of PHLF and FLR-volume, against 
post-operative bilirubin and DGE-MRI estimates of function. This was to compare if DGE-
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MRI function estimates had any added benefit over other currently used liver function 
assessment. 
Table 2: PICO for DGE-MRI in patients undergoing liver resection study 
Population Patients having major liver resection for CRLM 
Intervention DGE-MRI measured liver function of the FLR 
Comparison Post-operative bilirubin levels 
Outcome Strength of correlation 
 
This study identified that some DGE-MRI estimates of liver function, namely the FLR-
cellular uptake of gadoxetate and FLR-clearance of gadoxetate correlate significantly 
with post-operative bilirubin levels, and thus may have potential to predict post-operative 
function. Important negatives from this study were the lack of predictive capacity of 
volumetry and pre-operative clinical markers. This suggests that DGE-MRI estimates 
have a role beyond current pre-operative assessment standards in predicting post-
operative liver function. They have potential to be utilised in surgical planning for how 
much liver could be resected safely. The secondary outcomes demonstrated patients 
over 75 and those who required major resection had reduced gadoxetate excretion, 
suggesting impaired cellular metabolism and function, which has implications in surgical 
planning for older patients. 
Chapter 6 discusses implications of the results of these studies to current practice and 
future perspectives for ongoing studies. This covers a potential prospective study to 
improve on clinical outcome for older patients, and a future planned DGE-MRI study 
HEPARIM aiming to assess DGE-MRI’s ability to predict outcomes in patients requiring 
liver resection for both primary and secondary liver cancers, compared to gold standard 
measurement of function using indocyanine green (ICG). 
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Chapter 2 – Background 
2.1 Liver Surgery 
2.1.1 History of Liver Surgery 
To understand progress in the development of liver surgery; it is useful to review the 
discoveries over the centuries that have led to current practices. The descriptions of the 
liver’s anatomy, physiology, and the subsequent development of surgery and, in 
particular liver resection techniques has evolved rapidly. Over the last 100 years, 
understanding of human biology, surgical science and technology have developed 
significantly, and innovation is ongoing.  
2.1.2 Ancient history 
Until the 20th century, the liver’s function was unclear, but it was always viewed as being 
important for life. This is exemplified by Prometheus’ story of his daily hepatectomy by 
an Eagle. His liver seems to have been chosen as the organ to be continually devoured 
as it was considered to be the “seat of the soul and intelligence”(16). 
In the 2nd century AD, Galen, conducted research and experiments on various animals 
and through these he thought the liver itself was the producer of blood. He also felt the 
liver aided digestion by the heating the stomach: 
“why is the stomach surrounded by the liver? Is it in order that the liver 
may warm it and it turn warm the food? This is indeed the very reason is 
it closely clasped by the lobes of the liver, as if by fingers”(17) 
This was, of course incorrect, but Galen appreciated the liver was a highly important 
organ, one which without life was not possible. 
Surgery on the liver before anaesthesia was exceptionally rare, however as far back as 
the 4th century BC there have been descriptions of its occurrence. Hippocrates 
apparently had diagnosed liver abscesses in his patients, and advocated for the incision 
and drainage of such abscesses by use of “knife or cautery”, (18). In the 1st century AD, 
19 
 
 
 
Celsus(19) described surgery and debridement of exposed liver in war wounds of 
soldiers. 
2.1.3 Renaissance 
No real advances in anatomy or physiology occurred until the 15th century when 
dissection of executed criminals in Italy was permitted by the catholic church. An early 
anatomist, Vestalius, demonstrated the gross anatomy of the liver as having 2 lobes, left 
and right(20). 
The French Barber-Surgeon Amboise Paré, the royal surgeon to many French kings in 
the 16th Century, and otherwise notable for introducing ligation of vessels during limb 
amputation to stop bleeding(21) – discovered that the liver in vivo was extremely 
vascular. His most sage contribution to liver surgery was with this statement: 
"When the liver is wounded, much blood commeth out"(22)1 
William Harvey described the circular motion of blood around the body, and that it was 
being pumped by the heart, rather than the liver which was previously believed(23). 
Harvey’s student Francis Glisson described both the gross and microscopic vascular 
supply of the liver by a clever and careful dissection of the liver parenchymal from the 
vessels in 1654. He found that the liver has two separate inflows: one arterial and one 
venous. He also correctly predicted the microvascular connection between the portal 
venous and hepatic venous systems (interestingly he did this without using a microscope 
which didn’t become widely used until Robert Hooke published Micrographia in 
1665(24)). He also described the fibrous capsule around each liver lobule; the small 
subdivisions of the liver that contain the branch of the portal vein, hepatic arteries, bile 
canaliculi and the hepatic venules – the eponymously named Glisson’s Capsule(25). His 
 
1 This is often the first thing an aspiring liver surgeon learns, either through a traditional didactic approach, 
or through very bitter personal experience. 
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descriptions were lost until rediscovered in the 1890s, but his descriptions remains 
important(26). 
Despite the improved understanding of the liver’s structure and vasculature, surgery was 
confined to extreme situations in war time due to the lack of anaesthesia. Any ‘liver 
surgery’ from this period is limited to anecdotal reports of percutaneous debridement and 
extraction of liver pieces injured by sword wounds or ligating protruding liver from spear 
injury(27)(28), and as such these descriptions of early surgical adventures are interesting 
curios, but not really relevant to modern surgery. 
2.1.4 Era of anaesthesia 
In 1846, Diethyl Ether was found to produce effective anaesthesia when demonstrated 
successfully by William TG Morton and John Collins Warren, when they excised a tumour 
from the neck without causing the patient2 any distress or pain(29). From this, modern 
surgical practice could develop in earnest, and a huge array of operations would be 
described.  
The timeline of events for key 19th and early 20th century developments in liver surgery 
described below were identified by James Foster in History of Liver Surgery(18). 
The first case of planned liver surgery was in 1886. Luis reported that he had excised a 
large pedunculated tumour protruding from the liver of a 67 year old lady, but his attempts 
to stop the liver bleeding from where he had excised on the liver failed and she ultimately 
bled to death(30). A more successful attempt was published 2 years later by 
Langenbuch(31) where a 30 year old lady had a pedunculated tumour hanging off the 
left liver lobe excised. She also developed a post-operative haemorrhage and required 
a repeat operation later in the day and had a prolonged and difficult recovery but 
survived.  Patient survival bolstered surgeons, so more extensive operations took place, 
helped by improved technique and surgical instruments and materials(32).  
 
2 or indeed to the captive audience who had come to see the spectacle 
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The first described resection of part of the liver (as opposed to excision of a tumour 
hanging outside the liver) has been credited to Tiffany(33). In retrospect this resection 
from his description seems to be more removal of infected abscess tissue within the liver 
rather than liver tissue. Others followed with more substantial resections, principally by 
William Keen(34). Techniques at the time were crude; Keen describes cutting through 
liver with his thumbnail3. 
Morbidity and mortality were very high in these early years. Into the 1960s mortality for 
liver surgery was reported as being up to 50%(35). Such high risk was dispiriting for both 
surgeon and potential patients to consider such fraught and risky procedures. Lack of 
diagnostic imaging, and sole reliance on clinical examination cannot have helped. Blood 
loss was often uncontrollable and was a major barrier to successful surgery. 
2.1.5 Blood loss control 
The Pringle manoeuvre (described by J Hogarth Pringle(36)) was a step forward in 
control of bleeding. It involves compression the hepatoduodenal ligament at the liver 
hilum (which contains the hepatic artery, portal vein and bile duct). This controls bleeding 
by reducing blood inflow. Pringle’s reported outcomes were unfortunately 100% fatal (all 
were for trauma patients who were bleeding to death and succumbed to their injury), but 
the reasoning and the anatomical knowledge behind the manoeuvre was sound, and this 
technique has persisted to this day. Application reduces bleeding from cut surfaces of 
the liver. A Pringle manoeuvre has been reported to have been applied to the hilum  for 
up to an hour and the liver survived(37), however is quite an extreme length of time. 
Local practice is application of Pringle for no more than 15 minutes as it can lead to 
ischaemic damage to the liver, or subsequent reperfusion injury(38). 
Ischaemia-reperfusion injury is a complex inflammatory response that involves two 
stages – the initial ischaemic damage due to lack of available oxygen can lead to 
hepatocyte death. Reperfusion will lead to massive systemic cytokine release, which in 
 
3 Although ‘finger fracture dissection’ is still employed at times to this day – it provides a careful surgeon 
a gentle way of tissue dissection 
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turn can injure the liver. In addition, bacterial endotoxins re-entering the liver via the 
bloodstream can also be damaging(39). Back perfusion via the hepatic veins may reduce 
the extent of injury, and minimising the time applied reduces liver damage whilst reducing 
intra-operative blood loss(40). In Leeds, back perfusion is utilised throughout Pringle use 
to reduce risk of ischaemic-reperfusion damage. 
Resection along anatomical planes also reduces bleeding. This is called an anatomical 
resection. This involves ligation of the inflowing vessels to the area of liver to be excised, 
then subsequent division of the liver along the line of demarcation between the perfused 
and non-perfused liver. The first anatomical resection was reported by either by Von 
Harberer, who described ligation the left hepatic artery prior to excision of the left lobe 
(left hepatectomy)(41), or by Wendel(42)(43)(44)(45). Lorat-Jacob performed what was 
probably the first extended right hepatectomy(46), although nomenclature for liver 
resections was variable between reports until the Brisbane convention(47) standardised 
descriptions. 
Segmental anatomy was described by Couinaud in 1954(48) (although it has been 
suggested that Healey and Schroy(49) may have beaten him to it a year earlier(50)). 
Couinaud’s description based on the branches of the hepatic artery and portal vein into 
8 areas remains the anatomical description of choice to this day. This will be discussed 
later in the section on liver anatomy within this chapter (chapter 2.1.9). Couinaud’s work 
allowed surgeons to understand how to control inflow of blood into each segment, 
allowing segmental resections. Dissecting in inter-segmental, extra-glissonian planes 
reduces bleeding(51). This led to improved immediate survival of patients, and 
refinement of dissection with surgical instruments reduced parenchymal bleeding 
intraoperatively(52). 
Other novel attempts at controlling blood loss have been developed, often first used in 
trauma where surgeons innovate in desperate situations. Such methods includes 
hypothermic perfusion to cause vasoconstriction of the liver vessels(53)(54), aortic cross 
clamping(55), and inferior vena cava (IVC) control(56). Lin (57) described use of surgical 
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clamps on major vascular pedicles, and such clamps are still in use today(58).  The 
combination of anatomical extra-glissonian dissection and better control of blood inflow 
and outflow allowed surgery to be performed more safely.  
In addition to the technical aspects of surgery, factors such as increased understanding 
of disease processes; leading to better decision making for who should be a candidate 
for liver resection. For instance, liver haemangiomas were commonly excised due to 
uncertain natural history(59). With a better understanding of the pathophysiology of such 
benign lesions, surgery for haemangioma is now not indicated except in rare 
circumstances(60). 
The introduction of the ultrasonic dissector, of which the Cavitron ultrasound surgical 
dissector (CUSA) is a commonly used example, allowed more careful dissection of liver 
parenchyma from vessels due to the difference in mechanical impedance between the 
two(61). It has been widely adopted(62). The development and use of argon lasers to 
cause rapid and effective coagulation(63) has also entered routine surgical 
practice(64)(65)(66). Staplers, harmonic scalpels and hydrodissectors have also been 
used and are reported as being equally effective as CUSA(67). A randomised trial by 
Lesurtel and colleagues found that clamp crushing was preferable over other methods 
for patients with no parenchymal liver disease: quicker, cheaper, had less intra-operative 
bleeding and fewer transfusion requirements(68). The practice in Leeds at the time of 
recruitment for the studies described within this thesis was CUSA dissection, based on 
surgeon preference, familiarity with the technology, and availability. 
2.1.6 Modern developments and techniques 
The drive to achieve curative resection of what were previously considered non-
resectable has led to development of novel and occasionally radical surgeries. One 
reported technique is to perform a total hepatectomy, perfuse the liver with ‘backbench’ 
preparation, excise any tumour and then re-anastomose the livers hepatic artery, portal 
vein, bile duct and IVC. This was first reported in the late 1980s(69) but with a 33% 
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mortality, this technique has seldom been employed other than by highly specialised 
centres with liver transplant expertise.  
Tumours that had invaded vessels were once considered unsuitable for resection, 
however en-bloc liver resection with vascular excision was described in the early 
1990s(70). Despite short term technical success and patient survival, vascular invasion 
carries a worse prognosis for patients; most likely due to the tumour biology with 
increased recurrence and extrahepatic metastasis(71). 
 A more frequently used technique is a staged liver resection and allowing intra-
operative liver hypertrophy. For a patient with tumours in both right and left lobes of the 
liver, the first operation would involve resection of the tumours in one lobe (ipsilateral 
resection), leaving the contralateral tumours in situ. Following the first operation, the 
ipsilateral liver will hypertrophy. A subsequent operation to remove the contralateral liver 
tumours will take place after a few weeks, and the hypertrophy of the ipsilateral liver will 
have increased the remnant liver size sufficiently to provide effective function in the post-
operative period(72).  
Portal vein embolisation (PVE) was developed in Japan in the mid-1980s(73)(74). 
Occlusion of branches of the portal vein of the part of the liver that is to be resected 
(ipsilateral liver) is performed by injecting a sclerosing or obstructing agent, originally via 
a small laparotomy. A substance is injected into the portal vein or another mesenteric 
vein. It is now more commonly performed via a percutaneous route. Materials used 
include polyvinyl alcohol, gelatine sponges, n-butyl cyanoacrylate, fibrin glue, ethanol, 
coils, or vascular plugs(75). This leads to the ipsilateral liver becoming atrophic and 
stimulates the contralateral liver – the Future Liver Remnant (FLR) to hypertrophy4. It 
can induce the size of the FLR by as much as 10%-46%(76)(77)(78). PVE is established 
as an effective method of improving outcomes, and expanding the number of patients 
 
4 Future Liver Remnant or FLR is a hugely important concept in this thesis. It is the predicted part of the 
liver that will remain after the rest has been excised. Much discussion will follow regarding its potential 
volume and function 
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who are suitable for resection with a predicted small FLR(79)(80)(81). One demonstrable 
risk associated with PVE is sometimes there is an increased growth of tumour size, or 
even new tumour formation in the FLR in the time following PVE. Such tumour growth 
may render the liver inoperable. This can lead to a difficult balance between allowing 
enough time for adequate FLR hypertrophy to ensure safe surgery, and a delay that 
leads to tumour growth and inoperability(82). Another issue with PVE is that sufficient 
hypertrophy may not occur between 4%(75) to 37%(81) of the time, preventing surgery 
to proceed as required. PVE may not technically possible if there is portal vein 
thrombosis(83), and here has been recent reports of deaths due to complications from 
percutaneous approaches(84). 
One potential solution to the issues related to PVE is a novel surgical technique called 
“associating liver partition and portal vein ligation in staged hepatectomy” (ALPPS). This 
operation was discovered accidentally during a patient having hilar cholangiocarcinoma 
resected when the surgeon felt that should he continue with the original planned surgery 
the FLR would be too small, so abandoned surgery before completion of the 
resection(85). This involved the first stage resection as previously described, with ligation 
of portal vein branch to the ipsilateral liver and a splitting of the liver along Cantlie’s line. 
This induces rapid hypertrophy in the contralateral liver, and as such avoids the need for 
prolonged latent periods between first and second stage surgery, which can take place 
as soon as between 7 and 14 days(86), Initial outcomes reported quite high mortality 
and morbidity, but this has improved to acceptable rates(86). Laparoscopic first stage 
ALPPS may allow for patients to recover quicker than open surgery and have fewer 
complications, improving outcomes(87). Refinement of techniques, such as partial 
ALPPS, which does not involve such drastic dissection and liver partition shows 
comparable success in hypertrophy, with fewer complications(88). 
Anaesthetic techniques have also been used to achieve successful surgeries. Most of 
the improvements come from anaesthetic techniques to minimise blood loss, such as 
creating a low intra-operative central venous pressure (CVP)(89). 
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One study reported venesection of 0.7% of the patient’s weight in blood pre-surgery, to 
allow reduced CVP and a resultant reduced portal venous flow intraoperatively which led 
to reduced intra-operative blood loss. This pre-collected blood was then infused back 
into the patient as an autologous transfusion(90). 
2.1.7 Development of Liver Imaging 
Liver imaging has allowed clinicians to find out detailed information on the location and 
extent of tumours. Before imaging, decision making for surgical planning was based 
solely on clinical examination; you could only detect liver lesions if they were palpable 
(91). Indications for resections were also ill-defined. It is not possible to know how many 
patients had undergone a ‘diagnostic laparotomy’ for palpable masses that were not 
excised or not reported. As the diagnosis of liver lesions became possible without 
resorting to surgery, patient care and selection for those who do require surgery has 
greatly improved. 
Ultrasound was developed in the 1940s and used in liver diagnosis since the late 
1970s(92). Today liver ultrasound is frequently used to assess both diffuse liver diseases 
and identify discrete lesions; it is a cheap, safe and reproducible modality. However, it 
has a lower sensitivity than other imaging methods when used to diagnose liver 
metastases, it is more useful in excluding lesions. CT and MRI have proven to be more 
sensitive and specific in metastatic lesion diagnosis(93). Ultrasound is more operator 
dependant than other modalities which could lead to diagnostic errors, therefore CT and 
MRI are preferred for cases of cancer(94). 
Computerised Tomography (CT) use has led to major diagnostic improvements. CT 
angioportography was the main mode of imaging of metastases that exploited the fact 
that the liver parenchyma receives significant blood flow from the portal system, whereas 
metastasis being non-hepatic in origin do not. When a contrast agent is given the liver 
parenchyma will enhance during portal phase of contrast and metastasis will not(91). CT 
has mostly replaced ultrasound as imaging of the liver for discrete lesions although 
intraoperative ultrasound proved very useful after it was utilised to identify the location of 
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tumours within the liver that were not visible or palpable (95). Multidetector CT 
sequences are now available which gain excellent perfusion and dynamic images which 
improves acquisition speed and has narrower slice thicknesses which can identify 
smaller lesions. This has improved sensitivity and specificity of diagnosis of liver 
metastasis(see table 3)(96)(97). 
Positron Emission Tomography (PET)/CT is a combination of PET and CT in a single 
scanner which allows localisation of a radio-labelled tracers, most commonly in the form 
of glucose 18Fluorine-fluorodeoxyglucose (FDG) which decays and emits positrons which 
are detected by the PET. Cells which are termed ‘FDG avid’, namely those cells that are 
rapidly dividing and have a high glycolytic metabolism. Cancer cells are usually FDG 
avid, including most forms of colorectal adenocarcinoma. When the PET image is 
superimposed over a conventional CT, this can demonstrate very well the location of 
metastases, with the benefit of showing intra-hepatic and extra-hepatic disease(98). 
Magnetic resonance imaging (MRI) will be discussed in more detail below (chapter 2.4). 
Since it was developed by Sir Peter Mansfield and Peter Lauterbur(99)(100) it has been 
a major component of diagnosis of discrete liver lesions, and is frequently used in 
conjunction with CT in planning surgical resections. MRI caries some benefits over CT 
imaging in that it involves no ionising radiation, and sensitivity and specificity of diagnosis 
of various discrete liver lesions is improved over other modalities, particularly when liver 
specific contrast agents are used(101). Many centres, including Leeds, use it for all 
patients being considered for surgery. It also allows assessment of function with DCE-
MRI, which will be investigated in this thesis. 
Table 3: Summary of sensitivity and specificity for CRLM(93)(96) 
Modality Sensitivity (per patient) % Specificity (per patient) % 
Ultrasound (93) 63 86.3 
Multidetector CT 82 74 
PET-CT 74 94 
MRI with non-liver specific 
contrast agent (93) 
81.1 86.3 
MRI with Liver specific 
contrast agent 
93 87 
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2.1.8 Liver embryology, anatomy, and physiology 
Hepatoblasts form most of the precursor cells of the liver and arise from foregut 
endoderm in the third week of gestation. Hepatoblasts are bi-potential; capable of turning 
into hepatocytes, or for those cells next to the portal vein, become biliary epithelial cells 
(or cholangiocytes); part of the lumen of the future bile duct (102). Stromal cells, stellate 
cells, Kupffer cells and blood vessels are from mesoderm, and form in tandem with the 
mesodermal structures invaginating into the hepatoblasts mass. The forming liver bud 
develops greatly in size between week 9 and 15 and is an important erythropoietic organ 
for the foetus(103).  
These hepatocytes form a structure called the liver bud, which is considered part of the 
foregut, along with future structures of the gastrointestinal tract from the oesophagus to 
the second part of the duodenum. As a result, it receives arterial supply from the foregut 
artery. The liver bud presses into the embryological vitelline veins, surrounding them. 
The afferent part of the veins fuse to become the portal vein, and the efferent parts of 
these vitelline veins form the future right hepatic vein and inferior vena cava5. The middle 
and left hepatic veins develop separately from within the left side of the liver bud(104). 
This explains how the drainage of the left and right liver is functionally different, and a 
clear division between the two can be seen during surgery. 
The ductus venosus connects the left portal vein shunting blood to the IVC shunting 20-
30% of the blood flow to bypass the liver in the foetal stage(105)(106). The ductus 
venosus closes and subsequently fibroses after birth where it is known as the 
ligamentum venosus (or ligamentus teres6) which runs in the border of the peritoneal fold 
of falciform ligament. The requirement of the left portal vein to allow the shunt gives an 
 
5 This is a great oversimplification. They form from various other vessels in addition: a segment of the 
left vitelline vein, from the termination of the mesenteric vein to the middle inter-vitelline anastomosis; 
the middle or retro-duodenal inter-vitelline anastomosis; and the segment of the right vitelline vein 
comprised between the retro-duodenal and the subhepatic anastomoses. 
6 Teres means ‘round’ in Latin. There are at least 4 ligamentum teres in the body – the remaining 3 are 
found: 1. coming from the uterus, 2. attaching the femoral head to the acetabulum, and 3. surrounding 
the elbow 
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asymmetry of the left portal vein from the right – an important point to consider in surgery. 
The ligamentum venosus is an important landmark for a left hepatectomy – it marks the 
boundary for inflow for the left hemi-liver and thus gives a good guide to the edge of the 
correct resection margin(107). 
2.1.9 Anatomy 
The liver is a large intra-abdominal organ, roughly 2.5% (e.g. 1.5kg-2kg) of the total body 
weight of the individual. It is situated in the right upper quadrant of the abdomen, normally 
in health hidden beneath the rib cage and generally unpalpable clinically. Inferiorly the 
gallbladder is adherent to the liver in a recess known as the gallbladder fossa and these 
structures are separated by a thin fibrous layer. 
The gross anatomy of the liver is divided into 4 different lobes. The left and right lobes, 
which are either side of the falciform ligament make up most of the liver. The quadrate 
lobe found between the gallbladder fossa on the right and umbilical vein within the 
falciform ligament on the left, and the caudate lobe is surrounding the inferior vena cava. 
On the surface there is a visceral peritoneal covering, and deep to this there is a tough 
fibrous capsule called Glisson’s capsule (108). Superiorly, the peritoneum is absent as 
the liver touches against the diaphragm – the bare area. 
The liver receives 3 important structures that enter at the hilum. It receives the portal 
vein, hepatic artery, and the common hepatic duct. These 3 structures run together in 
what is known as the hepatoduodenal ligament7, also known as the portal triad. 
The arterial supply of the liver is from branches of the coeliac trunk – the mature foregut 
artery, a direct branch off the abdominal aorta. For most individuals, this is in the form of 
the common hepatic artery. After this artery trifurcates and gives off the gastroduodenal 
and right gastric arteries and runs towards the liver as the hepatic artery proper. This 
then bifurcates into right and left hepatic arteries which supply the right and left lobes 
respectively. Cadaveric studies have shown that there is the occasional (15%) incidence 
 
7 The hepatoduodenal ligament is the structure that is compressed during the Pringle Manoeuvre. 
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of a third artery branch – the median hepatic artery in addition to the right and left. This 
branch runs to either segment 4 or to 2/3. Between 25-40% of the time the right hepatic 
artery is a branch of the superior mesenteric artery (the midgut artery). Between 3% and 
13% of the time the left hepatic artery is a branch from the left gastric artery itself 
(109)(110). This is important for both surgery on the liver and for this this study for the 
identification of the arterial input function (AIF) in dynamic MRI imaging. 
The portal vein is created from the confluence of the splenic vein and the superior 
mesenteric vein that run behind the body of the pancreas. These veins (along with the 
inferior mesenteric which drains into the splenic vein behind the tail of the pancreas) 
come from the mid and hindgut structures of the abdomen, namely the small and large 
bowel, with some tributaries from gastric and lower oesophageal veins. The portal vein 
bifurcates into a left and right portal vein, normally within the liver parenchyma. There 
are small variations – a third branch, a median vein does come from the portal vein in 
15% of the time but there is less variation compared to the arterial system(109)(111). 
The common hepatic duct normally is derived from a left and right hepatic duct. There is 
a lot of variation with the occasional trifurcations and accessory ducts seen. This has 
less of an impact for functional assessment as there is no need to identify the biliary 
system in dynamic imaging, but is an important consideration for the surgeon for planning 
their surgery(111). 
The outflow of the liver is via 3 large veins: the left, middle and right hepatic veins. These 
3 veins drain into the inferior vena cava superiorly to the liver and here blood re-joins the 
systemic circulation. 
The functional right and left lobes are divided differently from the anatomical lobes. The 
functional division is the middle hepatic vein and the portal scissura known as Cantlie’s 
line(112). The portal triad structures will divide at or above the hilum giving right and left 
branches; right and left hepatic arteries, portal veins and hepatic duct. 
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Before Couinaud’s description, the liver’s anatomy was subdivided into 4 sectors. The 3 
Hepatic veins became the boundaries for this division. As a result, the right lobe was 
divided into 1) right posterior sector (lateral to the right hepatic vein) and 2) right anterior 
sector (between right and middle hepatic vein). The left lobe become 3) Left medial 
sector (between middle and left hepatic veins) and 4) left lateral sector (medial to the left 
hepatic vein)(113). 
The descriptions by Couinaud are the most important and clinically useful description of 
the internal anatomy of the liver. The arrangement and naming of the segments is based 
on the Arrondissiment of Paris, named 1-8, moving from posteriorly, medially, anteriorly 
and laterally in a clockwise manner(48). These segments are divided according to the 
arterial supply of the segments: the hepatic artery will divide into a left and right, which 
then further divide into sectoral arteries, then into the segmental artery. Occlusion of this 
artery will demarcate the segment itself. The branches of the portal vein run in between 
the segments, so in the left liver, the division of the segment 2 and 3 Is the left portal 
vein, the division between 5 and 8, and 6 and 7 is the right portal vein(114) 
Table 4: Summary of the various descriptions of the liver anatomy 
Couinaud Segment Sector name Gross Anatomical description 
Segment 1 Left medial Caudate Lobe (aka Spigel lobe) 
Segment 2 Left Lateral Left lobe 
Segment 3 Left Lateral Left Lobe 
Segment 4 Left Medial Quadrate lobe(115) 
Segment 5 Right anterior Right lobe 
Segment 6 Right posterior Right lobe 
Segment 7 Right posterior Right lobe 
Segment 8 Right anterior Right lobe 
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Figure 1: A map of Paris, demonstrating the arrangement of the arrondissement  
 
Figure 2 : The internal arterial supply of the liver (numbers corresponding to the 
segmental artery (adapted from Strasberg (47)) 
 
There have been alternative descriptions of the internal liver anatomy. Couinaud himself 
talked about a 9th segment located in the para-caval liver. He apparently changed his 
mind about its existence, but some consider it important when reporting on resection in 
this anatomical area(116)(117). A contemporary view felt the liver had 13 
segments(116). Although Couinaud’s description has been the most widely adopted, 
several authors have suggested sub-segmentation of each of these 8 segments into 2,3 
or even 4 subsegments based on additional branches observed(118). This has 
particularly been noted in some of the larger segments like 4 (subtitled 4a and 4b) and 8 
(subtitled 8d (for dorsal) and 8v (for ventral) (119)(120). The sub-segmentation if 4 into 
4a and 4b is commonly used, however the rest of segments remain simply 1, 2, 3, 5, 6, 
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7 and 8. The Couinaud description of segments will be used for the remainder of the 
thesis. 
Figure 3: Artistic impression of the liver segments used in Leeds Hospitals NHS Trust 
for patient information 
 
By compressing the portal triad to each segment (the segmental artery, portal vein and 
bile duct) the occlusion of the vascular pedicle will de-mark out that segment – so 
allowing a segmental resection when the parenchyma at the watershed area can be 
divided(121). 
2.1.10 Microscopic Anatomy and Physiology 
The liver has multiple functions; metabolic, endocrine, exocrine, and excretory. The liver 
is a highly vascular structure, receiving around 1.5L/min: around 80% is derived from the 
portal venous circulation and 20% from the hepatic arterial flow(89). 70% of the mass of 
the liver is made of hepatocytes. 
Microscopically, the functional unit of the liver is the acinus where the portal triads (again 
the artery, portal vein and bile duct) lie surrounding the draining hepatic venule. These 
form hexagonal units known as a lobule. The space between the triad and the hepatic 
venule is described as periportal (zone 1), mid-portal (zone 2), and pericentral (zone 3) 
of the lobule. This has clinical importance as the pericentral zone is the most prone to 
necrosis due to its relatively poor oxygenation(105)(122). Sinusoids run from the portal 
triad to the central vein. Hepatocytes are polygonal and form cords one or two cells thick 
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within the units separated by sinusoids, with those hepatocytes running with the portal 
tracks on the edge of the lobule form a limiting plate. Part of the hepatocyte face the 
sinusoid, part form biliary canaliculi with adjacent cells, so have an interface to allow 
excretion into the hepatic venous system and the biliary system(123). 
Figure 4: Histological structure of the microanatomy of the liver (from Fu(124)) 
 
Between the endothelial cells of the sinusoids and the hepatocytes lies the space of 
Disse(125). This space allows exchanges between the circulation and the liver tissue. It 
contains plasma and connective tissue forming a framework, and hepatic stellate cells 
(Ito cells). These stellate cells are myo-fibroblastic and allow constriction or relaxation 
and thus can control blood flow. Lymphatics also form in the space of Disse. 
Bile canaliculi form between hepatocytes polygonal edges and form tortuous routes 
within the lobule, and form into structures known as the canals of Hering, which drain 
bile ductules, and then into a terminal duct(126). 
The hepatocyte membrane allows bilirubin uptake into hepatic tissue from the 
bloodstream via transporter enzymes called organic anion transporting polypeptide 
(OATP) 1-B1 and B3(14). There, it is excreted into the biliary sinusoids via an active 
transporter multidrug resistant protein 2 (MRP2)(127). These transporters are key for the 
pharmacodynamics of the contrast agent Gadoxetic Acid (or Gadoxetate) as this utilises 
the same receptors for a large part of its excretion pathway(128). 
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2.1.11 Liver regeneration 
The liver’s capacity to regenerate and grow after partial resection had been noticed as 
early as 1879 when Tilmann noted enlargement of the remnant liver in animals after he 
excised part of the liver and subsequently carried out post mortems on these animals 
after their demise(129).  
Normal healthy liver has an ability to restore its architecture, size, and function to a 
remarkable degree. It is a very complex process that is not fully understood. During 
normal regeneration, bile acids are rapidly upregulated, and up to 100 serum factors 
rapidly induce regeneration in the liver(130). IL-6 seems to be the most important, at 
least in rodent models(130). During regeneration, non-parenchymal cells; macrophages, 
hepatic stellate cells and liver sinusoidal endothelial cells signal to hepatocytes to enter 
mitosis. There are no fibrotic changes in these instances. What leads to arrest of the 
regeneration again is complex, but involves upregulation of suppressors of cytokine 
signalling,  which act in a negative feedback loop, blocks IL-6 and initiates the termination 
of growth(130). 
In abnormal regeneration, hepatocytes are increasingly senescent and unable to divide 
efficiently, the hepatic stellate cells are activated to myofibroblasts and excessive scar 
tissue inhibits regeneration. Excessive cellular debris inhibits efficient liver regeneration 
(131). Animal models do offer some explanation of mechanism, however clinical human 
studies of liver regeneration often have participants exposed to multiple liver injuries 
which does make translational research more challenging(132). 
For healthy patients the liver will, after resection, regenerate to a volume comparable to 
the pre-operative liver, and functions can recover significantly(132). However, despite 
this regeneration, there are multiple factors that may impede regeneration in many 
individuals. Age(133) and various co-morbidities(6) may have significant impacts. This 
will be discussed further in the section on PHLF (chapter 2.2). 
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2.1.12 Current indications for Liver Resection Surgery 
Liver resection is most commonly performed for malignant liver tumours; primary cancers 
such as hepatocellular carcinoma, cholangiocarcinoma and neuroendocrine tumours 
(NET), or secondaries from colorectal, breast, gastric, melanoma and extra-hepatic 
primary NET(134). There is an indication for palliative debulking of NET metastasis with 
improved symptoms and survival(135). Surgery for benign lesions is also 
performed(136). Often patients with benign liver lesions are younger and fitter than those 
with malignancy so will have better outcomes, and surgery is considered safe(137). 
Recently there has been an increase in the number of benign lesions undergoing 
surgery, which may be to be due to the availability of laparoscopic and minimally invasive 
surgery(82)(138). 
The argument for resection of malignant disease is much more compelling as malignant 
liver tumours lead to significant morbidity and shortened lifespan, for HCC, untreated 
prognosis is ~20% 3 year survival(139)(140) and cholangiocarcinoma has a ~15% 5 year 
survival(141). The prognosis for patients with metastatic liver tumours does depend on 
the underlying aetiology, stage, and grade. Survival for patients with 
unresected/unresectable metastatic liver cancer is dismal at ~5% at 5 years(142). Well 
differentiated NET have much better prognosis with a 10 year survival of around 
18%(143). 
For benign disease it more controversial if to operate at all. Decision making is guided 
by the symptoms of the patient, weighed against the benefits and risks from surgery. 
Indications for surgery are taken on a case by case basis(136). 
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Table 5: Current indications for hepatic resection 
Benign indications(137) Malignant indications(43) 
Risk of 
Malignant 
transformation 
Uncertain 
diagnosis 
Symptomatic Transplantation Primary Cancers Metastatic 
Cancer 
Adenoma Haemangioma Cysts Live liver 
donation(144) 
Hepatocellular 
Carcinoma 
Colorectal  
Cystadenoma Focal nodular 
hyperplasia 
Intrahepatic 
Cholangio-
carcinoma 
Stromal 
Cysts Sarcoma Neuroendocrine 
Clear Cell 
carcinoma 
Breast 
Melanoma 
Locally advanced 
colonic 
Hilar Cholangio-
carcinoma 
Gallbladder 
Adrenal 
 
2.1.13 Pathogenesis of Colorectal Liver Metastasis 
Colorectal cancer is the fourth most common cancer and the second most lethal(145). 
Up to 50% of patients with colorectal cancer will develop colorectal liver metastasis 
(CRLM). Liver resection of CRLM is the most common indication for liver resection in the 
UK, accounting for 60-70% of liver resections in Western Countries(146). For this reason, 
it has been chosen as the main population for study in this thesis due to the significant 
burden of work, the recruitment timetable, and relative ease at modification of DGE-MRI 
protocols for patients with CRLM. 
Colorectal cancer develops from an adenoma to carcinoma sequence in the vast majority 
of cases(147). The process for this formation is complex, but in simple terms involves 
the ‘multi-hit hypothesis’: corruption of cellular mechanisms to promote cell immortality 
and turning off the apoptosis controls, the downregulation of tumour suppressor genes 
(such as adenomatous polyposis coli – APC and p53) and the activation of oncogenes 
such as Kirsten rat sarcoma viral oncogene homolog (K-Ras)(147). 
The liver itself is a frequent site of metastatic disease and seems to be susceptible for 
metastases to establish themselves, particularly from colorectal adenocarcinoma. 
The mechanism of metastasis is a multiple step process, in which a neoplastic cell or 
cells must invade into either lymphatic or capillaries, embolise systemically to reach the 
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site of metastasis, become adherent within the tissue, extravasate into the metastatic 
site and proliferate(148).  
Specifically for colorectal cancer, the liver is a ‘target organ’  and often the sole location 
of metastasis(149). The anatomy of the portal venous system allows metastatic cells 
from the colon to enter the portal venous system’s blood stream, spreading into the 
microvasculature of the liver. Sinusoids appear to allow rapid movement of metastatic 
cells from the intravascular space to beyond the basement membranes with alarming 
speed (<6h in experimental models) compared to movement of metastatic cells in other 
organs (followed next in speed by lung tissue at ~11h – the second most common site 
of metastasis of colorectal cancer)(150). Indeed the microstructure of the liver seems to 
‘help’ the metastasis enter tissue(151); as the liver’s basement membrane is less well 
defined as other organs; it seems to disintegrate upon exposure and this disintegration 
leads to proliferation of endothelial cells, and endothelialisation of tumour cells – 
promoting early angiogenesis and hence metastatic spread. 
The developing metastases may not be apparent at the time of diagnosis of the primary 
colorectal cancer, the phenomenon of metachronous (those developing at a later date) 
metastasis is frequently observed(152) and for this reason a 5-year surveillance follow 
up with CT of the thorax, abdomen and pelvis (CT TAP), tumour markers (commonly 
carcinoembryonic antigen - CEA) and clinical review for symptoms is 
recommended(153). 
2.1.14 Current pre-operative investigations for Liver Metastasis resection 
The decision to operate on CRLM comes down to achieving a curative resection, 
preferably with clear resection margins (R0). Around 30% of patients with CRLM will 
have resectable and curative liver metastases(154). There are options available to widen 
the scope and increase number of patients who have resectable disease such as 
neoadjuvant chemotherapy with the aim to reduce tumour bulk and volume(155). 
39 
 
 
 
Adjuvant chemotherapy after R18 resection conveys no survival benefit and therefore is 
not indicated(156). The recurrence rate remains present for a significant period of time, 
and patients will need to be followed up years after their surgery to detect late 
recurrence(157). In Leeds, current practice is for a 10-year follow up, due to cases of 
very late recurrent metastasis identified up to this time. 
Detailed guidelines exist for the multi-disciplinary approach to patient selection for 
surgery, chemotherapy guides and imaging strategies(142). 
For CRLM to be considered operable, they must fulfil certain criteria. These are 
summarised in the table below based on technical and the underlying biology of the 
cancer (table 6). 
Table 6: Technical contraindications to liver resection for CRLM(158) 
 Technical Oncological 
Absolute Absolute Impossibility of R0 
resection with ≥30% liver 
remnant  
Concomitant extrahepatic 
disease (unresectable) 
Presence of unresectable 
extrahepatic disease 
Relative R0 resection possible only 
with complex procedure 
(portal vein embolisation, 
two-stage hepatectomy, 
hepatectomy combined with 
ablation  
Number of lesions ≥5 
R1 resection Tumour progression 
 
After the technical aspects of the surgery have been considered, patients’ fitness for 
surgery is assessed. Even if a patient has resectable liver disease they would need to 
withstand the burden and risk of the anaesthetic, blood loss and physiological 
derangements that are unavoidable in surgery. This could be done by clinical review and 
decision from a senior surgeon, however different scoring systems have been developed 
and are utilised to try and form a more objective and translatable method of patient 
selection. 
 
8 This is macroscopically cleared tumour margins but microscopic involvement 
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2.1.15 Patient factors and fitness for surgery 
Performance Status 
Performance status is a widely adopted method of a patient’s fitness assessment and 
has a prognostic impact. It is simple and helpful in screening for fitness for both surgery 
and for chemotherapy or radiotherapy use(159). It is a subjective assessment that can 
lead to interobserver bias(160). In current practice, a patient would only be deemed fit 
enough for elective cancer resection surgery if their performance status is 0 or 1, as any 
lower performance would reflect reduced physiological reserve. 
Table 7: Performance Status(161) 
Grade Explanation of activity 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light housework, office work 
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. 
Up and about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours 
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or 
chair 
5 Dead9 
 
ASA 
American Society of Anaesthesiology’s grading system (ASA)(162) gives a good overall 
view of a patient’s physiological reserve and is proven to have a correlation between 
increased score and increasing morbidity and mortality(163)(164). It is entirely subjective 
and there will inevitably be interobserver variability as with performance status. It is a 
useful screening tool that is quick, easily understood and implemented(165). Most 
candidates for surgery would be ASA 2 (or less commonly ASA 3) as the cancer itself 
counts towards their systemic disease, and when above 2 the patients physiology many 
be sufficiently impaired prohibit major surgery. 
 
 
9 Very unlikely to be used 
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Table 8: ASA 
ASA  Description 
1 A normal healthy patient 
2 A patient with mild systemic disease 
3  A patient with severe systemic disease 
4  A patient with severe systemic disease that is a constant threat to life 
5  A moribund patient who is not expected to survive 
 
Frailty scoring 
Frailty scoring is a more recent introduction. Robinson and colleagues combined seven 
measures that have been used independently in terms of frailty by Care of the Elderly 
physicians. They defined frailty as non-frail (0-1), pre-frail (2-3) and frail (≥4). They found 
the higher the patient’s frailty, the more complications they developed(164). It does not 
seem to have yet been applied to liver resection surgery but includes major intra-
abdominal and cardiac operations which both have a significant physiological insult as 
liver surgery. As a result they could theoretically be applied to liver surgical patients in 
the future(166). At present is not commonly currently used in patient selection in Leeds. 
Table 9: Robinson’s frailty scoring(166) 
Test Method Abnormal result 
Timed ‘Up-and Go’(166) The time needed to stand up 
from a chair, walk 10 feet, 
return to the chair, and sit 
≥15 seconds.  
 
Katz Score (167) independence of activities of 
daily living (bathing, 
dressing, transferring, 
walking, toileting, and 
feeding)  
dependence in one or more 
activity of daily living. 
Mini-Cog (168) paired three-item recall and 
clock draw task  
score ≤3.  
 
Charlson Index (169) 
 
19 categories of co-
morbidities weighted on their 
risk of one-year mortality 
score ≥3. 
Anaemia of chronic disease 
(170) 
 Haematocrit < 35%. 
Poor nutrition (171)  serum albumin level below 
3.4 g/dL. 
Geriatric syndrome of 
falls(172) 
Number of falls in prior six-
months  
≥1 fall in the six-months prior 
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CPEX 
Cardio-Pulmonary Exercise Testing (CPEX) has been employed pre-operatively for 
many major surgeries; cardiac, lung and intra-abdominal surgeries(173). 
This involves the patient using an exercise bicycle. They have a spirometry test during a 
3-min rest period, followed by 3 min of freewheeling and then pedalling against a ramped 
resistance/workload to determine the patient’s anaerobic threshold (VO2 ml/kg/min) by 
measuring expired CO2. It has been used for risk stratification for patients undergoing 
anaesthetic for major surgery. Specifically when investigated in liver surgery patients, 
Kasivisvanathan and colleagues determined a cut-off of <10.2 ml/kg/min as having an 
increased risk of morbidity development post-operatively(174). It has yet to become 
established practice in patients considered for liver resection in Leeds, unless there is a 
specific concern or indication raised by the anaesthetic team, and so no patients included 
in this thesis routinely underwent this test. 
Physiology scoring systems 
Other physiology scores such as APACHE III (175) and P-POSSUM(176) are detailed 
scoring systems which are more commonly used for emergency general abdominal 
surgery(177) but neither have an established role. P-POSSUM is not effective for 
predicting morbidity or mortality(176) and APACHE III is calculated post-operatively and 
so cannot be used for pre-operative risk stratification(176). 
The combination of patient fitness and technical and oncologically resectable disease all 
need to be satisfied for a patient to be deemed suitable for surgery. At the time of 
recruitment for the studies included in this thesis, preassessment modalities utilised were 
ASA and performance status. CPEX was rarely performed and frailty assessment took 
place in an outpatient clinic review rather than formal frailty scoring. 
Such pre-operative assessments cannot effectively exclude all patients at risk from 
surgery, which indicates that alternative risk stratification methods are required in liver 
surgery to maximise patient safety. 
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2.1.16 Liver resection technique and hemihepatectomy 
To resect a segment of liver, the parenchyma needs to be divided with excision or 
occlusion of the vascular inflow and outflow as much as possible to minimise blood loss. 
A major liver resection is defined as excision of 3 or more segments in a single 
operation(47). Most liver resections are currently performed via an open/laparotomy 
technique with an incision in the right upper quadrant and a midline extension – often 
termed a ‘reverse L’. More recently, laparoscopy is utilised(121), which has some 
promising improvements in early patient recovery(178) A currently ongoing randomised 
trial, ORANGE II PLUS, is comparing outcomes of laparoscopic versus open right and 
left hepatectomy is expected to report in early 2020(179). At the time of this study, all 
major liver resections were done via laparotomy in Leeds. 
Figure 5: Intra-operative picture of a right hepatectomy in progress  
 
For a right hepatectomy, one commonly used method involves an incision (called a 
hepatotomy) into segment 4 in the gallbladder fossa, then a second hepatotomy made 
inferior to the main right portal branch near the caudate lobe. A blunt clamp is then 
passed superior from the hepatotomy in segment 4 through liver parenchyma and then 
exiting via the inferior hepatotomy – surrounding the right portal triad, staying outside the 
Glissonian capsule as previously described by Launois(180)(181). A vascular clamp is 
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used to compress this tissue and right portal pedicle allowing for demarcation of the right 
lobe. Once this is confirmed, the pedicle can be ligated or stapled.  
For a left hepatectomy, the hilar plate is elevated, and the left portal pedicle is identified 
in the umbilical fissure. A hepatotomy is made at the level of lowering the hilar plate and 
a second hepatotomy in the back of segment II. The same clamp should be used to come 
around this pedicle with subsequent vascular clamping to check for demarcation and 
then a vascular stapler to transect the left portal pedicle(114)(182). 
For segmental liver resection (excision of isolated segments) the inflowing portal triad 
can be found within the liver parenchyma, carefully clamped to allow demarcation and 
subsequent dissection via the preferred technique (in Leeds it is the CUSA) to minimise 
bleeding and the segments triad is ligated or stapled to complete the segmental 
resection(183)(184). 
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2.2 Complications of Surgery 
All surgery carries a risk of complications. Surgical complications traditionally were 
classified in terms of if they were local to the site of surgery, or systemic, and related to 
their time, immediate, early, or late. Historical descriptions were subjective and variable 
– one surgeon’s complication could be another’s variation on normal. Since the early 
1990s Clavien and colleagues have worked to create a unifying scheme of the 
description of complications, first for cholecystectomy(185), then liver transplants, before 
applying their method to all surgery – the Clavien-Dindo classification(186). This has 
been widely adopted in reporting across multiple surgical subspecialties and is currently 
considered the most robust reporting method and the current gold standard for reporting 
complications(187)(188)(189). 
Table 10: Clavien-Dindo Classification of Surgical Complications(186) 
Grade Definition 
I Deviation from normal postoperative course without need for intervention 
(including antiemetics, antipyretics, analgesics, diuretics, IV fluid, Physio, local 
wound management 
II Pharmacological intervention 
III Surgical/Endoscopic/Radiological intervention 
a No GA 
b GA 
IV Life-threatening complications needing ICU management 
a Single organ dysfunction 
b Multiorgan dysfunction  
V Death 
Suffix d Prolonged disability after discharge (e.g. cardiac insufficiency post MI, faecal 
incontinence post injury of nerves, stroke etc. 
 
2.2.1 Complications of Liver Surgery and Post Hepatectomy Liver Failure 
Other than the general risks of surgery as discussed above, the resection of liver leads 
to a reduction of functional liver mass. If extreme, this can lead to the development of 
Post Hepatectomy Liver Failure (PHLF). This has been recognised phenomena for 
many decades. The two most commonly recognised risk factors first identified were 
background liver disease, and extent of resection. 
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2.2.2 Background liver disease and PHLF 
PHLF leads to an increased complication rate and mortality in patients undergoing 
surgery for HCC who have a background of cirrhosis or chronic cholestasis. This 
population had higher morbidity and mortality compared to the same degree of resection 
on patients with no liver disease(190)(191). Jaundice due to other pathology at the time 
of surgery was found to have a poor outcome(146)(192). The underlying pathology of 
malignant disease over benign disease was felt to increase risk of both morbidity or 
mortality(191). Cirrhosis itself increases the risk of infection, due to impaired endotoxin 
clearance and increased TNFα release(193). The Kupffer cells act as gatekeepers for 
haematogenous bacterial infection(194) and the dysfunction of the reticuloendothelial 
system seen in cirrhosis combine to impair immunity(195). 
2.2.3 Future Liver Remnant 
The FLR is the predicted volume of the remaining liver after surgical resection. It can be 
described either in terms of remnant segments, or % of remnant volume.  
For example, a patient having a right hepatectomy will have segments 5, 6, 7 and 8 
resected. The FLR will be segments 1, 2, 3, and 4. If you calculate the volume of the 
whole liver, and then subtract the volume of the resected segments it will give a 
percentage which is the FLR %. Segments vary in size from person to person, so the 
number of segments in the FLR does not always correspond to the volume, and more 
commonly FLR is described as a percentage rather than number of remnant segments. 
If the FLR is deemed too small after surgery the term small for size is used, like the 
problem encountered in liver transplantation when the graft size is inadequate(3). 
2.2.4 Extent of resection and PHLF 
Major resection surgery is known to be associated with increased incidence of 
complications, which increases with a smaller FLR(196). Early resection surgeons 
adopted a dogmatic approach to leave at least one third of the liver as the FLR – although 
this size was not scientifically determined. It was based on the experience of other 
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surgeons’ reported outcomes. Studies from the late 1990s described the critical remnant 
size of the FLR as the volume at around 20-30% in non-cirrhotic livers(197)(198). Schindl 
and colleagues determined a critical threshold of FLR determined by CT volumetry in 
patients with normal pre-operative liver tests of 26.6% for patients to avoid development 
of PHLF(4). 
For those patients with cirrhosis, the FLR is always considered to be much higher, a 
minimum of 40% FLR has been advocated by some authors(199)(200) however such 
estimations are complex. A patient-centred approach assessing fitness, understanding 
potential prognosis for their disease and a detailed multi-disciplinary input is always 
required. 
2.2.5 PHLF in CRLM resection 
Liver failure has been reported in patients who had major resection for CRLM since the 
1990s(201). In their study, Laurent and colleagues(202) reported PHLF after CRLM 
resections was seen worsen the short term outcome for morbidity and mortality. Such 
patients also had a reduced 5-year survival rate; which the authors suggested could be 
due to the increased regeneration response allowing neoplastic promotion and increased 
recurrence(203).  
2.2.6 Different definitions of PHLF 
At least 56 descriptions and definitions of PHLF have been described, as collated in the 
ISGLS consensus summary(5). In the interest of brevity, only selected definitions will be 
discussed which have been commonly used in published reports. Most use the same 
biochemical markers in their definitions, with some extra clinical parameters added. The 
shifting definitions are due to progress and evolution of criteria, with multiple incremental 
changes as understanding of the underlying pathophysiology has improved over time. 
Early studies use clinical biochemical markers of synthetic function with coagulation 
factors (often as a prothrombin time (PT) or international normalised ratio (INR)) and 
excretory function of serum bilirubin(197). Factors such as albumin levels which can be 
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affected by many factors have been demonstrated to have poor correlation with 
outcomes and as a result are not often used in the context of surgical outcomes(204). 
Transaminases such as Alanine Transferase (ALT) and Aspartate Transferase (AST) 
are used as markers of hepatocellular damage and are released on cellular injury into 
the circulation. Despite this, they seem to have poor correlation with outcome post-
operatively and are considered by many to have no prognostic value(204)(205). A report 
by Olthof and colleagues seems to contradict the received wisdom and does find raised 
transaminases in the first 24h to have a correlation with a worse outcome, particularly 
with perihilar cholangiocarcinoma patients(206). However, no scoring system of PHLF 
utilises them and overall, they are not used in this thesis in post-operative assessment. 
Hemming and colleagues described one of the earliest definitions of PHLF in 2003 which 
they defined  as: ‘development of encephalopathy, ascites requiring sustained diuretics 
or paracentesis, or coagulopathy unresponsive to vitamin K requiring FFP after the first 
24 hours postresection’(207). Although this clearly does represent a non-functioning 
liver, it is quite a serious condition for a patient, and would correspond to a Child’s C 
status patient. It would eliminate patients with less severe, but definite liver dysfunction. 
Also, the time of 24 hours was selected arbitrarily and may be too short a period of time 
to fully establish the clinical picture in terms of liver function. The same authors later 
revised their definition to include a bilirubin greater than 10 mg/dL or refractory ascites 
that persisted longer than 10 days post resection(208). This was further modified by 
Vauthey into the more precise: ‘Bilirubin >10 mg/dL (unrelated to biliary obstruction or 
leak) and/or INR >2 more than 2 days after resection and/or clinically significant 
ascites/hepatic encephalopathy’(208)10. They used the term ‘hepatic insufficiency’ – a 
synonym of PHLF that is often used. Presence of ascites post-operatively, was 
 
10 It is worth noting there is a difference in how biochemical values are reported in US and European 
studies. Most American studies use the mg/dL, whereas the rest use the SI units µmol/l. For conversion, 
mg/dL needs to be multiplied by 17.1 (e.g. 10mg/dL = 171µmol/L) or alternatively to convert from 
µmol/L it should be multiplied by 0.059(208). 
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subsequently shown not to be associated with degree of failure, or morbidity or mortality 
and was not used in following definitions(209).  
Schindl and colleagues, in the same paper as that which determined a critical FLR 
volume, devised a scoring system based on their study of 104 patients(4). This was 
based on the association of elevated bilirubin, prolonged PT, evidence of ischaemia 
(measured by lactate) and encephalopathy observed in PHLF patients(79)(146)(209). 
Lactate is often used as a marker of tissue ischaemia(210). The authors reported a good 
correlation between their liver dysfunction scores and % volume of FLR. This seems to 
be the first study to consider liver dysfunction as a spectrum and divided their results 
ordinally rather than a nominally as in the previous literature. 
Table 11: Schindl’s PHLF score 
Score 0 1 2 
 
Bilirubin  (mmol/L) <20 21-60 >60 
PT (seconds above 
normal 
<4 4-6 >6 
Lactate <1.5 1.6-3.5 >3.5 
Encephalopathy 0 1-2 3-4 
 
Severity (the four domains above are added together to give a sum value – this then 
stratifies patients into 4 groups range is 0 to 8) 
None Mild Moderate Severe 
0 1-2 3-4 >4 
 
Balzen and colleagues described the ’50-50’ criteria. This was the most commonly and 
robust method used for 6-7 years(211) until the current ISGLS definition was adopted.  
It used bilirubin and PT as previous studies had done and defined PHLF as: 
𝑃𝐻𝐿𝐹 =  𝑃𝑟𝑜𝑡ℎ𝑟𝑜𝑚𝑏𝑖𝑛 𝑇𝑖𝑚𝑒 > 50% 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑎𝑛𝑑 𝑆𝑒𝑟𝑢𝑚 𝐵𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛 
> 50µ𝑚𝑜𝑙/𝐿 𝑜𝑛 𝐷𝑎𝑦 5 𝑝𝑜𝑠𝑡 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑣𝑒𝑙𝑦. 
This was devised based on the observation on the trend of the kinetics of both bilirubin 
and PT over the first week of surgery. The authors did select their cut-off values arbitrarily 
but were based on the reported values in Child Pugh Scoring (CPS) as measures of 
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impaired excretory function with bilirubin, and impaired synthetic function with PT. They 
didn’t use CPS in this study as they felt it would be biased in the post-operative period. 
As they investigated the trend over time of these two parameters, elevated bilirubin on 
day 5 had a 15% mortality, and elevated PT had a 33% mortality. With persistent 
elevation of both bilirubin and PT on day 5 had a 59% mortality, whereas both elevated 
on day one had a 14% mortality. They conclude that early rises in bilirubin and PT 
particularly between day 1 and 3 are representative of a normal physiological response. 
It would be in this phase that massive regeneration of the liver is starting its process, and 
enough regeneration has occurred by day 5. Those patients with inadequate 
regeneration by this would seem to be those who will not regenerate sufficiently in time, 
and by consequence have persistent liver dysfunction and PHLF. 
Mullen and colleagues determined a critical post-operative value in their series of over 
1000 resections of bilirubin alone >7mg/dL (~120µmol/L) as a defined PHLF (they used 
the term ‘insufficiency’) and reported strong correlation with adverse outcome. This value 
had high sensitivity and specificity of 93% and 94% respectively. This was indeed 
stronger than prolonged PT (they used INR >2) independently or even in combination – 
sensitivities and specificities around 70-75%; and was better than the ’50-50 criteria’, at 
least in their population(1). Although this is a robust study demonstrating an important 
threshold, it again only represents the extreme of patients who develop PHLF – severe 
cases who die or are affected with complications, and such a value could not be used 
for the mild or moderate cases that will be more commonly observed. 
Rahman and colleagues examined post-resection C-reactive protein (CRP) as a 
biomarker for PHLF. The authors reported that a CRP of less than 32g/dL on day one 
post-operatively was associated with PHLF and increased mortality. They concluded 
CRP concentration reflected the synthetic capacity of the remnant liver and low levels 
represented both a reduced synthetic function, and also an impaired metabolic role for 
regeneration(212). 
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Many of these studies detected major biochemical parameter changes and the ones 
associated with poor outcome, every publication used their own system. As an answer 
to this, the International Study Group of Liver Surgery (ISGLS) performed a systematic 
review of the literature and highlighted papers with the most robust results (which were 
those discussed above) and determined a consensus definition, and classification of 
severity. 
“A postoperatively acquired deterioration in the ability of the liver (in 
patients with normal and abnormal liver function) to maintain its synthetic, 
excretory, and detoxifying functions, characterized by an increased INR 
(or need of clotting factors to maintain normal INR) and 
hyperbilirubinemia (according to the normal cut-off levels defined by the 
local laboratory) on or after postoperative day 5. If INR or serum bilirubin 
concentration is increased preoperatively, PHLF is defined by an 
increasing INR (decreasing prothrombin time) and increasing serum 
bilirubin concentration on or after postoperative day 5 (compared with the 
values of the previous day). Other obvious causes for the observed 
biochemical and clinical alterations such as biliary obstruction should be 
ruled out”(5). 
Table 12: ISGLS definition of PHLF 
Grade A PHLF resulting in abnormal laboratory parameters but requiring no change in the 
clinical management of the patient. 
Grade B PHLF resulting in a deviation from the regular clinical management but 
manageable without invasive treatment. 
Grade C PHLF resulting in a deviation from the regular clinical management and requiring 
invasive treatment. 
 
This definition has, as a result become the most frequently reported description of PHLF 
since 2011 in subsequent publications (6) (10) (83) (213) (214) (215) (216) (217). It will 
therefore be the definition that is used throughout the rest of this thesis. 
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2.2.7 Risk factors for PHLF 
Risks for PHLF are multifactorial and there is not a complete understanding of which are 
the most important, or how much they contribute a risk to PHLF development. Most 
identified risk factors have been identified as a secondary objective as part of large 
retrospective analyses based on either large databases or single centre studies. There 
is often a large variation of resection size and therefore subsequent FLR size that could 
be confounding results. Although each of the factors discussed below seem plausible to 
be contributing to PHLF development, and would satisfy Bradford-Hill’s criteria for 
association and causation11(218), there is a requirement for more evidence to 
understand the true impact  of contributing factors on the pathogenesis of PHLF. A large 
number of risk factors were identified in Tzeng’s large retrospective database study 
involving 894 elderly patients; their findings are discussed below(219). 
2.2.8 Pre-operative risk 
Diabetes 
Diabetes is a common endocrine disease that leads to hyperglycaemia, reduced cellular 
metabolism of glucose, and can lead to organ dysfunction via multiple mechanisms. It 
seems to be a risk factor for increased mortality and morbidity in patients undergoing 
liver resection. Diabetic patients have increased risk of non-alcoholic fatty liver disease 
(NALFD)(220). Patients requiring insulin have been reported to have higher operative 
times, transfusion rates and prolonged ventilation requirements after liver surgery – all 
which are independent risks for complications. Tablet controlled diabetes, however do 
not seem to have any particular risk of these factors, which Gedaly and colleagues 
believe is due to tablet controlled diabetic patients having better glycaemic control, and 
their diabetes less severe than those requiring insulin(221). Wiggans and colleagues 
found that diabetic patients had three times increased 90-day mortality and doubled 
increased risk of developing acute kidney injury (AKI). They did not comment on any 
 
11 Bradford-Hill’s criteria to show association is due to causation were strong strength of association, 
consistency between studies, specific exposure leading to outcome, correct time association, evidence 
of a exposure/response biological gradient, and plausibility of explanation. 
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association between diabetes and PHLF specifically, but given its association with 
increased mortality, it can be considered as contributing to a PHLF syndrome – as death 
would count as PHLF in its severest form(222).  
Renal insufficiency 
Wiggans and colleagues also reported development of renal insufficiency increases 90-
day mortality from 2.7% in patients with no immediate complications to 10%; as risky as 
PHLF itself. When AKI and PHLF are both present, mortality leaped from 10% to 
45%(222). Regarding chronic kidney disease (CKD), there doesn’t seem to be any prior 
clear studies into its effect on liver surgery specifically, but it is mentioned as a risk factor 
for PHLF in some publications(146). CKD and AKI are felt to be highly intertwined with 
each other, and each is a risk factor for the others development(223). It seems plausible 
given the associated outcomes that CKD should be viewed with concern for PHLF, even 
if no study until present had examined this independently. 
Obesity 
Obesity is the pandemic of our times, with over a third of the population in Western 
countries, such as the USA, being obese(224). There have been conflicting results 
regarding obesity and surgery; with evidence that complications such as wound 
infections are more common in obese patients(225) however there is compelling 
evidence that obesity itself does not increase risks of general surgical operations(226). 
Liver surgery, however does present a different case; as obese patients are more likely 
to have steatosis of the liver(227) and steatosis seems to have a deleterious outcome 
on liver surgery(228) it can be extrapolated that obesity is a risk factor. Certainly, obese 
patients undergoing liver resection have longer operations, more transfusions and longer 
hospital admission than non-obese patients(221). 
Chemotherapy 
Pre-operative use of chemotherapy is commonly used in metastatic disease and for 
CRLM. It can be used for regression and reduction of tumour burden in the 
liver(142)(155). Many commonly used agents for CRLM are associated with liver injury 
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and chemotherapy induced liver injury (CILI) (see table 13 below). Development CILI is 
a risk factor for PHLF due to the chemotherapy agent’s injury to liver parenchyma, 
sinusoidal dilatation (termed sinusoidal obstructive syndrome or SOS), atrophy of 
hepatocytes, and/or hepatocytic necrosis. This leads to impaired function both in the 
short term, and potential development of chronic liver disease(229)(230)(231). If liver 
injury is seen, reflected in elevated bilirubin beyond normal reference ranges (over 
20µmol/L), it will lead to a delay in operation until any recover is seen, or even render 
the patient inoperable, or reduce the extent of resection possible(232)(233)(234). Most 
centres including Leeds will always delay surgery for at least 6 weeks following 
chemotherapy administration to hopefully allow time for the liver to recover from any 
actual or potential CILI. 
Table 13 - Commonly used chemotherapy agents in CRLM(142) 
Chemotherapy agent Associated with CILI 
5-Fluorouracil (5-FU) Yes(142) 
Capecitabine no(232) 
Irinotecan yes(231) 
Oxaliplatin yes(231) – associated with SOS 
Trifluridine and Tipiracil no(233) 
 
Hepatitis, fibrosis, and cirrhosis 
A significant amount of resection is for primary cancers, particularly in East Asian 
countries. This is often related to the development of cirrhosis due to viral hepatidies. In 
particular Hepatitis B(235)(236) and C(237)(238) are strongly associated with cirrhosis 
and the subsequent development of HCC requiring a liver resection(239). As cirrhosis is 
defined by the development of liver dysfunction in both synthetic or excretory roles, it is 
evident that its presence would have increased risk of PHLF as such patients are already 
in a clinical state of liver dysfunction, its risks have been well documented(1)(3)(240). 
These patients will have impaired excretion and may be jaundiced, and have impaired 
synthesis, and may be coagulopathic. Pre-operative hyperbilirubinaemia in itself (either 
in absence or presence of cirrhosis) was found to have six-fold increased risk of death 
after liver resection(241). As a result, any obstructive biliopathy (such as tumour 
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associated bile duct obstruction) is generally relieved prior to surgery because of this 
increased risk. 
It is possible for patients with cirrhosis to develop CRLM and all patients are screened 
for it prior to surgery(242). Consumptive thrombocytopenia due to the associated 
splenomegaly seen in cirrhosis (due to portal hypertension and venous engorgement of 
the spleen)(229) and coagulopathy before surgery is associated with an increased 
relative risk of death of 2.7 times(219).12 
The risk of surgery on patients with fibrotic liver disease, which is a precursor to cirrhosis 
development, can increase risk of PHLF development due to fibrosis reducing the rate 
of liver regeneration(190)(228)(243)(244). 
Malnutrition 
Malnutrition can refer to either undernutrition which leads to wasting and micronutrient 
deficiency, or overnutrition – obesity which has been discussed above. In this section, 
the focus is on undernutrition: weight loss >10% was associated with a 3 times increased 
mortality risk (5% vs 15%) in the elderly(219). In the UK, the malnutrition universal 
screening tool (MUST) score has been adapted in almost every hospital as is regarded 
as the current gold standard for nutrition screening(245). High MUST scores are 
associated with poorer outcomes in the national emergency laparotomy audit (NELA) 
data on emergency surgery(177). It is worth noting there is a proposed study upcoming 
– the NURIMAS study that is to investigate malnutrition and liver surgical candidates 
prospectively(246). 
Lung disease 
Formally diagnosed chronic obstructive pulmonary disease (COPD) increases risk to 3 
times that of non-COPD patients (219). Undiagnosed lung disease (evidence of  
dyspnoea on minimal exertion) and smoking is associated with 1.7 times increased risk 
 
12 This does not include patients who are deliberately anticoagulated 
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of mortality(241). This association ties into the results of CPEX testing discussed in the 
section on pre-operative risk stratification(174). 
Age 
Age is a contentious risk factor for surgery in general and also in liver surgery. Historically 
patients of advancing age, termed ‘geriatric’ patients, were excluded from being 
considered for surgery, a form of ageist discrimination. This has improved recently, but 
no doubt still exists to some degree(247). In the UK, the NHS has mandated there is no 
age discrimination in their charter(248). There is limited evidence on ageing and surgery, 
due to elderly patients being excluded from high quality research studies and only 
reported in anecdotal or limited series(249).  
It is known that our population is getting older as people are living longer. Following 
efforts to tackle age discrimination and investigate outcomes of elderly patients, multiple 
studies investigated age and outcomes, and there is evidence on both sides of the 
argument, some saying the risk is much higher than the younger population, some 
stating risk is acceptable for oncological surgery and as beneficial as for the younger 
population. Others say risk remains significantly high and as a result careful patient 
selection is required. A summary of such publications is found in table 14.  
The overall number of patients who are elderly and have surgery is now higher than ever. 
Several of the later published studies below rely on large national databases of disease 
outcomes, morbidity, and mortality. Such databases are highly useful and important for 
understanding outcomes when there are relatively few cases of procedures done in 
limited centres, but do have their drawbacks, namely the possibility of missing values, 
incorrectly entered data, curse of dimensionality, and lack of bias control. Such 
databases cannot test causality, resulting from residual confounding and reverse 
causation effects, and so such studies should be interpreted carefully with vigilance(250).  
One issue with many reports is the use of arbitrary cut-off ages. Over 65, over 70 and 
over 75 are frequently given as the nominal binary representation between ‘old’ and 
57 
 
 
 
young’ which muddies the ability to compare different studies. Study heterogeneity leads 
to difficulty in translation, with 20-year variation in the various studies’ definition of elderly.  
If age is to be investigated as a risk factor, a more quantitative continuous approach, 
rather than discrete analysis is required to understand its impact.  
Table 14: Comparison of the effect of age on surgical outcome 
 Type of 
Surgery 
Elderly 
definition 
(age) 
Number of 
participants 
Reported 
Morbidity % 
Reported 
mortality % 
Authors conclusion of acceptable risk of ageing 
Dunlop(251) All >65 8,899 8.3 4.1 
Leung(252) Non-cardiac >70 544 11.2 3.7 
Adam(253) Oesophageal >80 31 22.5 16 
Patel (Meta-analysis) 
(254) 
Colorectal 65-74 11,625 19 1.8x13 
75-84 9,232 23 3.2x 
>85 2,735 25 6.2x 
Stroumbakis(255) Urology >80 44 51 4.5 
Susini(256) Gynaecology >70 213 17 2.8 
Djokavic(257) All 80 500 Not 
reported 
6.2 
Authors consider increased risk 
Liu(258) All 80 367 25 4.6 
Massarweh(259) Intra-
abdominal 
65-69 29,705 14.6 2.5 
70-74 27,094 16.1 3.8 
75-79 21,032 18.8 6 
80-84 13,855 19.9 8.1 
85-89 6,851 22.6 12.6 
>90 2,781 22.7 16.7 
Marusch(260) Colorectal >80 2,932 43.5 8 
Due to the findings of such studies, surgery in the older population is considered 
acceptable, but with increased risks of morbidity and mortality and patients will need to 
be counselled carefully so they can make an informed decision if they wish to undergo 
surgery. The use of the previously discussed adjuncts of pre-operative assessment are 
highly important to be able to appropriately convey risk. 
Liver surgery represents a separate issue. Tzeng and colleagues reported that older 
patients have reduced physiological reserve and thus a reduced speed of hypertrophy. 
They reported that older patients had increased morbidity (23.9% vs. 18.4%); more than 
 
13 This study did not report the actual mortality, just the increased relative risk the <65-year-old 
group 
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double the mortality (4.8% vs. 2%), and for patients who developed a complication they 
were twice as likely to die than younger patients (20% vs 10%)(219).  
From a physiological point of view, it has been demonstrated previously that older people 
have a slower rate of liver regeneration(133). Older patients have a higher baseline 
bilirubin level than younger people, which may reflect a global reduction of excretory 
function(261). Cieslak and colleagues demonstrated impaired function in older patients 
using their Technetium-99m-mebrofenin study(262). Age can be considered a risk 
factor for surgical complications. However, many studies have reported safe outcomes 
in elderly patients (see table 28), and so increasing numbers of patients are being 
considered for surgery. The difficulty arises due to knowing the extent of liver resection. 
A patient who has a small metastatectomy with a couple of millimetres of liver 
parenchyma surrounding and a FLR of >95% will not have to endure the physiological 
insult of a right hepatectomy where the FLR is ~40%. Many of the studies reported 
include all sizes of resection, minor and major. This makes conclusions much more 
difficult to translate to major resections in the elderly, as a major resection and a minor 
resection may well behave very differently in the post-operative period. 
The uncertainty of the true impact of ageing, and of other risk factors on the outcomes 
of liver surgery leads to the study to address these highlighted issues, described in 
chapter 3, which investigates age as a primary risk factor. This included only major 
resections and examines age to determine if there is any increased risk of PHLF, and if 
so, at which age could be considered a threshold point, and to ascertain the outcomes 
related to older patients and development of PHLF. 
2.2.9 Intraoperative risks 
Blood loss and transfusion 
Intraoperative transfusion rates in patients who have liver resection is a marker of 
operative complexity – certainly it is seen more in major resections due to large vessel 
ligation and the extent of parenchymal division and injury. Transfusion is used when 
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there is clear blood loss, which will lead to intra-operative hypotension. Menon and 
colleagues found a hazard ratio of 2.4x risk to life when >3 units were transfused(263). 
Tranchart found patients with intra-operative transfusion during liver surgery had a post-
operative complication rate of 33% vs 2% for patients not requiring transfusion (264).  
Hypotension in surgery can lead to organ ischaemia which can adversely impact on the 
liver’s regenerative ability(130). It may induce an effect like ‘hepatic shock’ or ischaemic 
hepatitis, whereby prolonged hypoperfusion causes ischaemic hepatocyte necrosis in 
the pericentral area (zone 3) - centrilobular hepatic necrosis. Interestingly this leads to 
marked transaminase increases initially rather than raised bilirubin, so cannot solely 
explain the features of PHLF, but certainly hypoperfusion is best avoided in 
surgery(265)(266). 
Massive transfusion reactions have only recently been examined for their physiological 
effects, but it is now known than multiple transfusions can in themselves make a patient 
coagulopathic, acidotic, hypocalcaemic, hyperkalaemic and hypothermic(267) – all that, 
if uncorrected leads to continual blood loss unless reversed. This is essentially the ‘triad 
of death’ that has been observed in major trauma patients(268).  Jin and colleagues felt 
that the metabolic effects of transfusion were deleterious in liver surgery, especially that 
the liver itself has its own role in coagulation and thermoregulation and the two combined 
could lead to PHLF(213). 
2.2.10 Post-operative risk 
Post-operative bleeding 
As with intra-operative blood loss and transfusion use, the main risk of post-operative 
bleeding is hypotension and subsequent organ ischaemia. Jarnagin and colleagues 
found an increased relative risk of 1.35 of complications when patients had a bleed post 
operatively(146). The best way to avoid this is careful intra-operative haemostasis, and 
monitoring and correction of coagulation and electrolyte disturbance post-operatively. 
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Post-operative infection 
There is a risk of infection following abdominal surgery. Common sites are chest, (due 
to reduced inspiration caused by pain), surgical site infection, urinary (from 
catheterisation of patients) and intra-abdominal collection/abscess14. Tzeng and 
colleagues reported intra-abdominal infection was found to have an increased PHLF risk, 
associated with prolonged hospital stay after liver surgery (219).  
It is established that the liver is liable to be injured in sepsis. The liver has a role in 
bacterial clearance in bloodborne infections and sets off a pro-inflammatory 
response(269) but pathogens, toxins, or inflammatory mediators can also cause liver 
injury and cellular necrosis. Counterintuitively, the liver can respond to bacteraemia 
associated with infection with an immunosuppressive effect; a function believed to be 
related to the balance of commensal gut bacteria – to prevent destruction of this 
important ecosystem if bacteria translocate haematologically(270). Either over 
expression of the pro-inflammatory response with subsequent ‘cytokine storm’ and liver 
injury or excessive immunosuppression release can exacerbate liver injury(271). Add 
into the mix that the liver size and function is reduced, it can potentially lead to either 
promotion of infection, or an infection causing liver injury and PHLF. Increased infection 
rates in patients with small FLR have been observed, and the authors in those studies 
felt this was due to the overall reduction in Kupffer cells and their role in innate 
immunity(272) and reduction of cellular signal production, particularly IL-6(273). 
 
 
 
 
 
 
14 Remembered by medical students as ‘winds, waters and wounds’ 
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Table 15: Risk factors associated with development of PHLF (from Kauffman(6)) 
Patient related Surgery related  Post-operative management  
Diabetes mellitus Blood Loss >1,200 mL Post-operative haemorrhage 
Obesity Intra-operative transfusions Intra-abdominal infection 
Chemotherapy-
associated 
steatohepatitis 
Need for vascular resection  
Hepatitis B, C >50% liver volume resected 
Malnutrition Major hepatectomy 
including right lobectomy  
Renal insufficiency Skeletonisation of 
hepatoduodenal ligament  
Hyperbilirubinemia <25% of liver volume 
remaining Thrombocytopenia 
Lung disease 
Cirrhosis 
Age >65 years 
 
All risk factors described above are now considered when planning surgery. If at all 
possible, these are either corrected or accounted for during surgical planning. However, 
despite correction, PHLF still occurs; indeed, sometimes patients with few or no risks 
may develop it, and others with multiple did not. A study into the extent of risk factors in 
development of PHLF in major liver resection patients was required. This is the rationale 
for the study described in chapter 3. 
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2.3 Current and alternative methods of determining liver function 
Liver function is a complex, involving synthetic, excretory, and detoxifying functions 
and as such it is difficult to state one simple process of stating how the liver is actually 
working(5). As a result, many different methods have been described, each with its 
strengths and drawbacks, and these will be discussed below in sections 2.3.1-2.3.4. 
DGE-MRI is a novel imaging-based assessment of liver function which could provide a 
solution to the drawbacks of currently available methods. It has yet to be investigated 
whether it has any benefits over current function assessments in a surgical population. 
Chapters 4 and 5 describe the results of studies assessing the utility of DGE-MRI in 
patients undergoing liver resection. 
2.3.1 Global measures 
Indocyanine Green (ICG) 
This is commonly used in other countries such as Japan(12)(274), but isn’t currently 
licenced in the United Kingdom for hepatic assessment. ICG is a dye that binds to 
albumin in the plasma and subsequently is exclusively taken up by hepatocytes via 
organic-anion-transporting polypeptide (OATP) 1B3 and sodium-taurocholate co-
transporting polypeptide 15. It is excreted unchanged into the bile by the multidrug 
resistant protein (MRP) 2. These are the same receptors involved in bilirubin metabolism 
and excretion. It is not reabsorbed via the entero-hepatic circulation, therefore follows 
simple pharmaco-dynamism (12)(275).  
Following injection, an interval sample is taken (at 15 minutes post injection) to determine 
the retention fraction – the amount of ICG remaining in the blood that hasn’t been 
excreted(276). It has been shown that a high ICG retention fraction is associated with an 
increase in mortality for patients having liver resection for HCC(277). This test is non-
toxic in the administered doses of 2mg/kg (lethal dose in 50% (LD50) is 50-80mg/kg)(12) 
and provides an excellent measure of global liver function. It has mostly been used to 
assess patients with parenchymal liver disease. It can only be used as a discriminator 
for patients with already severe liver dysfunction as to whether to even attempt surgery. 
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In isolation with a patient with supposed normal functioning liver it would be difficult for 
ICG to be able to help in risk stratification. 
Galactose Elimination Capacity Test (GECT) 
This test is performed in a similar fashion to the ICG test; a substrate is injected 
intravenously, in this case galactose. It differs from ICG by the measurement of 
galactose’s breakdown products rather than the substrate itself. Galactose is 
phosphorylated intracellularly by galactokinase to galactose-1-phosphate, which in turn 
is converted to glucose-1-phosphate (G1P) within the liver. G1P is  then measured 
directly(278).  An interval blood test is taken at around 20-50 minutes and the G1P levels 
are determined(279). In states of fasting or where there is concurrent liver regeneration 
there is a high false positive result(280). As with ICG, this would only give a global liver 
function and has the same limitations. It cannot not be used to determine the extent of 
surgery, only if there is enough function to even consider surgery(281). 
LiMAx test 
This method, available since 2008, uses radioactively labelled 13C-methacetin – a 
prodrug for paracetamol that is metabolised throughout the liver by cytochrome P450 
1A2 enzyme with the release of the labelled 13-C. This is excreted as 13-CO2, which can 
be measured in the patient’s respiratory expiration. 
The lower the expired value seems to indicate reduced liver metabolism and function, 
and as such has proven useful in being able to exclude patient from surgery or lead to 
altered surgical planning given the degree of the LiMAx result(282). 
It can be used in two ways: initially it can be used to risk stratify patients into: 
• low risk (LiMAx >315µg/kg/h) → suitable for surgery 
• moderate risk (140-315 µg/kg/h) → risk stratification via combined assessment with CT 
volumetry 
• high risk (<140µg/kg/h) → unsuitable for surgery 
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Should a patient fall into the moderate risk group a comparison of a CT measured FLR 
volume compared to the LiMAx for the FLR can be used to allow a risk stratification: 
• <80 µg/kg/h – unsuitable for surgery 
• 80-100 µg/kg/h - critical resection (parenchymal preserving) 
• 100-150 µg/kg/h – feasible resection 
• >150 µg/kg/h – regular resection 
The utility of LiMAx has been demonstrated by Jara and colleagues who reported that 
following their implementation of LiMAx testing by the above method they reduced their 
incidence of PHLF and mortality – they attribute this to the LiMAx allowing improved 
patient selection for resections(283).  
LiMAx does provide an excellent stratification of risk for surgical candidates and it is 
much more commonly being used for this purpose. At the time that the present study 
was designed and recruited its participants it was not being used in Leeds either in 
patient selection or in conjunction for study, and therefore its relationship to the findings 
of DGE-MRI in chapter 5 cannot be compared. 
2.3.2 Anatomical assessment 
These methods use imaging providing a more detailed assessment of the liver and 
involve radiological imaging as part of the investigation. These methods are the most 
comparable in principle to our proposed mode of investigation DGE-MRI, although they 
rely on other modalities of imaging, from nuclear medicine studies to CT. 
Galactosyl Serum Albumin Scintigraphy (GSA) 
This is a nuclear medicine technique, in which 99m-technetium (99mTc) labelled GSA is 
injected intravenously. GSA is an analogue ligand of the Asialoglycoprotein (ALG) that 
binds to ALG receptors expressed on hepatocytes cell membranes on the sinusoidal 
surface facing the space of Disse. ALG receptor expression is decreased in chronic liver 
disease; therefore, uptake of GSA into the liver (given as a ratio of hepatic uptake 
compared to that observed in the circulation) is reduced in this case after 15mins(284). 
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It has been investigated in chronic liver diseases(285). Despite combinations with CT 
scans to provide increased anatomical information (286) this has proved inadequate and 
method can only distinguish vague regional liver function, therefore it is unable to provide 
the level of anatomical and region function that is required(274). In addition, it is only 
approved for use in Japan and is unavailable in the UK at present, and therefore cannot 
be studied locally(280). 
Technetium-99m Mebrofenin Hepatobiliary Scintigraphy 
Radioactively labelled Mebrofenin is an albumin-bound substrate taken into hepatocytes 
by OATP1B1 and B3 and excreted by MRP2, (again like bilirubin, ICG and Gadoxetic 
Acid (287)). This has been shown to provide some anatomical difference in function, and 
has demonstrated a correlation between predicted function remnant liver preoperatively 
and postoperatively, as well as biliary excretion assessment(288). The images this 
method produces tend to be low resolution and the quality in detailed anatomy required 
to differentiate segments is difficult. Analysis is limited to demonstrating heterogeneity 
between left and right lobes only, which could be useful for left and right hepatectomy 
patients. Studies by Cieslak and colleagues(13) have demonstrated combination with 
CT scans increases accuracy of regional liver function (274), and subsequent the ability 
to predict post-operative outcomes(289). The combination with single photon emission 
Computed Tomography (SPECT) and CT minimises patient exposure to ionising 
radiation(286), Alternative methods such as DGE-MRI have potential benefits over 
Mebrofenin scintigraphy if it can demonstrate the same predictive capacity without 
radiation exposure. 
CT Volumetry 
This is the most utilised method locally in Leeds and within the UK. It cannot measure 
function per se; but relies on the concept that the liver’s volume and function can be 
correlated. This is the most common radiological assessment for surgical planning(11). 
This involves calculation of the volume of the liver, and the volume of the FLR. Freehand 
drawing of total liver volume (termed standardised liver volume or SLV) and predicted 
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FLR(290). A percentage of FLR can be calculated, and operative decision making to 
allow sufficient FLR volume and avoid small for size liver remnant. Automated computer 
modelling is available and is equivalent to freehand methods; automation is much quicker 
and can be used to assess many patients in a timely manner(291). 
There have been studies that demonstrate CT volumetry’s benefit; when the FLR value 
is low, it has been associated with PHLF and complications. Schindl and colleagues 
showed a threshold of 26.6% for FLR volume was associated with poor patient 
outcome(4) and Kishi and colleagues showed 20% as their critical FLR for PHLF 
development(292). It assesses the volume of the liver in millilitres (or cm3) and can 
predict the amount of volume that is to remain after resection. It can also be used to 
measure the degree of liver hypertrophy after PVE, with decisions about whether new 
growth has been adequate based on the volumetry of the new FLR post-embolisation 
(e.g. volume of segments 2 and 3 if an extended right hepatectomy is required).  
One potential drawback with this method is it assumes that liver volume and liver function 
are equivalent, and function is homogenously distributed. Ribero and colleagues 
compared the outcome of patients with a measured FLR volume (called the mFLR) 
compared to an estimated FLR based on their weight and body surface area (BSA) with 
the following calculation: 
𝑒𝑇𝐿𝑉 (𝑐𝑚3)  = −794.41 +  1267.28 ×  𝐵𝑆𝐴 
BSA was calculated using weight and height according to the Mosteller formula(293): 
𝐵𝑆𝐴 =  [𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)  ×  ℎ𝑒𝑖𝑔ℎ𝑡 (𝑐𝑚) ÷  3600]1/2 
They found that 11% of patients who had an adequate mFLR developed some degree 
of PHLF, and these would have been detected by using the eFLR method, which 
suggests measured volumetry isn’t as robust as it needs to be, that even when patient’s 
measure FLR volume was expected to be enough, it wasn’t. This fact becomes 
particularly important around the threshold values for accepted FLR; those with a 
measure FLR volume 20-30%(10). It is plausible that such patients may have enough 
remnant volume, but that volume is not functioning adequately or, if that liver’s 
regenerative capacity is diminished for some reason.  
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Another issue with CT is the significant ionising radiation burden which is a proven 
carcinogen(294). CT imaging in patients who already have a diagnosis of cancer is often 
the desired modality. In these patients the benefits of CT for diagnosis outweighs the 
small associated risk of the radiation, particularly as the ‘lead time’ from exposure to 
malignant transformation can be decades(295), but certainly for younger patients (such 
as those in their 30s or 40s) who undergo treatment with a curative intent for CRLM then 
it is worth considering this increased risk in their surveillance strategies. Other modalities 
that do not require ionising radiation doses should be considered(296), for which MRI 
could be a suitable alternative. 
2.3.3 Concept of liver inhomogeneity 
There was an assumption that liver function was homogeneous throughout, giving a 
rationale for volumetry(297). Global measures have been useful in predicting hepatic 
reserve, as a result the amount of liver to leave as the FLR was one that was calculated 
by algebra – if a person required a certain critical threshold FLR, then the volume that 
could be removed would be calculated by subtracting the FLR-volume from the total liver 
volume(297). Shoup and colleagues reported <25% FLR is associated with PHLF15 
however 2 patients out of their series of 126 had less than <25 and were clinically fine, 
and conversely 20 patients with >25% FLR developed PHLF(197). There is no clear 
answer why some will be fine post-operatively despite being small of size, and the others 
with ‘acceptable’ FLR developed dysfunction. One possible explanation is that rather 
than uniform distribution of function, there is inhomogeneity of function – certain parts or 
segments of the liver work better than others, known as a Functional Bias. This is where 
a patient’s liver per unit of volume is either over- or under-functioning relative to its 
volume. 
 
15 Albeit a different definition for PHLF, defined by the authors as prothrombin time greater than 18 
seconds or serum bilirubin level greater than 3 mg/dl. This definition was discussed in more detail in the 
section describing 56 various methods reviewed by ISGLS 
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In studies examining perfusion and functional uptake of contrast agents in cirrhotic liver 
diseases such as in Nilsson and colleagues studies on primary sclerosing 
cholangitis(298), primary biliary cirrhosis(299), alcohol or viral induced cirrhosis(300) 
there was differences between areas affected by the disease having inhomogeneous 
perfusion and uptake of contrast. It has been suggested in a simulated study of left 
hepatectomy, those with inhomogeneity in their FLR would have a lower measured 
function(301). These studies involve patients with established liver disease with impaired 
clinical and biochemical dysfunction. It is much less clear if those patients with either 
normal livers or patients with CRLM who appear to have normal liver have any 
inhomogeneity. The fact that some patients who have resection of CRLM develop PHLF 
despite pre-operative planning does lead to some credence that some factor is leading 
to this(215); a patient which adequate FLR volume who still develops PHLF is difficult to 
explain, unless the FLR volume is under-functioning – a functional bias in favour of 
function < volume. This idea that function is inhomogeneously spread – where the 
volume is adequate there has to be a ‘small function for size’ concept. 
Figure 6: Uptake in a healthy volunteer showing homogeneous uptake (images from S 
Sourbron, University of Leeds, data from H Nilsson, Karolina Institute, Stockholm) 
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Figure 7: Uptake in a patient with PSC showing inhomogeneous uptake, with under-
functioning left hemi liver (images from S Sourbron, University of Leeds, data from H 
Nilsson of the Karolina Institute, Stockholm) 
 
2.3.4 Dysfunction Scoring models 
Risk stratification based upon clinical parameters are easily determined and have been 
extensively evaluated for their benefits in patients with established liver disease. They 
are proven to have important prognostic roles in such patients, but they cannot be utilised 
in patients with apparently normal or sub-clinical liver problems. 
Child Pugh Score (CPS) 
This scoring system was originated in1963(302) and  was modified to include coagulation 
parameters in 1973(303). It has been used and is known to predict mortality in patients 
with chronic liver disease from multiple aetiologies. It is simple to calculate, using 
objective data routinely measured in patients (tables 16-18). The original cohort of 
patients were surgical, however they were not undergoing liver surgery itself, instead 
they were having other operations and had liver disease as a comorbidity. 
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Table 16: Child Pugh Score 
 Score 
1 2 3 
Hepatic encephalopathy grade None 1-2 3-4 
Serum bilirubin (μmol/l) <35 35–50 >50 
Serum albumin (g/l) >35 35–28 <28 
Prothrombin time prolongation (s) <4 4–6 >6 
International normalized ratio <1.7 1.7–2.3 >2–3 
Ascites Absent Mild–moderate Severe 
 
Table 17: CPS and predicted mortality16 
Child-Pugh grade % Survival 
   1 year 5 years 10 years 
A (5-6) 84 44 27 
B (7-9) 62 20 10 
C (10-15) 42 21 0 
 
Table 18: West Haven Criteria for Hepatic Encephalopathy 
West Haven Criteria for Hepatic Encephalopathy (209) 
Grade Features Asterixis 
0 No abnormality detected Absent 
1 Impaired higher function  Usually absent 
2 Lethargy, personality change, inappropriate behaviour, and 
disorientation 
Usually present 
3 Confusion and gross disorientation, increased somnolence Present 
4 Coma Absent 
This method, although simple and validated, can only be used for patients with 
established liver disease. For patients who are otherwise well with presumed normal liver 
(apart from their metastatic burden), it cannot be used. Any patient with evidence of pre-
surgery liver dysfunction was excluded from the analysis in the forthcoming chapters an 
so CPS scores in those cohorts would be not applicable.  
MELD/UKELD 
The Model for End-stage Liver Disease was developed to assess prognosis following 
trans-jugular intrahepatic portosystemic shunt (TIPS) for portal hypertension(304), and 
 
16 This table’s risk of death is not related to surgery specifically, it is all cause mortality. 
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then applied to patients with cirrhosis on the liver transplant waiting list for prognostic 
purposes(305). 
𝑀𝐸𝐿𝐷 = 3.8 ∗ 𝑙𝑛(𝑏𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛[𝑚𝑔/𝑑𝐿]) + 11.2 ∗ 𝑙𝑛(𝐼𝑁𝑅) + 9.6 ∗ 𝑙𝑛(𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒[𝑚𝑔/𝑑𝐿])
+  6.4 ∗ (𝑎𝑒𝑡𝑖𝑜𝑙𝑜𝑔𝑦: 0 𝑖𝑓 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑎𝑡𝑖𝑐 𝑜𝑟 𝑎𝑙𝑐𝑜ℎ𝑜𝑙𝑖𝑐, 1 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒) 
The UKELD is a later modification that includes the serum sodium level, specifically for 
transplant waiting list mortality(306): 
𝑈𝐾𝐸𝐿𝐷 = [(5.395𝑥𝑙𝑛(𝐼𝑁𝑅)) + (1.485𝑥𝑙𝑛(𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒)) + (3.13𝑥𝑙𝑛(𝑏𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛))
− (81.565𝑥𝑙𝑛(𝑠𝑜𝑑𝑖𝑢𝑚))] + 435  
As with CPS, this has proven useful for established cirrhotic disease, and as such is 
frequently used by transplant teams during allocation and for risk assessment of patients 
with a scarcity of liver donors. It has little role in those with no known liver disease. As a 
result, they are of limited use in patients who have no evidence of liver dysfunction, such 
as patients with resectable colorectal liver metastasis. 
Despite the availability of these methods, none can be applied to population of patients 
who require liver resection for CRLM; this is a population who normally have biochemical 
markers in the normal reference range. CPS, MELD and UKELD are global measures 
that can only lead to a risk stratification of suitability to undergo surgery for patients with 
established liver disease, and the alternative measures of liver volumes and function are 
either not able to give good anatomical assessment of segments or rely on the concept 
that volume and function are equal throughout the liver, which may not be the case. One 
potential solution to these issues is the development of MRI imaging with dynamic 
contrast enhancement (DGE-MRI). 
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2.4 Magnetic Resonance Imaging 
MRI is a widely available modality with excellent diagnostic sensitivity and specificity 
(table 3). The scientific principles of MRI are described in below in chapter 2.4.1.  
Recently developed liver-specific contrast agents such as Gadoxetate have improved 
the quality of liver MRI and it is seen as essential for liver cancer staging(96). The 
mechanism of action of contrast agents and why gadoxetate is effective for function 
assessment is discussed in chapter 2.4.3.  
Acquisition sequences can be readily modified to obtain dynamic imaging which can be 
used to assess function per segment, without compromising high quality diagnostic 
imaging. It may offer a more robust pre-operative assessment of function, with the 
development of DCE-MRI and quantitative functional assessments. The development of 
DGE-MRI acquisition in described in chapter 2.4.5. 
2.4.1 How MRI Works 
A hydrogen atom (H1) consists of a single proton nucleus, so has a positive charge. It 
will demonstrate a phenomenon known as ‘spin’ when an external magnetic field is 
applied. Application of a magnetic field of sufficient strength to the proton will align the 
spin and the atom will move much like a gyroscope – a so called  “precession of spinning 
magnetic dipolar structure with a magnetic vector”(307). This speed of precession, also 
called the Larmor frequency, is proportional to the strength of the external magnetic field, 
and is calculated by the following Larmor equation: 
𝜔 = −𝛾𝛣 
• ω = angular frequency (MHz) 
• γ  = gyromagnetic ratio (MHz/tesla) 
• Β = magnitude of the applied magnetic field (tesla) 
If the energy of magnetic pulse (delivered by an external Radiofrequency (RF) coil such 
as one contained in an MRI scanner) has the same frequency as the Larmor frequency 
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then hydrogen protons will align and precess (rotate) in-phase, in a state called 
longitudinal magnetisation. If the RF pulse is longer and stronger it will cause the 
magnetization vector to flip to 90° and the atom’s precession moves sideways, which is 
called transversal magnetisation. When the RF pulse stops, the spin will ‘relax’ and 
return to its resting state and release a small amount of energy which can be measured, 
hence an MRI scanner is able to detect this energy signal. Any molecules containing 
hydrogen, such as water (H2O) are strongly affected by magnetism; and as the human 
body is abundant with water it allows use of MRI to delineate tissues, based on the extent 
of water content contained within them. 
Those atoms that have been spinning longitudinally will return to their relaxed state 
(regaining their magnetic vector) on cessation of RF, and the time it takes for the 
magnetic vector to return to 63% of its original strength is known as the longitudinal 
relaxation time or T1 relaxation. 
Those atoms precessing in-phase will lose this on cessation of RF and revert to their 
normal position, losing their transverse magnetisation. When they have lost 37% of the 
maximal magnetism, this is called ‘transverse relaxation’ or T2 relaxation(307). 
Different tissues contained within humans will relax at different times based on their 
individual content– this fact allows differentiation of different tissues by the MRI 
depending on the time of the relaxation. 
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Figure 8a and b: Strength of magnetisation for T1 and T2 relaxation in different tissues 
 
 
T1 is longer than T2 in most tissues. Generally T2 times are longer in liquids than in fat, 
which in turn is longer than muscle or liver which is important when imaging different 
tissues(308). Tissue that has more liquid contained within will have a longer T2 time and 
so can be distinguished from the surrounding liquid-less structures and will appear 
differently. The classical teaching to surgeons (who are not trained beyond the basics in 
MR theory) is that T1-weighted imaging provides better anatomical delineation, and T2-
weighted imaging demonstrates pathology due to the increased enhancement of fluid 
that is seen in inflammatory disease processes and oedematous tissue. DGE-MRI 
typically uses T1-weighted images as the basis for analysis(218) 
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Figure 9 – The difference in T1 relaxation time in fat vs. water  
 
2.4.2 MRI and Liver Imaging 
MRI and diagnostic liver imaging has been reported as far back as 1988(309) and has 
become a mainstay of liver disease diagnosis. It is often for staging for metastatic 
disease, and is highly useful in distinguishing equivocal lesion seen on CT to know if 
they are benign or malignant (310). See table 3 for sensitivity and specificity for CRLM 
diagnosis. 
Given the complex anatomy and physiology of the liver; the dual inflow, the metabolic 
and excretory functions, and structure it is widely accepted that order to obtain diagnostic 
images, the MRI is used in conjunction with a contrast agent(14). Contrast agents are 
adjuncts to enhancing and defining the nature of the liver parenchyma and generally can 
be divided into two types: ‘unspecific extracellular fluid space agents’ and ‘targeted and 
organ-specific agents’.  
2.4.3 Contrast Agents 
MR contrast agents are used to enhance the visibility of tissues by the MRI scanner, and 
are either Gadolinium-based or Iron-Based. Gadolinium is a metal that exhibits 
paramagnetic properties; when a magnetic field is applied, a magnetic effect is observed 
but does not retain magnetism unlike iron(311). Although unbound gadolinium is toxic, 
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when it is chelated it is generally safe for human use(312). The ligands which chelate 
the gadolinium determine its biological behaviour within the body. 
Gadolinium based agents shorten the T1 time of protons, which produces a higher signal 
intensity and therefore ‘enhances’ the contrast between the tissue that the gadolinium is 
within compared to surrounding tissue. 
Iron-based agents, known as superparamagnetic particles of Iron-Oxide (SPIO) are 
taken up by Kupffer cells in the liver. They are useful for distinguishing liver tissue from 
non-liver tissue such as metastases. As metastases are not liver tissue, they will not 
contain any Kupffer cells. However, they cannot determine significant discrete lesions of 
liver origin such as FNH, and they do not provide any information of hepatocytes, and 
therefore cannot be used in studies that relate to function, metabolism and excretion of 
hepatocytes(313). SPIO therefore cannot be used assess function.  
Use of liver specific gadolinium-based contrast agents are most beneficial in assessing 
the metabolism of the liver, and in lesion characterisation. Gadoxetic acid (Gd-EOB-
DTPA) and Gd-BOPTA are the two currently available commercially. 
Gadoxetic acid enters hepatocytes through the organic anion transporting polypeptides 
OATP1B1 and OATP1B3 and exits through the ATP-dependent canalicular membrane 
multidrug resistance protein MRP2, MRP3 and MRP4 – the same receptors and 
transporter proteins that bilirubin17 is metabolised and excreted through. Around 50% of 
Gadoxetic acid is excreted this way, which compared to 3-5% of Gd-BOPTA, the other 
available liver-specific agent(128)(314). Based on the pharmacodynamics of Gadoxetic 
acid, it is the most suitable contrast agent to assess hepatocyte uptake – which is highly 
important for DGE-MRI assessments of cellular function. This increased hepatic 
enhancement allows much better assessment of liver parenchyma, and the rate of its 
 
17 And ICG for that matter 
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diffusion from the extracellular to the intracellular space can reflect hepatocyte 
membrane function – which can be extrapolated to inform us of the cellular function. 
Figure 10: Chemical structure of Gadoxetic Acid 
 
 
Table 19: Non-specific and liver-specific MRI agents (Adapted from Sommer(14)) 
Non-specific contrast agents Liver Specific contrast agents 
Gadopentetate dimeglumine  Ferumoxide 
Gadodiamide Ferucarbotran 
Gadoterate meglumine Mangafodipir trisodium (Mn-DPDP) – no 
longer commercially available 
Gadoteridol Gadobenate dimeglumine (Gd-BOPTA)  
Gadobutrol Gadoxetic acid (Gd-EOB-DTPA) 
Gadobenate dimeglumine 
 
2.4.4 Breathing and MRI 
An important consideration for liver MRI is that the liver moves on breathing. Imaging 
with free breathing (i.e. normal respiration) may degrade image quality and artefact 
formation. Multiple MRI techniques such as diffusion weighted imaging (DWI) will exhibit 
artefacts, increased signal-to-noise and contrast-to-noise problems(315). One solution 
is ‘breath-hold’ sequences, where the patient holds their breath during the period of 
acquisition. However, this method, although it reduces artefacts can restrict image quality 
due to reduced scan duration (typically no more than 20 seconds is feasible), problems 
of the quality of breath-hold, and some patients will simply not be able to hold their breath 
for enough time to be able to image. Another solution is ‘triggered’ or ‘gated’ imaging, 
where acquisition is programmed to occur in a timely manner, such as a phase of 
respiration, or after a period of time. This again can lead to problems due to breathing 
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position drifts and changes in breathing patterns may lead to sequences getting out 
sync(316). The ideal liver MRI would not require breath holding.  
2.4.5 Liver DCE-MRI 
Radiological investigations produce either a static image at one moment in time, such as 
a chest radiograph or can produce dynamic images where imaging occurs over time, 
such as ultrasonography. Most conventional liver MRI imaging is static, allowing a single 
image to be created during a certain time, either during contrast introduction, when 
contrast is in the arterial phase, in the venous phase or delayed after uptake and diffusion 
of contrast agents. 
DCE-MRI is a form of dynamic imaging that has been recently developed to assess liver 
function and perfusion. Multiple studies have reported being ‘dynamic’ and ‘dynamic 
contrast enhanced’ even as far back as 1986(317), however these studies are very 
different in methodology; due to technical limitations and focus on lesion identification 
and bear no impact on current contexts. 
Sommer and colleagues define the aims of DCE-MRI as being the ability to:  
“determine perfusion parameters and quantify the microcirculatory status of 
liver parenchyma and focal liver lesions” by “quantiﬁcation and comparison 
of important parameters of tissue perfusion and tissue characteristics like 
blood (or plasma) ﬂow, arterial blood ﬂow fraction, extracellular volume or 
mean transit time”(14). 
DCE-MRI as reported today is a more robust, reproducible, and quantitative rigorous 
study, was first used in a Rabbit model in 2004 by Ryeom and colleagues, wherein they 
scanned rabbits using Gadoxetic Acid in a DCE-MRI sequence18, followed by the 
induction of liver injury by giving the rabbits carbon tetrachloride. Following a repeat MRI 
 
18 AIF in the aorta, ROI in the liver, FLASH, TR/TE = 11/4.2 milliseconds, flip angle = 15, acquisition time 1 
second, slice thickness = 5 mm, matrix = 128×128, field of view = 120 mm) sequence with 1.5 sec time 
intervals 
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by the same sequence, the authors calculated the hepatic extraction fraction (HEF). After 
this, the rabbits were euthanised for histological examination of their liver to correlate 
between degree of liver injury and their HEF. They found that HEF dropped from 100% 
(defined as the baseline pre-injury level) to ~77%.  
An important methodological improvement described in this paper is the introduction of 
mathematical modelling. Using deconvolutional analysis based on Brown and colleagues 
method(318) to calculate a HEF, this introduced a more objective, quantitative 
assessment of the change in function(319). This methodology was implemented in a 
human study by Nilsson and colleagues shortly after, which showed DCE-MRI was viable 
and able to calculated HEF reproducibly(320). Both studies used a single input, single 
compartment model due to measurement of combined contrast intensity within the liver 
and no differentiation between arterial or venous inflow.  
Nilsson and colleagues have used this model in investigation of different function seen 
in primary sclerosing cholangitis (PSC)(298), primary biliary cirrhosis (PBC)(299), 
cirrhosis(300) and described inhomogeneous functional distribution within the liver(301). 
One drawback for these studies is the acquisition method. These involved participants 
having to perform 41 breath-holds of 12 seconds each, which is a significant burden on 
the participant. A healthy volunteer may do this, but it will become more challenging for 
patients with any respiratory or cardiovascular disease, as their ability to hold breath is 
diminished. Use of this protocol in clinical practice is unfeasible for the majority of 
patients who actually need liver imaging without significant alterations to the acquisition 
methodology. 
This single input, single compartment model is an improvement on previous DCE-MRI 
studies that used ‘semi-quantitative’ measures such as maximal signal intensity (SMAX), 
the time to reach SMAX (TMAX), the half-life (T1/2) and the area under the curve(321). Semi-
quantitative measures are easily calculated but they are not reproducible between 
studies. Values  vary between different contrast agent dose, different body size of 
patients (the ‘dilution effect’), different sequence parameters and imaging sequence, and 
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variation in physiological state lead these to be unfit for quantitative function 
assessment(14). 
Ryeom and Nilsson’s studies were important steps in creating a viable, reproducible and 
precise method of quantitative function assessment. The model they described is 
adequate for an organ like the kidney that has only an arterial inflow (322),  the liver has 
2 inputs rather and the one, and as such cannot fully reflect the liver physiology, and 
can only provide limited perfusion information.  
Materne and colleagues had described a dual input, single compartment model in a 
study using Gadoteric acid (Gd-DOTA), a non-specific liver agent. This model measured 
both arterial and venous inflows and allowed for a physiological delay time (arterial delay) 
to expand the number of perfusion measurements. It assumed continuous and 
impedance-free movement between the capillary bed and the extracellular space of 
Disse which, in normal healthy tissue seems to be the case(323). Gadoxetic acid does 
seem to behave in the extracellular space in the same way as the non-specific 
agents(324). However, in either diseased liver; fibrosis or cirrhosis, or in presence of 
tumour, there may not be such free movement. As a result, Sourbron and colleagues 
enhanced the model to have a dual input, two compartment model(218). The two 
compartments in question are the extracellular compartment (comprising of intravascular 
and extracellular – the space of Disse) and an intracellular compartment (in this case the 
hepatocytes). Another key improvement of this study was the pragmatic use of free-
breathing throughout the DCE-MRI over a 5-minute period using a T1 time-resolved 
angiography with interleaved stochastic trajectories (TWIST) sequence which was well 
tolerated by participants19. An arterial delay is added to separate out the arterial and 
venous signals derived by interpolation(218). 
The dual input, two compartment model has the benefit over the previously described 
models, in that it not only allows direct measurement of both arterial and venous inflow 
 
19 The authors used a sequence with a temporal resolution of 2.2 s, 3D T1-weighted spoiled gradient-
echo sequence TWIST 
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and perfusion, but the use of 2 compartments in modelling can determine function of the 
liver. It allows a pragmatic and tolerable sequence to be obtained and is readily 
reproducible This model had yet to be examined in patients due to undergo liver 
resection, and it was not clear if it can detect more subtle functional differences, as it has 
so far only been applied to patients with diseased livers. It has been reported there is 
correlation with ICG and GSA(274) – well established measurements of hepatic function. 
It may be able to measure function pre-operatively with added benefit of detailed 
segmental assessment. Chapter 4 includes the results of differing models and the effect 
on function and perfusion estimates.  
Figure 11: Example of the dual input two compartment model data curve 
 
Figure 12: Representation of the alteration to MRI acquisition to include DGE data 
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DCE-MRI enhanced with Gadoxetic acid (DGE-MRI) could be used to assess function in 
each segment. By using this segmental assessment and a pre-operative FLR-function 
can be estimated and could be used to predict post-operative function. Chapter 5 
describes a study aimed to investigate this hypothesis. 
Figure 13 – Summary of the various input models used in DCE-MRI Liver (from 
Sommer and colleagues(14)) 
 
 
 
 
 
 
 
 
Table 20: terms used in DCE-MRI 
HEF The amount of contrast agent removed from the extracellular space by the liver over 
time 
SMAX Maximum signal intensity 
TMAX Time taken to reach maximum intensity 
T1/2 Time until the signal has decayed to half the maximum strength 
AUC The area under curve 
 
2.4.6 Current role of DGE-MRI and future developments 
DGE-MRI continues to develop with improving acquisition methods, and the use of 
gadoxetate has proven to be the most effective liver-specific contrast agent for function 
Key: 
FA - arterial inflow 
FV - venous inflow 
VP - plasma (in capillary bed) 
volume 
VE - extravascular volume 
(synonymous with Space of 
Disse) 
VC - intracellular (intrahepatic 
volume) 
PS - permeability of the 
hepatic cells 
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assessment due to its high hepatic excretion rates. There remain questions on some 
technical aspects of acquisition, and uncertainty for its utility in clinical surgical practice.  
A dual input, two compartment model appears to be the most robust available to 
determine both perfusion and function of the liver, however this has yet to be examined 
in detail whether a model of this complexity is necessary or beneficial. There is 
uncertainty in what is the best method of acquisition of DGE-MRI; particularly around the 
required rate of image acquisition (temporal resolution) and special resolution to give 
optimal quality. These questions are addressed in chapter 4 which reports on a study 
comparing acquisition sequences and a comparison of the effect of different input and 
compartment models has on perfusion and function parameters. 
DGE-MRI reporting has focussed on patients with established liver disease  where there 
is inhomogeneous function(298)(299)(300). At present, no study has reported on 
patients undergoing surgery if DGE-MRI estimates of function have a role in surgical 
planning. Chapter 5 describes a pilot study examining the predictive capacity of DGE-
MRI estimates of liver function and clinical outcomes post liver resection. 
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Chapter 3 – The impact of age on post-operative liver function 
following right hepatectomy 
This study has been published in HPB:  
D Longbotham, A Young, G Nana, R Feltbower, E Hidalgo, G Toogood, JP Lodge, M 
Attia, KR Prasad (Pre-print) The impact of age on post-operative liver function 
following right hepatectomy: a retrospective, single centre experience HPB 2019 
Jul 20  
Due to the retrospective nature of the study ethical approval for this study was not 
required. Patients consenting for surgery in Leeds Teaching Hospital consent for the use 
of anonymised patient clinical and biochemical data being used for audit and research. 
The design and publication were approved by the Department of Hepatobiliary and 
Transplant Surgery at St James’s University Hospital, Leeds. 
3.1 Abstract 
Background 
An increasing number of patients undergoing liver resection are of advancing age. The 
impact of ageing on liver regeneration and post-operative outcomes following a major 
resection are uncertain. We aimed to investigate risk factors for patients who developed 
Post Hepatectomy Liver Failure (PHLF) following right hepatectomy with age as the 
primary risk-factor. 
Method 
Patients undergoing right hepatectomy between July 2004-July 2018 in a single-centre 
were included. Receiver operating characteristic analysis (ROC) was performed to 
identify at which age PHLF development-risk increased. Secondary endpoints were 
length of stay (LOS), post-operative complications, and cost.  
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Results 
332-patients met inclusion criteria. ROC demonstrated a cut-off age of 75-years in which 
PHLF risk increased. >75 there was an increased risk of PHLF (35% >75yrs vs. 7% 
≤75yrs (p=<0.001), OR=8.8 (95% CI=3.6-21)). There was no difference between the age 
groups for any other PHLF risk factor. Patients >75yrs had longer LOS (11-days vs. 7-
days (p=0.04). Patients who developed PHLF had increased hospital costs: 
£10,987.50(£6,175-£46,050) vs. £2,575(£900-£46,050 p=0.01). 
Conclusions 
Patients >75yrs have increased risk of developing PHLF after right hepatectomy, 
contributing to increased mortality and economic burden. Pre-operatively identifying 
patients at risk of PHLF is important to consider liver volume optimization strategies and 
improve outcomes. 
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3.2 Introduction 
Major liver resection surgery is increasingly being considered for both benign and 
malignant disease with improving outcomes(5)(325)(326) Despite such advances there 
remains a significant risk of developing Post Hepatectomy Liver Failure (PHLF); reported 
in up to 12% of liver resections(5). PHLF is associated with increased morbidity and 
mortality(6). 
The cause of PHLF is multifactorial and patient selection for major resection is important 
to minimise this risk. 
There are conflicting accounts of the impact of age as an independent risk factor for 
PHLF. Many studies report no increased risk for over 70-year olds developing 
PHLF(214)(219)(235)(327)(328)(329), despite increased mortality, and others 
demonstrated no risk for long term outcome(149)(330) on liver cancer resection, 
ascribing their reduced patient survival to co-morbidities in older populations. These 
studies did not solely consider patients having major liver resection, but also included 
minor resections. 
Patients who are older have a higher prevalence of fatty liver disease(331). Older people 
may have reduced liver function due to age-related physiological changes(332). There 
seems to be an association between ageing and a higher background bilirubin(261), 
suggesting possible reduction in function in ageing populations. Such patients may be at 
risk of PHLF when subjected to major liver resection. In addition, a recently published 
large population-cohort study showed patients >75 had higher mortality after liver 
surgery for Colorectal Liver Metastasis (CRLM), which in part may be due to PHLF(333). 
As such, the data on advancing age, PHLF and outcomes following major liver resection 
is conflicting.  
Given the uncertainty of the effect of ageing on patient’s postoperative liver function 
when undergoing a major resection, we analysed the effect of ageing on right 
hepatectomy with a primary outcome of PHLF development. 
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3.3 Methods 
3.3.1 Patients 
A prospectively maintained liver resection database for St James’s Hospital, England, 
UK was scrutinised for patients undergoing right hepatectomy for both cancer and benign 
disease. Right hepatectomy (segments 5, 6, 7 and 8 as defined by the Brisbane 2000 
nomenclature of liver resections)(47)was chosen for study as it is a commonly 
performed, standardised major liver resection with anticipated adequate future liver 
remnant (FLR) (79). Confirmation of the surgery was performed by review of 
histopathology results, operation notes and clinical correspondence.  
All patients undergoing right hepatectomy between July 2004 and July 2018 were 
examined and the following exclusion criteria applied: concurrent metastatectomy, re-do 
resection, second staged resection, benign liver cyst (due to the likely small volume of 
liver parenchyma resected), pre-operative portal vein embolisation (PVE), and liver 
dysfunction pre-operatively (defined as bilirubin >50µmol/L or International Normalised 
Ratio (INR) >1.5 in absence of anti-coagulation). 
All right hepatectomies were performed using a similar open surgical technique by 5 
surgeons in our centre; an extra-glissonian approach to the porta, liver dissection 
using Cavitron Ultrasonic Surgical Aspirator (CUSA) and intermittent Pringle (a 
maximum of 15-minutes on and at least 5-minutes off) as required. 
We applied the International Study Group for Liver Surgery (ISGLS) grading system for 
PHLF(1). We performed a ROC analysis to determine if age itself carried a risk for PHLF, 
and subsequently determined a cut-off value for study, comparing those above and 
below this age-point. The following demographic, clinical and histopathological data were 
analysed: 
• Pre-operative risk factors: sex, estimated Glomerular Filtration Rate (eGFR) <90 
(Chronic Kidney Disease  grade 2(15), neo-adjuvant chemotherapy, diabetes, 
American Society of Anaesthesiologist’s Physical Status (ASA) grade, 
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background liver disease (on resection histology), elevated Charlson Index (with 
malignancy excluded from the index score)(334) and degree of steatosis 
(<33%=mild, 34-66%=moderate and >66%=severe) based on the pathologist’s 
report. 
• Intra-operative risk factors: operation time, intra-operative blood transfusion.  
• Post-operative factors: bilirubin, INR, PHLF grade, length of stay (LOS), surgical 
complications, medical complications, peak serum C-reactive protein (CRP), R1 
resection, vascular invasion status of the tumour, 30- and 90-day mortality(6).  
3.3.2 Volume measurement 
Retrospective Computed Tomography (CT)-volumetry using PMI was performed on the 
pre-operative staging CT of those patients over-75, performed less than 8-weeks before 
surgery, to assess if there were differences in FLR for both those who developed PHLF 
and those who did not. 
The clinical outcome was blinded to the author who performed this (DL) at the time of 
analysis. This allowed calculation of the total liver volume and FLR (based on the 
identification of the middle hepatic vein) with tumour volume subtracted 
3.3.3 Cost Analysis 
The cost of inpatient stay was obtained from the Trust’s coding and finance departments, 
and checked against tariffs for the Department of Health’s coding guides and the 
Intensive Care Society figures(335). The total cost for LOS was calculated based on 
itemised cost of £1700/day (~$2550) on ICU, £1000/day (~$1500) on HDU and £225/day 
(~$337.50) on a surgical ward.  
3.3.4 Statistical Analysis 
Univariable analysis was performed using Chi-Squared, and Mann Whitney test for LOS 
and CRP. Multivariable logistic regression analysis was carried out to identify variables 
that were independently predictive for PHLF grade B / C, with the latter defined as the 
dependent variable. We included known risk factors for PHLF in the model to assess the 
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size and level of association: pre-operative chemotherapy, background liver disease, 
diabetes, ASA ≥3, male sex, elevated Charlson Index, intraoperative transfusion, surgery 
over 4 hours and intraoperative Pringle use. A separate multivariable logistic regression 
analysis was additionally performed on a subgroup of those with steatosis and replacing 
background liver disease with a variable for moderate and severe steatosis. 
A significance level of 0.05 was assumed. All statistical analysis was performed using 
SPSS v22 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp). 
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3.4 Results 
3.4.1 Patients 
2989 patients underwent liver resection during the study period. 390 patients had a right 
hepatectomy, and 332 patients were included for analysis after rigorous checks for the 
defined exclusion criteria. 17 patients were excluded due to pre-operative hepatic 
dysfunction, 25 for pre-operative PVE, and 16 for benign liver cysts.  
Median follow-up was 991 days (90-4439). Indications for resection are listed in table 23.  
Table 21: Indication for right hepatectomy 
Indication for resection Number of cases 
Malignant n=307 
Colorectal Liver Metastasis 237 
HCC 36 
Associated hepatitis B infection 1 
Intrahepatic Cholangiocarcinoma 18 
Neuroendocrine Metastasis 6 
Breast Liver Metastasis 4 
Anal Squamous Cell Carcinoma Metastasis 1 
Tongue Squamous Cell Carcinoma 
Metastasis 
1 
Renal Clear Cell Carcinoma Metastasis 1 
Ampullary Cancer Metastasis 1 
Fallopian Tube Cancer Metastasis 1 
Gallbladder Squamous Cell Carcinoma 
Metastasis 
1 
Benign n=25 
Focal Nodular Hyperplasia 9 
Live Liver Donation 4 
Haemangioma 5 
Caroli’s disease 3 
Pseudotumour 1 
Adenoma 1 
Post Cholecystectomy complication 2 
 
A ROC analysis was undertaken and a cut-off value of 74.5 years old was identified for 
increased risk of PHLF with an area under the curve (AUC)=0.73 (CI:0.58-0.78; 
p=0.001). Patients were subsequently stratified by age group: under-75yrs (n=283) vs 
over-75yrs (n= 49) for analysis. 
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Figure 14: ROC Analysis of age compared to incidence of PHLF. A cut-off was 
identified at 74.5 years old. (AUC = 0.73) 
 
Risk factors 
There was no significant difference between the two age groups for sex, neo-adjuvant 
chemotherapy, diabetes, ASA, background liver disease, degree of steatosis, elevated 
Charlson Index, operation time >4hours, intraoperative transfusion, surgical 
complications, medical complications, CRP level, R1 resection, or vascular invasion 
status of the tumour (table 22).  
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Table 22: Univariable analysis of age < 75 vs. > 75 
 Under 75 n= 
(%) (n=283) 
Over 75 (%) 
(n=49) 
χ2 test 
Median Age 62 (19-74) 78 (75-83)  
Pre-operative factors    
Male Sex 155 (55) 20 (40) 0.56 
Pre-Operative Chemotherapy 124 (44) 17 (35) 0.23 
Background Liver Disease 124 (44) 20 (45) 0.8 
No steatosis 189 (67) 30 (61) 0.42 
Mild Steatosis 80 (28) 17 (34) 0.42 
Moderate Steatosis 11 (4) 2 (5) 0.9 
Severe Steatosis 3 (1) 0 (0) 1 
Pre-op GFR <90 75 (27) 35 (71) <0.001 
Diabetic patients 24 (8) 8 (16) 0.086 
ASA 3 or 4 28 (9) 3 (6) 0.4 
Charlson Index >1 (with malignant status 
excluded) 
90 (32) 17 (35) 0.69 
Intraoperative factors 
Pringle Use 192 (68) 33 (68) 0.96 
Intraoperative transfusion 18 (6) 3 (6) 0.95 
Surgery over 4 hours 25 (9) 6 (12) 0.45 
PHLF    
ISGLS grade A (Bilirubin >50) 39 (14) 19 (40) <0.001 
PHLF ISGLS grade B/C definition) 21 (7) 20 (41) <0.001 
Post-operative outcomes 
Surgical complication (e.g. bile leak, 
intraabdominal collection) 
31 (11) 2 (4) 0.081 
Medical complications (e.g. pneumonia, 
myocardial infarction, Stroke) 
34 (12) 8 (16) 0.4 
Reoperation 6 (2) 1 (2) 0.86 
30-day mortality 3 (1) 1 (2) 0.42 
90-day mortality 8 (3) 4 (8) 0.12 
Median Length of stay (range) 7 (3-66) 11 (3-580) Mann Whitney 
test = <0.001 
Median Peak post-operative CRP 
(range) 
67 (8-292) 77 (45-146) Mann Whitney 
test = 0.4 
Cancer patients only N=251 N=41  
R1 resection 40 (16) 5 (12) 0.74 
Disease recurrence (in either primary, 
liver or other metastasis) 
100 (40) 18 (44) 0.3 
Vascular invasion of tumour 85 (34) 9 (22) 0.09 
There was a significantly higher level of pre-operative Chronic Kidney Disease (CKD) in 
patients >75yrs (71% vs 27%, p=<0.001) however CKD was not associated with PHLF 
development when this was examined separately in a multivariable model (table 23).  
There was no significant difference between pathology (metastatic, primary, or benign) 
and any risk factor. There was a higher incidence of diabetes in primary cancer patients.  
Primary cancer patients also had higher disease recurrence rates (table 24). 
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Table 23: Multivariable model of Risk Factors for development of PHLF 
Table 24: Comparison of patients with CRLM and other metastatic cancers, primary 
liver cancer and benign disease 
 Metastatic% 
(n=253) 
Primary cancer % 
(n=54) 
Benign disease % 
(n=25) 
 P 
value 
Pre-operative factors 
Age over 75 37 12 0 0.23 
Male Sex 53 53 84 0.17 
Diabetes 8 19 0 0.04 
Background liver 
disease 
42 46 60 
 
0.67 
ASA grade 3 or 4 10 11 0 0.99 
eGFR <90 31 46 24 0.09 
Chemotherapy 40 46 0 0.8 
Charlson 29  43 40 0.75 
Intra-operative factors 
Pringle     
Surgery >4h 9 9 8 0.64 
Intra-operative 
transfusion 
6 8 0 0.26 
PHLF 
ISGLS A 15 26 4 0.26 
ISGLS B/C 12 13 12 0.72 
Post-operative factors 
Surgical 
complications 
12 5 8 0.11 
Reoperation 2 2 4 0.88 
Medical complication 13 17 4 0.2 
30-day mortality 1 2 0 0.74 
90-day mortality 4 2 0 0.56 
Cancer patients only 
R1 resection 14 29 n/a 0.46 
Vascular invasion 25 45 n/a 0.14 
Disease recurrence 16 85 n/a <0.001 
 No PHLF % 
(n=291) 
PHLF B/C 
% (n=41) 
Odds ratio 
(95% CI) 
P-
value 
Known risk factors for PHLF 
Age >75 vs age<75 10 49 8.8 (3.6-21) <0.001 
Male sex vs Female 53 73 0.44 (0.2-
0.98) 
0.05 
Chemotherapy use vs None 43 41 1.3 (0.58-
2.7) 
0.98 
Diabetes vs none 8 20 1.8 (0.5-2.7) 0.35 
None/mild steatosis vs 
moderate/severe 
34 32 1.6 (0.44-6) 0.47 
Any Background liver disease 
(including steatosis, fibrosis etc.) vs 
none 
45 37 0.48 (0.13-
1.7) 
0.26 
eGFR <90 pre-operatively vs >90  30.5 51 1 (0.4-2.4) 0.99 
ASA ≥3 vs <3 10 7 0.6 (0.12-
2.7) 
0.5 
Charlson Index >1 (with malignant 
status excluded) 
31 41 1.4 (0.5-3.8) 0.5 
Intraoperative risk factors for PHLF 
Intraoperative transfusion 13 10 2.2 (0.5-9.1) 0.26 
Surgery over 4 hours 10 2 0.2 (0.02-
1.5) 
0.13 
Pringle use 64 63 0.89 (0.326-
3) 
0.85 
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Due to the complex aetiology of PHLF it is important to assess each known variable, 
although it is unknown which factors will contribute most strongly. We were unable to 
discriminate by excluding any risk factor from the analysis.  
If only hepatotoxic factors were included a multivariable model; chemotherapy use, 
background liver disease and intra-operative transfusion, then there is still find a 
significant result; indeed, the OR increases to 9.1 (see table 25). 
Table 25: Alternative multivariable model of hepatotoxic factors 
 Odds Ratio (95% CI) P value 
Age >75 (1)  9.1 (4.4-19)  < 0.001  
Chemotherapy given  1.3 (0.6-2.7)  0.5  
Background Liver Disease  0.6 (0.3-1.3)  0.2  
Intra-operative transfusion  1.9 (0.6-6.9)  0.3  
 
3.4.2 Post Hepatectomy Liver Failure 
41 patients (12%) in total developed PHLF grade B/C as defined by ISGLS: 21 patients 
under-75 (7%) and 20 over-75 (49%). The odds ratio was significant for those over-75 
developing PHLF (OR=8.8 (3.6-21), p=<0.001) Additionally, there were more patients 
over-75 with ISGLS grade A PHLF (elevated bilirubin on day 5) (40% vs 14%, p=<0.001). 
There was no difference in Pringle Manoeuvre times: for those who developed PHLF 
grade B, median total time = 29 minutes (4-81minutes) vs. 28 minutes (5-70minutes), 
p=0.82; hepatic ischaemia therefore did not contribute. 
There was no difference in 30- or 90-day mortality observed between the age groups. 
There was a significant increased 30 and 90-day mortality seen in those patients who 
developed PHLF. (30-day: no PHLF 0.5% vs PHLF 13% p=<0.001, 90-day: no PHLF 2% 
vs 13% p=0.01), but no increase in complications. A summary of complications and 
reasons for return to theatre is found in table 26. Of the patients who developed bile leak, 
1 had reoperation, all other cases were managed radiologically or endoscopically. 
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Table 26: Post-operative complications 
Complication Number of cases (%) (n=332) 
Chest Infection 29 (9) 
Wound Infection 12 (4) 
Bile Leak 9 (3) 
Encephalopathy 5 (1.5) 
Acute Kidney Injury requiring Renal 
Replacement Therapy 
5 (1.5) 
Intra-abdominal Collection  5 (1.5) 
Post-operative Haemorrhage (requiring 
reoperation) 
3 (1) 
Myocardial Infarction 2 (0.6) 
Small bowel obstruction 1 (0.3) 
Gastroparesis 1 (0.3) 
Dehiscence 1 (0.3) 
Biliary Stricture 1 (0.3) 
Aspiration 1 (0.3) 
Reoperations  7 (2) 
Indication for reoperation (n=7) 
Bleeding  3 
Intraabdominal Abscess 1 
Bile Leak 1 
Wound dehiscence 1 
Biliary Stricture 1 
 
3.4.3 Steatosis 
There was no difference between the degree of steatosis in those over-75 and those 
under-75 (table 22). Furthermore, there was no association with PHLF development in a 
separately performed multivariable model that excluded other background liver 
pathologies (e.g. fibrosis) (table 23). Age remained an independent risk factor in this 
model. There were 5 patients (all under-75) with HCC and fibrosis but no cirrhosis. Three 
patients had severe steatosis, all in their 50s, none developed PHLF. 
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Table 27: A separate multivariable analysis of patients with moderate or severe 
steatosis, excluding liver disease of other causes 
 
3.4.4 CT Volumetry 
Volumetric analysis was retrospectively performed on all patients with PHLF where 
images were obtained (40 out of 49). All 40 patients were in the over-75 years age group. 
The median volume of liver with tumour volume subtracted was 1204ml (666ml-2302ml) 
and the FLR was 486ml (306ml-1166ml).The FLR for those over-75 measured a median 
of 42.5% (range 25%-72%) for those who developed PHLF grade B and 47.4% (32%-
51%) for those who did not (p=0.925). None were below 25% volume.  
3.4.5 Cost analysis 
Patients who developed PHLF had a longer median total hospital stay (11 days vs 7 
days, p=0.04), and longer ICU stay: 6 days (3-16) vs 0 (0-18) p=<0.001). There was no 
difference in HDU stay. The calculated cost demonstrated that the bed stay for PHLF 
was higher: £10,987.50 (£6,175-£46,050) vs £2,575 (£900-£46,050 p=0.01). 
(USD=$16,481.25 ($9,262.5-$69,075) vs. $3,862.50 ($1,350-$69,075)). 
 
 
 
 No PHLF % 
(n=280) 
PHLF B/C % 
(n=36) 
Odds ratio 
(95% CI) 
P-
value 
Known risk factors for PHLF 
Age >75 vs age<75 11 38 6.3 (1.1-14) 0.03 
Male  sex vs Female 54 69 1.5 0.7-4) 0.4 
Chemotherapy use vs None 16 31 1.2 (0.45-3.6) 0.69 
Diabetes vs none 6 19 2.2 (0.48-9.5) 0.3 
None/mild steatosis vs 
moderate/severe 
49 38 0.8 (0.1-0.97) 0.9 
None/mild/moderate vs severe 87 0 - - 
eGFR <90 pre-operatively vs 
>90 
27 46 1.1 (0.3-3.4) 0.98 
ASA ≥3 vs <3 11 4 0.2 (0.02-1.8) 0.16 
Intraoperative risk factors for PHLF 
Intraoperative transfusion 7 8 2.5 (0.3-14.5) 0.3 
Surgery over 4 hours 11 0 - - 
Pringle use 62 62 1 (0.6-4.2) 0.89 
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3.5 Discussion 
This is a large series, all with a comparable FLR due to a standardised right hepatectomy. 
Patients had a similar co-morbidity profile with comparable ASA (no cases with ASA 4 
underwent right hepatectomy), eGFR and Charlson Indices – suggesting patients were 
fit-for-surgery and would not be expected to be at increased risk of PHLF. Our results 
show that when the cut-off identified by ROC-AUC, patients over-75 are at a higher risk 
of developing PHLF and have longer LOS and greater inpatient cost.  
There were no significant differences between other known risk factors for PHLF when 
analysed in the multivariable model as these will have been corrected through patient 
selection. Patients who develop PHLF have a reported mortality of 12%(5) The mortality 
in our series is comparable with a 13% 90-day mortality.  
3.5.1 Previous studies 
Allard and colleagues quoted a risk ratio of 5.6 for PHLF in the  over-70 age group in 
their major liver resection study of 277 patients(214), but no risk on their multivariable 
analysis. Other studies had no difference in rates of liver failure or 
mortality(235)(328)(329). Unlike the present study, none of these series accounted for 
variation in the extent of resection.  
All patients in this study had an anatomical resection of segments 5,6,7 and 8, the 
majority having <50% FLR. Older patients may be at no increased risk from smaller 
resections or metastatectomies, but major resections present a massive physiological 
stress to patients, and factors like sub-clinical reduced synthetic/excretory function may 
explain our findings of increased PHLF development.  
Vallance and colleagues(333) recently published a population study of 6081 CRLM 
resection patients and found an increased Hazard Ratio for death of 1.47 for those over 
75, in line with the age cut-off identified by this series. Although they did not look 
specifically at outcomes of PHLF, our findings of increased risk are consistent, and as 
such those over-75yrs should be managed with this risk in mind. 
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Tzeng and colleagues(219) considered the fact that older patients have reduced 
physiological reserve and thus a reduced speed of hypertrophy. It has been previously 
demonstrated that older people have a slower rate of liver regeneration(133) and 
certainly this would be in keeping with the results of higher PHLF for the older cohort; 
these patients did not ‘catch up’ to provide adequate function. 
We summarise previous studies investigating liver resection in the elderly in Table 28. 
Unlike the present series, most patients included in those studies were minor resections, 
or specific outcomes of PHLF were not discussed. Our study differs from the negative 
findings of previously published studies (Table 7) as it eliminates confounding differences 
in resection extent, and analyses specifically for PHLF by the updated definition of  “a 
post-operatively acquired deterioration in the ability of the liver to maintain its synthetic, 
excretory, and detoxifying functions, which are characterized by an increased INR and 
concomitant hyperbilirubinemia on or after postoperative day 5”. By using this definition, 
we eliminate those patients with post-operative hyperbilirubinaemia due to such causes 
as bile leak, as these patients would not have impaired coagulation. 
Table 28: Comparison of other studies examining outcome of older patients 
 Number 
of 
patients 
% Older 
patients 
% Major 
resections 
Difference in 
Complication 
Rate Older vs. 
Younger 
Patients 
(Relative 
Risk) 
% 
PHLF 
in 
Older 
% PHLF 
in 
Younger 
patients 
Fong et 
al(330) 
128 100 34 n/a 5 2 
Caratozzola 
et al (336) 
392 13 32 1.7 n/a n/a 
Hanazaki et 
al (337) 
483 31 24 1.05 0.6 1.5 
Bockhorn 
(338) 
59 100 27 n/a 3.3 n/a 
Mann (339) 191 25 66 1.5 2 3 
Menon(263)  517 25 100 0.93 n/a n/a 
Present 
series 
332 15 100 8.8 (OR) 49 10 
Our results in terms of mortality itself are comparable, although not significant, but death 
in those who develop PHLF was 13%. Complications for those who did and did not 
develop PHLF were comparable, and we cannot say whether any complications that 
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developed led to impaired liver regeneration, or vice-versa, again in line with Vallance 
and colleagues’ findings(333). 
3.5.2 Other Risk factors 
There were no other known risk factors found to be associated with PHLF development. 
This may be due to careful patient selection to exclude clearly at-risk patients from major 
resection. As such, known risk factors such as Diabetes (222)(239), where patients 
requiring insulin have been reported to have higher operative times and transfusion rates 
after liver surgery(221) were not found to have significantly increased risk. For a similar 
rationale, we conclude this to be the reason for comparable Charlson Indices (169)(334); 
the well-recognised measure of categorising co-morbidities. Pre-operative assessment 
for higher risk candidates/higher modified (excluding malignancy) Charlson Index 
patients were excluded prior to coming to surgery. 
Similarly, although neo-adjuvant chemotherapy is associated with liver injury and 
steatohepatitis(229)(230)(231), any patient who developed these would have been 
excluded from this series; hence why no risk was demonstrated here. Our protocol was 
to wait 6-weeks between chemotherapy cessation and surgery, ensuring there was no 
preoperative evidence of hepatic dysfunction. 
During the length of the study period, chemotherapy regimens and treatment protocols 
changed in response to new evidence. Most commonly in management of colorectal liver 
metastases (CRLM), 5-fluorouracil and Oxaliplatin were introduced while capecitabine 
and Irinotecan were used in other cases. As such, it was not possible to perform reliable 
analysis of varied chemotherapies utilised and their effect on PHLF. 
There was no evidence of background liver disease contributing to failure. Just over half 
of patients had background liver disease, however it was mainly mild steatosis (there 
were 3 cases of severe steatosis, all in younger patients in their 50s) with minimal 
fibrosis. There were 3 patients with confirmed autoimmune hepatitis, 2 with primary 
sclerosis cholangitis, 1 with hemochromatosis and 1 patient with HBV – all aged under 
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55, and no other viral hepatitis cases. Our study population did not include patients with 
cirrhosis; such patients would have had a more parenchymal-sparing surgery or PVE. 
Pre-operative renal insufficiency and liver resection has rarely been discussed in the 
literature, more often it is featured in studies examining the development of renal 
dysfunction or acute kidney injury (AKI) postoperatively(146)(222)(326). Our results 
show that the over-75 age group have a higher prevalence of CKD stage 2 or above(15) 
but in itself CKD did not place a significant increased risk of PHLF in this series. No 
patient with eGFR <40 was included and so the effect of more advanced renal 
dysfunction cannot be assessed here. The retrospective nature of this analysis means 
we cannot say how many patients were planned for right hepatectomy but then an intra-
operative decision was made that the liver was not of sufficient quality to safely proceed 
which could have led to selection bias.   
Overall our results show that despite careful preoperative patient selection for major 
resection older patients remain at higher risk. In addition, our analysis shows that the 
inpatient LOS for a patient that develops PHLF would cost on average £8,412 more than 
a patient without.   
3.5.3 FLR 
Most centres would consider 25% to be their threshold for the limit of resection in 
otherwise normal liver tissue(3)(4) without requiring procedures to induce pre-operative 
hypertrophy. All the patients included for Volumetry analysis had a volume greater than 
this threshold, with the median volume for those with PHLF 42.5%. The right 
hepatectomy was chosen for investigation for this study, as we would expect the remnant 
volume to be well above the threshold and therefore have low level of PHLF, which is 
demonstrated. So, despite adequate FLR-volumes, our older cohort still developed 
PHLF more frequently, suggesting that measurement of FLR-volume alone in this age 
group may not be enough to ensure adequate post-operative function. Factors such as 
increased fat fraction, differences in vascularisation and bilious drainage of remnant liver 
could be more prevalent in the older population(340). 
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There was no difference in R1 resections or vascular invasion between the ages or those 
who developed PHLF. This reflects that the degree of resection did not significantly differ 
between the two groups. An extended right or trisectionectomy may have achieved a 
higher R0 resection rate, but would have carried an inherent increased risk of PHLF(2). 
3.5.4 Potential solutions for improving outcomes for older patients 
One potential solution to improve outcomes for patients over-75 could be PVE. Despite 
our cohort’s FLR being above the accepted 25% threshold, PHLF developed nearly half 
the time; one explanation is that patients over-75s require a larger FLR, similar to those 
patients with parenchymal liver disease. Older patients who require resection of ≥4 
segment could be considered. 
One influential randomised controlled trial by Farges and colleagues(79) showed there 
was no benefit for patients to undergo PVE before right hepatectomy, however the age 
group of this cohort was much younger, with the mean age being 53 for those without 
PVE and 58 for those undergoing PVE. Our cohort is much older, and we feel that this 
older group should be considered differently due to different physiology in older patients. 
PVE costs approximately £5,000 per procedure. If performing PVE on those over-75 
years could prevent PHLF then it would be cost-effective, notwithstanding the potential 
for improved clinical outcomes.  
However, a dedicated prospective study to investigate this hypothesis should take place 
as, although PVE does increase FLR(81)(75), it may induce some tumour growth in the 
contralateral liver in patients, which could render disease inoperable(341), in addition to 
the risk of complications from PVE itself such as abscess, cholangitis or thrombosis(75).  
3.5.5 Limitations 
Certain known risk factors such as BMI and malnutrition status, estimated blood loss 
couldn’t be included in analysis as this data was not consistently documented in the 
notes or patient database.; a recognised weakness given the retrospective nature of data 
review. The practice at the unit was to screen and manage all malnourished patients with 
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dietitian input and enteral support. All patients were subject to enhanced recovery 
protocols post-operatively. We have used surrogate markers of blood loss (e.g. 
transfusion) which may not reflect directly blood loss to overcome this limitation.  It is 
impossible to know if patients who would otherwise have been considered for a right 
hepatectomy underwent more limited parenchymal-preserving surgery at their planning 
stage or were denied their operation based on anaesthetic assessment, or significant 
co-morbidity altered their operative plan. This could have led to some degree of selection 
bias as our patient selection strategy may not be the same as other units’ individual 
patient selection policies. 
Using our defined age of 75 years old we find there is a sensitivity of 50%, specificity of 
90%, PPV of 41% And NPV of 93% for PHLF. As such, age is a low-sensitivity, high-
specificity test. As such we could not advocate age solely as an indication or contra-
indication for surgery, as we appreciate certain older patients may have robust 
physiology sufficient to cope with the stress of major hepatectomy. This can be difficult 
to assess, however. Our findings demonstrate age allows a good risk stratification, 
enough to consider older patients at risk.  
The consequences of development of PHLF is severe, we wish to promote to colleagues 
the importance of a potential increased risk this age group, and assessment in a holistic 
manner to maximise the chance of good outcome, with careful patient assessment and 
pre-operative work-up which may mean either hypertrophic procedures or a more limited 
resection. A prospective study in a multi-institutional setting may provide a definitive 
answer. 
We feel our study’s main strength: a large series with homogeneous resection 
population, identifies a significant risk for over-75s to develop PHLF.  This contributes to 
our understanding of how best to manage this at-risk population of elderly patients who 
are considered for life-saving liver surgery, allowing better patient selection criteria to 
improve outcomes and reduce cost. 
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Chapter 4 – DGE-MRI acquisition and analysis methods 
Prior to embarking on a clinical DGE-MRI study (chapter 5), a pilot study was performed 
to identify an appropriate acquisition and analysis method. See Appendix B for detailed 
recruitment strategy. This chapter presents the results of this pilot, part of which 
(describing the comparison of different post-processing models) was presented at the 
International Hepato-Pancreatobiliary Association meeting (IHBPA) and Association of 
Surgeons of Great Britain and Ireland meeting (ASGBI) in Manchester 2015 and 
published in HPB April 16 Volume 18 S2 Page e697. 
4.1 Abstract 
Aims  
DGE-MRI of the liver provides perfusion and functional estimates which have potential 
clinical applications for liver disease assessment. There are methodological issues 
regarding appropriate acquisition method and analysis modelling. Data can be analysed 
with a dual-input uptake model, but it is unknown this is necessary. Visual assessment 
of image quality and time curves is a simple way to assess suitability of an acquisition 
protocol. This study aimed to assess suitability of 3 different acquisitions sequences, and 
compare accuracy of DGE-MRI perfusion and function parameters generated by a dual-
input model, and simplified models. 
Methods 
3 acquisition protocols previously reported were performed on 5 patients each. Protocol 
1: spoiled gradient 3D sequence, temporal resolution (TR) =2.4 seconds, protocol 2: 
TWIST 3D Sequence, TR = 1 second, Protocol 3: 2D multiplanar imaging, all post-
injection of 10 ml of Gadoxetate for 7 minutes. Visual examination of each led to selection 
of the most suitable for further study. 5 more patients were subsequent recruited and 
imaged using the selected protocol. Their dynamic images were analysed the following 
models: dual input with, and without arterial delay, arterial input function (AIF) only and 
venous input function (VIF) only. Region of interests (ROI) were identified within each 
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segment in normal-appearing liver. Mean values for all ROIs were calculated using each 
model. Mean perfusion measurements (total plasma flow (TPF), arterial flow fraction 
(AFF) and extracellular volume (ECV)) and function measurements (uptake fraction 
(UF)) were compared using T test (Microsoft Excel 2015). 
Results  
Protocol 1 was selected as most suitable to evaluate different post-processing models. 
There was a significantly lower TPF with AIF-only model (dual-input with delay 
152ml/100ml/min vs. AIF-only 70ml/100ml/min p=0.003) and a significantly higher UF 
observed (dual-input 9.4% vs AIF-only 16% p = 0.001). Removing arterial delay reduced 
AFF from 30% to 11% (p=0.01). The dual input model with arterial delay provided results 
similar to previous published reports. There was no difference in ECV fraction in any 
model (38% vs 37%). 
Conclusions 
An AIF-only analysis is only suitable for the measurement of ECV, which has been 
identified as a potentially useful parameter in the evaluation of fibrosis. Accurate TPF 
and UF are needed to fully assess function, so a dual-input model is required. 
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4.2 Introduction  
DGE-MRI has emerged as an imaging-based modality to measure partial liver function 
with promising results(14). DGE-MRI is a relatively recent innovation, with multiple 
reported methods of data acquisition(218)(274). Two technical issues need to be 
addressed to allow a standardisation of DGE-MRI methodology:  
a) it has not been established which of the many available acquisition methods would 
give optimal quality image data without compromising on temporal or spatial resolution, 
b) it remains uncertain if is any improvement in data precision and accuracy by applying 
complex dual input modelling following acquisition.  
There are many available acquisition sequences that give variable temporal and spatial 
resolutions(218)(274)(300)(322)(342), and increasingly complex analysis that can be 
applied in post-processing to dynamic MRI data. The introduction of mathematical 
modelling that can separate AIF, VIF and intracellular and extracellular spaces has led 
to the option of a dual-input, two compartment model (see chapter 2.4.5)(218) but it is 
unknown such a model is necessary or beneficial to obtain accurate measurements of 
perfusion and function. The lack of standardised methodology could mean comparison 
between different published reports is not possible.  
4.2.1 Acquisition optimisation 
Recently published studies utilised a spoiled-gradient 3D acquisition which has proven 
effective, but has potential flaws due to a relatively long temporal resolution and lower 
spatial resolution than other available techniques(218)(274). An acquisition using time-
resolved angiography with interleaved stochastic trajectories (TWIST) could lead to a 
shorter temporal resolution by interpolation of measurements. This could potentially 
produce more accurate perfusion measurements, due the shorter interval between 
images during the arterial and venous contrast phases(218)(300).  
Another approach is the use of multiplanar 2D sequences which are free from intra-frame 
artefacts and have been used in DCE-MRI of the kidneys(322)(342). Such a technique 
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could provide improved spatial resolution and image quality making identification of ROI, 
AIF and VIF more robust. Conversely, displacements between neighbouring slices due 
to breathing motion could render proper motion correction and segmentation difficult.  
4.2.2 Application of dual input model 
Data can be analysed with a dual-input two-compartment uptake model that accounts 
for arterial delay(218) (343)(344). The role of adding an arterial delay into the model is 
thought to be required due to the unique dual inflow anatomy of the liver; having 
predominantly venous inflow of ~80% and ~20% arterial inflow. Contrast will enter the 
liver at different times in the cardiac cycle. Automated measurements by linear 
regression modelling are thought to improve measurement parameters to improve 
precision and accuracy, but often the time delay generated will be non-physiological, 
often in the range of 8-12 seconds, whereas in reality this delay would be less than 1 
second. It is uncertain why this non-physiological delay occurs(345). 
Identification of the VIF can be difficult on some sequences due to reduced spatial 
resolution and movement artefact. If comparable perfusion or functional values exist 
without the need for VIF measurements, it would be both technically easier and quicker 
for analysis.  
4.2.3 Aims 
Given the variety of methods for image acquisition and post-processing that are 
available, before embarking on a study assessing the utility of DGE-MRI in a clinical 
setting, this pilot study aimed clarify on these two technical issues:  
a) identification of a suitable acquisition method by image quality assessment of 3 DGE-
MRI acquisition methods: 3D spoiled gradient, 3D TWIST and 2D multiplanar imaging 
by visual examination to select the most suitable for further study 
b) assessment of the most suitable model for analysis by comparison of the effect on 
key perfusion and functional parameters when analysed with a dual input model with and 
without arterial delay, compared to simplified models. 
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This study was approved by submission to the REC committee South Central - 
Hampshire A and the application is included in Appendix B for detailed recruitment 
strategy (page 226-246). 
4.3 Methods 
Patients with histologically confirmed CRLM (selected as the most common indication of 
liver surgery and staging liver MRI) were recruited consecutively after they had been 
selected for curative liver resection in the hepatobiliary multidisciplinary team meeting 
based on preoperative CT findings. A DGE-MRI protocol was added into their planned 
diagnostic MRI. The study was performed in 2 phases, the first assessing acquisition 
optimisation, the second comparing analysis methods. 
4.3.1 Acquisition optimisation 
The following 3 free-breathing protocols were visually compared. 5 patients were 
recruited to each of 3 protocols: 15 patients were included in total.  
1. Standard 3D Sequence obtaining images every 2 seconds: 3D spoiled gradient 
echo sequence with a temporal resolution of 2.4 seconds over a 8-min acquisition 
(3D fast low angle shot MRI (FLASH), temporal resolution (TR)/Echo Time 
(TE)=2.45/0.76ms, Flip Angle=24°, acquisition matrix=128x77, 61 phase 
encoding steps, reconstructed matrix 128x128, Field of view (FOV)=400x400 
mm, slice thickness 10mm, 30 slices, reconstructed pixel size 3.125mm.  
2. TWIST 3D Sequence obtaining images every second: 3D TWIST sequence 
(TR/TE = 2.8/1.1 ms, FOV = 400 mm, matrix = 128, flip angle=25°) with a 
interpolated temporal resolution of 1 second. 
3. Pre-bolus 2D slice sequence with a multi-slice 2D sequence every 6 seconds 
(TR/TE = 1/1.1 ms, FOV = 400 mm, matrix = 128, flip angle=24°) . 
For protocols 1 & 2, a dose of 10ml Gadoxetate (Primovist, Bayer) was delivered at 
1ml/sec. Protocol 3 also received a dose of 10ml Gadoxetate (Primovist, Bayer) but an 
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initial pre-bolus of 1ml was given prior to acquisition, followed by the remaining 9ml 
delivered at 1ml/sec. 
In addition to the DGE-MRI acquisition, a full diagnostic MRI was obtained for each 
patient: pre-contrast sequences included coronal and transversal T2-weighted imaging, 
axial T1-weighted Dixon imaging, axial fat-saturated T1-weighted imaging. The DGE-
MRI sequence was followed by Echo Planar Imaging (EPI) diffusion imaging with b-
values and repeat of the axial fat-saturated T1-weighted imaging at 20 minutes post 
contrast injection (hepatobiliary phase).  
Each patient’s DGE-MRI data was examined visually to assess image dynamics, 
maximum intensity maps, VIF time curves and delineation, image artefacts, and 
continuity of time curves using in-house software PMI 0.4 (sites.google.com/ 
site/plaresmedima). The most appropriate acquisition sequence was decided prior to 
application of post-processing modelling. 
Following the decision of the most suitable acquisition, 5 more patients were examined, 
10 patients in total, using the selected sequence and analysed in PMI for comparison of 
different post-processing models.  
4.3.2 Post processing modelling 
The maximum signal change over time was calculated and an AIF and VIF were defined 
on this map by drawing a small ROI in the abdominal aorta and portal vein (figures 15).  
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Figure 15: Identification of the AIF in the Aorta and VIF in the Portal Vein 
 
An ROI was identified within each liver segment in normal-appearing liver tissue, 
avoiding any visible metastasis and benign discrete lesions, with no motion correction. 
A total of 8 ROI curves per patient were identified and mean values for all ROIs (a total 
of 80 separate analyses were performed, 8 from each patient included – figure 16) and 
patients were calculated by fitting signal-enhancement time courses to a dual-input two-
compartment uptake model with arterial delay as described by Sourbron and 
colleagues(218) and described previously in Chapter 2.4.5.  
Figure 16: Identification of ROI in Segments I-VIII 
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The fit was then repeated with three simplified models: (1) no delay fitted (i.e. arterial 
delay fixed to zero), (2) AIF only, (3) VIF only. The effect of the model simplification on 
the mean values of perfusion parameters (total plasma flow (TPF), arterial flow fraction 
(AFF) and extracellular volume (ECV)), and function parameters (uptake fraction (UF)) 
were tested by comparing the means with Student T test.  
Data analysis was performed by two authors (David Longbotham and Steven Sourbron) 
using PMI 0.4. Statistical significance was defined at p<0.05 and performed using 
Microsoft Excel (2019). 
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4.4 Results 
4.4.1 Selection of Acquisition Protocol 
Protocol 1 yielded an image quality that was relatively free of artefact, allowing segmental 
ROI delineation, AIF and VIF identification in all 5 patients, with appearances of time 
curves consistent with previous studies (see figure 11). 
Image quality for participants undergoing Protocol 2 suffered from significant artefacts. 
The image quality was inferior to those obtained by protocol 1, and it did not appear that 
the improvement in temporal resolution had any difference on the appearance of time 
curves, therefore was rejected for further study as VIF identification could be more 
difficult. 
Protocol 3 imaging could not be analysed in the PMI software. Due to nature of 2D 
multiplanar sequences and the free breathing acquisition, each slice was taken during a 
different part of the breathing cycle, making motion correction difficult without additional 
data. Measurement of the liver volume was compromised, with a mismatch of the true 
liver and segmental volumes. This yielded an unsuitable acquisition method, therefore 
was rejected for any further study. 
Protocol 1 (described in 4.3.1) was therefore chosen as the most appropriate acquisition 
method. 5 extra patients with CRLM underwent data acquisition using this protocol. 
4.4.2 Application of post-processing modelling 
TPF was significantly lower with the AIF-only model (dual-input 152ml/100ml/min vs. AIF-
only 70ml/100ml/min p=0.003) and there was a significantly higher uptake fraction (dual-
input 9.4% vs AIF-only 16% p = 0.001). There was no difference in ECV (38% vs 37%); 
suggesting ECV to be robust parameter that is independent of the details of the model. 
Models that excluded VIF had a significantly reduced measurement of plasma flow and 
uptake fraction but ignoring the arterial input did not affect the mean values. The 
functional parameter uptake fraction is not sensitive to the use of an arterial delay. The 
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arterial delay caused a significant reduction in measured AFF but did not affect the TPF 
(table 29). 
Table 29: Results comparing use of the full model (left) and three simplified versions  
 Dual-inlet model 
with arterial delay 
No delay 
(Mean (SD)) 
AIF only 
(Mean (SD)) 
VIF only 
(Mean (SD)) 
Total Plasma Flow 
(ml/100ml/min) 
152 (66) 158 (35) 70 (31)* 192 (28) 
Arterial Flow Fraction % 30 (13) 11 (6.7)* N/A N/A 
Extracellular Volume 
Fraction % 
38 (7.6) 42 (12) 31 (3.6) 45 (18) 
Uptake Fraction % 9.4 (5.2) 8.8 (5.6) 16 (7.6)* 7.5 (4.9) 
Arterial Delay (secs) 9 (5.9) N/A 10 (2.1) N/A 
*p=<0.05 T test    All values above are given as Mean (SD) 
4.5 Discussion 
4.5.1 Dual input compared to single input models  
If a measurement of the AFF is required in order to derive functional parameters, then a 
dual-input model is needed. The choice of fitting an arterial delay parameter has a 
significant effect on the mean value of the AFF, but not on the other measured 
parameters. In particular the measurements of function are not affected by the choice of 
the arterial delay strategy. As no gold-standard is available this study cannot identify 
whether fitting an arterial delay produces more accurate results, but AFF values fitted 
with a delay are more consistent with literature values(346). On the other hand, the fitted 
delay values are higher than expected for a transit from aorta to liver. This is similar to 
those reported in studies by Chouhan and colleagues(345), however given the potential 
for a multitude of DGE-MRI models and acquisition sequences it can be difficult to 
extrapolate data between inter-departmental studies – something which requires 
development to standardise within the literature. 
If perfusion parameters are not required, there is no need to include the AIF in the 
analysis, as a single inlet model with VIF alone does not affect the mean parameter 
values of the uptake fraction. In such a case this step in the analysis protocol can be 
eliminated, and a simpler and faster model fit can be performed. This may have 
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significant implications for the practicality of the method and robustness of single-pixel 
results.  
A single-input model with an AIF alone is most attractive from a practical point of view 
as the AIF is more easily identified than the portal vein. Given the significant different 
measurements of TPF between the models, and the need for plasma flow in function 
analysis then both AIF and VIF need to be included as they may affect the accuracy of 
function measurement, and all further analysis will need both input functions to be 
measured. These results suggest that an AIF-only analysis is only suitable for the 
measurement of ECV, which has been identified as a potentially useful parameter in the 
evaluation of fibrosis due to the increased water content of fibrotic tissues(299). No 
patient included in the study had any evidence of fibrosis, or significant parenchymal liver 
disease so this could not be tested further. The results are consistent with the relatively 
low contribution of arterial perfusion in healthy liver. 
Table 30: Summary of models and which data is obtained 
Model used Data obtained 
Dual-input model with arterial delay Liver Function and Perfusion 
Dual-input model with no delay Liver Function and Perfusion (less accurate) 
AIF only Extracellular volume (fibrosis measurement) 
VIF only Liver function only 
 
4.5.2 Limitations 
The small cohort size analysed may impact on the validity of the results leading to a type 
1 error. The lack of defined gold-standard values of any DGE-MRI parameters remain 
challenging to address what should be the ‘correct’ range of measurements, we 
concluded that previously published results were in line of what was expected. With the 
technology being in the early development stages with no large population studies to 
validate reference ranges, caution is always required regarding validity of results. Along 
the same lines this study cannot identify whether fitting an arterial delay produces more 
accurate results. 
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The lack any quantitative assessment for the selection of protocol 1 over the other 
examined acquisitions reduces the validity of the conclusions of protocols 1’s perceived 
benefits. It was decided, given the extensive artefacts on protocol 2 that it would make 
the VIF more difficult to identify. It was not possible to analyse protocol 3 at all, and it 
was felt further data collection was unnecessary. By rejecting these 2 acquisition 
protocols, 10 patients were recruited for study and no data was included in the clinical 
study, as described in chapter 5. Given the tight recruitment timetable and paucity of 
available patients, in retrospect, it was unnecessary to obtain so many scans to select 
the acquisition protocol and the decision could have been made at an earlier stage in 
patient recruitment. Those 10 patients underwent their diagnostic imaging in addition to 
the DGE-MRI sequences, so their care was not compromised, with completed liver 
staging MRI reporting by a liver radiologist and appropriate surgical intervention as per 
their disease state.  
4.5.3 Conclusions 
The 3D spoiled gradient DGE-MRI sequence with a TR of 2.4 seconds was thought to 
be the most suitable acquisition. A dual-input model is required to separate arterial and 
venous perfusion. All other parameters can be measured using a single-input model with 
a venous input. Accurate TPF and uptake fractions are needed to fully assess function, 
so a dual model is required for any future analysis of DGE-MRI estimates of liver function, 
but options of simplified models exist for fibrosis assessment. Parameter values suggest 
that an arterial delay must be included when a dual-input model is used, but a question 
remains why the values for the arterial delay appear non-physiological. A future 
simulation study may help to provide a more conclusive answer. 
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Chapter 5 - Prediction of post-hepatectomy liver function 
with Dynamic Gadoxetate-Enhanced MRI 
This study was approved by the REC committee Wales 6. For the detailed recruitment 
strategy see Appendix C. Chapter 5 has been prepared with the intention to submit to 
HPB for consideration of publication. It has been accepted for presentation at the 28th 
International Society for Magnetic Resonance Imaging in Medicine (ISMRM) annual 
meeting and exhibition in Sydney, Australia, April 2020. 
This chapter describes the results of a study assessing DGE-MRI estimates of function 
compared with post-hepatectomy clinical outcomes. The primary outcome was 
correlation of FLR-function estimates with post-operative bilirubin. Secondary outcomes 
were assessment of DGE-MRI function estimates with volumetry, and risk factors for 
PHLF development. 
5.1 Abstract 
Aims 
Risk assessment for major hepatectomy relies on predictions of FLR volume, but this is 
a poor surrogate of FLR function in the presence of liver disease. We hypothesize that 
FLR-function as estimated by DGE-MRI provides a more reliable and widely available 
assessment of surgical risk. The aim of this study is to identify DGE-MRI biomarkers that 
can predict post-hepatectomy liver function. 
Material and Methods 
29 patients with normal liver function requiring resection for CRLM were recruited. DGE-
MRI was added to their pre-surgery staging MRI. Imaging biomarkers were derived, 
characterizing whole liver and FLR-volume, perfusion and function. Primary outcome 
was post-operative bilirubin. DGE-MRI and biochemical biomarkers were correlated 
individually against the primary outcome to identify those with predictive potential using 
linear regression models. Secondary outcomes tested FLR-function with FLR-volume, 
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and association of function parameters (principally gadoxetate uptake rate (UR), fraction 
(UFr) and function (UFu) with PHLF risk factors development using T test and Mann-
Whitney test. Significance was defined as p<0.05. 
Results 
Four DGE-MRI biomarkers of FLR-function were predictive of hyperbilirubinaemia, 
including FLR-uptake rate (r=-0.57, p=0.007) and FLR-clearance (r=-0.53, p=0.014). 
Notably neither FLR-volume, or pre-operative biochemistry were correlated with post-
operative bilirubin. Secondary outcomes showed there was strong correlation between 
FLR-volume and FLR-function (R2 = 0.977 p=<0.001). Older patients had reduced 
function: a lower UR (6.1ml/100ml/min vs 14.6ml/100ml/min p=0.02), UFu (78.6ml/min 
vs 211ml/min p=0.01) and UFr (5.7% vs 10% p=0.009). Patients who underwent major 
resection compared to limited resection had a significantly lower UFu (181ml/min vs 
294ml/min p=0.047) and UFr (7.6% vs 12.6% p=0.047). 
Conclusions 
DGE-MRI estimates of function show potential to inform patient selection and surgery 
planning, relevant in patients with liver disease where volumetry isn’t reliable. Older 
patients and patients with higher metastatic burden had reduced uptake and metabolism 
of contrast; suggesting such patients have impaired liver excretory physiology. Future 
studies should aim to confirm this hypothesis using direct post-operative function 
measurements with ICG. 
 
 
 
 
 
 
117 
 
 
 
5.2 Introduction 
Determining liver function is increasingly required for patients who require major liver 
resection for CRLM; the commonest indication for surgery(3)(157)(347). It is important 
to have a robust pre-operative method of determining liver function to reduce risk of 
complications caused by inadequate functioning liver, such as PHLF; a condition with 
high morbidity and mortality(5)(6).  
Methods such as ICG(12), GECT(278), and LiMAX(282)(283) are effective in assessing 
global liver function, however such methods are inadequate for surgical planning if there 
is heterogeneity of liver tissue or the FLR volume is expected to be marginal or potentially 
insufficient (as discussed in chapter 2.3).  
CT volumetry is most commonly used for pre-operative planning, however it does come 
with some limitations(199)(348). In particular there is uncertainty around the correlation 
of CT volumetry with liver function and postoperative outcome(349). Even an estimated 
FLR based on patient weight has been demonstrated to be superior to measured FLR 
for prediction of PHLF (see chapter 3.4.4)(10).  
FLR-volume may not reflect FLR-function when there is underlying parenchymal disease 
or hepatic comorbidity such as fibrosis, CILI(350), cirrhosis, or steatosis leading to 
inhomogeneous liver function(351). A functional bias may be observed. However, if 
function is homogenous then volume and function will be equivalent. For patients with 
CRLM and no other liver disease this may be the case. Scintigraphy has demonstrated 
that there is a role in segmental function assessment of the liver in patients undergoing 
major hepatectomy which is more robust than volumetry alone(13). Unfortunately, 
hepatobiliary scintigraphy is underused. 
More recently, Gadoxetate-enhanced MRI has emerged as a more widely available 
alternative imaging-based method to measure liver partial function(14) (chapter 2.4.3). 
Static Gadoxetate-enhanced imaging has diagnostic benefit(352) for lesion 
characterization in the hepatobiliary/delayed phases; for benign(353), malignant(354) 
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and cirrhotic liver disease(355). It is commonly used in pre-operative staging of CRLM. 
Signal enhancement indices correlate with reference measurements of global liver 
function: ICG and GSA in animal(356) and human models(357).  
Segmental liver function and perfusion can be quantified by DGE-MRI, which involves 
rapid dynamic imaging in the minutes after injection of the agent and data interpretation 
by pharmacokinetic analysis (218) (358). Since function can be measured at a segmental 
level, DGE-MRI can potentially provide a direct prediction of post-operative liver function 
in absolute units (mL) blood cleared of Gadoxetate per min and per kg body weight) by 
defining the FLR-function accurately based on expected extent of resection. 
There is currently limited data on the added value of DGE-MRI functional assessments 
for patients undergoing liver resection as compared to current pre-operative 
assessments such as biochemical tests and FLR-volumetry. Reports by Nilsson and 
colleagues showed DGE-MRI can accurately predict function in patients with expected 
liver segmental function heterogeneity such as PBC(299), PSC(298) and alcohol-related 
and viral-induced Cirrhosis(300). One study demonstrated potential utility in liver surgery 
planning, by simulating a left hemihepatectomy (segments 2, 3 and 4) in patients with 
cirrhosis and control studies(301). However, there are so far no studies correlating pre-
operative DGE-MRI measurements of liver function directly with post-operative 
outcomes.  The optimal management of PHLF is to accurately predict when it will develop 
and use this prediction to tailor an operative plan to optimise the FLR. It is postulated 
DGE-MRI could have a role in the prediction of liver dysfunction, most pertinently 
predicting PHLF.  
PHLF risk factors are numerable and it is unclear what is the exact mechanism for their 
contribution to the PHLF syndrome (discussed in chapter 2.2 and 3). If the causative 
reason that factors such as age increase PHLF risk is because of a pre-operative 
impaired liver function that was not clinically detected, it would be important to identify 
this prior to subjecting patients to major surgery. DGE-MRI could have a role in 
identifying such impaired physiology(218)(Chapter 5.4.2). 
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Study objectives 
The primary aim of this study is to determine if any pre-operative DGE-MRI biomarkers 
of liver function and perfusion can predict post-operative outcomes. The question was 
addressed by measuring correlations between pre-operative DGE-MRI biomarkers with 
post-operative liver function, using bilirubin as the primary outcome and surrogate 
marker for function.  
Secondary outcomes aimed to assess the correlation of functional estimates with 
volumetry to demonstrate if DGE-MRI can demonstrate if liver function is homogeneous 
in patients with CRLM, and whether DGE-MRI estimates of function can predict PHLF 
itself, or if any known PHLF risk factor is associated with liver dysfunction(6). 
5.3 Materials and methods 
5.3.1 Subjects 
This was a single centre, prospective non-randomised observational study approved by 
the local research ethics committee. 29 patients with confirmed CRLM were recruited 
consecutively after they had been selected for curative major liver resection in the 
hepatobiliary multidisciplinary team meeting based on their preoperative CT. Additional 
inclusion criteria were: >18 years old, histologically confirmed colorectal carcinoma: 
either resected or expected resectable primary disease with radiological evidence of 
resectable metastatic disease. Exclusions were pregnancy, allergy/intolerance to 
Gadolinium-based contrast agents, and inability to undergo MRI. Their histology 
specimen was used to determine evidence of parenchymal liver steatosis based on the 
pathologist’s report. 
5.3.2 MR scanning 
All participants underwent a pre-operative staging MRI on a Siemens Aera scanner 
(1.5T) as part of their routine pre-surgical assessment. For this study, the routine protocol 
was modified by including a DGE-MRI sequence. DGE-MRI data were not shared with 
the clinical care team to avoid an influence on operative management decision making.  
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DGE-MRI was performed with a free-breathing protocol using a 3D spoiled gradient echo 
sequence describe in detail in chapter 4.3.1 (protocol 1), briefly, this was a spoiled 
gradient 3D sequence with a temporal resolution of 2.4s and 8-min acquisition. A 10ml 
dose Gadoxetate was delivered at 1ml/sec. Diagnostic imaging included  pre-contrast 
sequences included coronal and transversal T2-weighted imaging, axial T1-weighted 
Dixon imaging, axial fat-saturated T1-weighted imaging. The DGE-MRI sequence was 
followed by EPI diffusion imaging with b-values and repeat of the axial fat-saturated T1-
weighted imaging at 20min post contrast injection (hepatobiliary phase). 
5.3.3 Surgery 
Patients underwent liver resection appropriate to their oncological and radiological 
staging based on their MRI and CT reports, and ‘fitness for surgery’ assessment. 
Hepatectomies were performed using a similar open surgical technique by 5 different 
surgeons; an extra-glissonian approach to the porta hepatis, liver dissection using CUSA 
and intermittent Pringle as required. Intra-operative ultrasound was occasionally applied 
for lesion identification. The descriptions of segments resected and the naming of the 
operations were based on the Brisbane Classification(47) and are described as such 
throughout (see chapter 2.1.9). 
5.3.4 Post-operative care 
All patients were admitted to a High Dependency Unit following resection for a minimum 
of 24 hours, as part of an enhanced recovery program. Their biochemical and clinical 
progress was observed, and the patient was discharged home when medically fit.  
5.3.5 DGE-MRI post-processing 
The post-processing analysis of the DGE-MRI was performed by two of the authors (DL 
and SS); blinded to the clinical outcome of any of the patients at the time of analysis. 
Images were post-processed using PMI 0.4 (218). Five independent parameters were 
produced for each segment: TPF (ml/min/100ml), arterial delay (sec), AFF (%), ECV (%), 
hepatocellular UR (ml/min/100ml). 
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The details of the image processing have been described previously (218). Briefly, AIF 
and VIF were defined semi-automatically on a maximum signal-enhancement map, 
using an interactively defined threshold to select pixels with high enhancement values 
inside the aorta and portal vein, respectively. Tissue ROIs were drawn semi-
automatically to cover each liver segment on a map of the area under the enhancement 
curve. First, threshold was set interactively to identify liver tissue in 3D and exclude 
metastases and discrete benign lesions. Second, segments were delineated manually 
on these thresholded ROIs using IHPBA’s segment definition(47) and Dodd’s 
radiological description(359) using as landmarks the inferior vena cava, the right hepatic 
vein, middle hepatic vein and the falciform ligament. Concentration-time curves for each 
segmental ROI, AIF and VIF were calculated by assuming linear signal-relationship by 
subtracting the baseline signal. The dual-input two-compartment uptake model was then 
fitted to these data on a segment-per-segment basis. Figures 15 and 16 (chapter 4.3.2) 
demonstrate the drawn ROI defining the AIF, VIF and segments. 
5.3.6 FLR volume and function measurement 
The segmental volumes (V, ml) were determined for each segment by following the same 
segmentation approach as for the DGE-MRI but applied to the late-phase post-contrast 
breath hold T1-weighted imaging.  
A segmental uptake function (UF, ml/min) was determined by multiplying segmental UR 
and V (UF = UR*V). Absolute FLR function (ml/min) and absolute FLR volume (ml) were 
calculated by adding up UF and V, respectively, for all the segments in the FLR. Whole 
liver function and -volume were determined in the same way by adding up UF and V, 
respectively, for all segments. To arrive at directly comparable quantities and align with 
surgical convention, a relative FLR function (%) and relative FLR volume (%) were 
calculated by dividing absolute FLR function and –volume by the corresponding whole 
liver quantities.  
A segmental plasma flow (PF, ml/min) was determined by multiplying segmental tissue 
plasma flow and V. FLR plasma flow was calculated by adding up PF for all the segments 
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in the FLR, and whole liver plasma flow was calculated by adding up PF for all the 
segments. 
A complete measure of liver function needs to account for the blood flow to the liver as 
well as hepatocellular function and should be considered relative to patient size to allow 
comparisons between subjects. The most direct measure of function is therefore the liver 
clearance (CL) of an indicator in units of mL/min/kg (mL blood plasma cleared of the 
indicator per min and per kg body weight). CL for the FLR and the whole liver are 
calculated using a known formula as UF * PF / (UF + PF), and subsequently divided by 
body weight. 
Total liver function and -volume were determined in the same way by adding up UF and 
V, respectively, for all segments. To arrive at directly comparable quantities and align 
with surgical convention to express cut-offs on FLR volumes as a percentage of total 
liver volume, we calculated relative FLR function (%) and relative FLR volume (%) by 
dividing absolute FLR function and –volume by the corresponding total liver quantities. 
5.3.7 Data Analysis 
Post-operative bilirubin measured on day 5 was chosen as the primary outcome 
biomarker due to sharing the same cellular excretion as Gadoxetate, and its common 
use as surrogate for liver function and a marker of post-surgery dysfunction(215)(360).  
The primary objective was assessed with a linear regression model and Pearson’s test 
to measure strength of correlation between FLR-based biomarkers with post-operative 
bilirubin levels. We also tested predictive value of whole liver biomarkers to determine 
whether there is an added benefit in measuring the FLR separately. In order to determine 
whether DGE-MRI has added value over cheaper and readily available clinical markers, 
we also correlated common clinical risk factors for hepatic dysfunction(6) and 
biochemical measures against post-operative bilirubin levels. Available pre-operative 
clinical factors were weight (kg), age, diabetes status, BMI >30, pre-operative 
chemotherapy use (defined as receiving one or more cycle), renal insufficiency (defined 
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as eGFR <90), presence of background liver steatosis, and predicted number of 
segments removed. Available pre-operative biochemical markers were bilirubin, ALT, 
Alkaline Phosphatase, Albumin, INR, Prothrombin time, Lactate. 
5.3.8 Secondary outcomes 
Secondary analyses tested the strength of correlation between FLR-volume and FLR-
function using Pearson correlation to determine if liver function was homogeneous in the 
studied population.  
Any difference between the main risk factors for PHLF(6) and DGE-MRI estimates of 
function and perfusion was tested with T-test and Mann-Whitney test. The dependant 
variables were: 
• Perfusion Parameters: Total Plasma Flow, Arterial and Venous Flow Fraction, 
Extracellular Volume, and Mean Transit Time.  
• Function Parameters: Uptake Rate, Uptake Fraction and Uptake Function.  
• Volume 
• Functional bias 
The Functional bias, a measure of the discrepancy between volume and function was 
calculated: 
𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝐵𝑖𝑎𝑠 = 𝐹𝐿𝑅 𝑉𝑜𝑙𝑢𝑚𝑒 % − 𝐹𝐿𝑅 𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛 % 
The independent variables were known risk factors for liver dysfunction: 
• Pre-operative factors: chemotherapy, background liver steatosis, diabetes, BMI >30, 
renal dysfunction (eGFR <90), pre-operative liver dysfunction (bilirubin >20)  
• Intra-operative factors: major vs. minor resection  
• Post-operative factors: post-operative infection 
A ROC analysis was performed for each variable to assess the effectiveness of the DGE-
MRI parameters as a diagnostic test.  
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A significance level of 0.05 was assumed. All statistics were performed using SPSS v22 
(IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, 
NY: IBM Corp). 
5.4 Results 
5.4.1 Patient Demographics 
29 patients were recruited, and 28 patients were included. 1 was excluded due 
incomplete dynamic data collection. The median age was 63 years (Range 41-83). 18 
were male. 23 patients underwent liver resection: 15 patients had major liver resection; 
8 patients underwent a more parenchyma-preserving limited resection. 6 patients were 
deemed inoperable, either due to findings on their staging MRI of more extensive liver 
metastasis or extra-hepatic disease, or subsequent clinical reasons for being unfit for 
surgery, and hence excluded from analysis of FLR prediction. Patients who received 
chemotherapy underwent a minimum of 3 cycles of either oxaliplatin plus fluorouracil and 
leucovorin (FOLFOX) or single agent Capecitabine. No patient had hyperbilirubinaemia 
prior to surgery. All cases of histologically confirmed steatosis were mild only (<5% total 
liver volume). Demographics are included in table 31. A detailed description of each 
patient’s results included in Appendix A. 
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Table 31: Patient demographics 
 
Major Liver 
resection 
(n=15) 
Minor Liver 
Resection 
(n=8) 
No liver resection 
(n=6) 
Age 63 (41-83) 63 (47-78) 63 (49-69) 
Patients aged Over 75 % 27 12.5 0 
Median Number of segments resected 3 (3-5) 2 (1-2) 0 
Median Remnant Liver Volume (%) 55 (27-60) 73 (67-90)  n/a 
Median Remnant Liver Function (%) 53 (24-62) 74 (65-91)  n/a 
Pre-operative chemotherapy use (%) 73 37.5 100 
Evidence of background liver steatosis 
(%) 
53 75 n/a 
                     Pre-operative bilirubin 18 (5-20) 8 (5-26) 
Pre-operative ALT 20 (11-96) 21 (9-56) 
Pre-operative ALP 231 (155-
555) 
231 (150-336) 
Pre-operative Albumin 45 (41-50) 44 (41-48) 
Pre-operative INR 1 (0.9-1.1) 1 (0.9-1) 
Pre-operative PT 11 (10-12) 11 (10-11) 
Pre-operative Lactate 1 (0.9-1.3) 1 (0.9-1) 
 
5.4.2 DGE-MRI function estimates and post-operative function 
Three parameters measuring FLR function were negatively correlated with post-
operative bilirubin (Table 32, Figure 17 and 18): FLR-UR (r = -0.57 p = 0.007), FLR-CL 
(r =-0.53, p=0.014), FLR-UF (r = -0.45, p = 0.04). In particular FLR volume, either in 
absolute or relative units, was not predictive of post-operative function. Equally, FLR 
perfusion and related parameters such as the arterial fraction were not predictive of 
outcome.  One whole liver parameter (WL-UR) was significantly correlated (r = -0.43, 
p=0.04), but not as strongly as the equivalent parameter for the FLR.  
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Figure 17: Comparison of post-operative bilirubin with FLR-GC (r =-0.53, p=0.014) 
 
Figure 18: Comparison of post-operative bilirubin with uptake rate (r=-0.57 p=0.007)  
 
5.4.3 Clinical markers 
There was no correlation of FLR-volume with post-operative bilirubin (table 32). As 
mentioned, volumetry is considered an important assessment to ensure adequate FLR 
to avoid post-operative dysfunction, so this result is important in context of this study as 
the predictive value of function assessment has increased utility over volume. 
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5.4.4 Pre-operative biochemical biomarkers 
There was correlation with an elevated pre-operative bilirubin, and the presence of 
background liver steatosis as per the pathology report (R=0.43 p=0.04), and although 
there was no association of patients’ weight, when corrected into BMI there was an 
associated with post-operative bilirubin (R=0.46 p=0.03). It is known that obese patients 
have a higher incidence of NAFLD, and this may explain this finding. No other risk factor 
examined was predictive of post-operative function (table 32). 
Table 32: Correlation of DGE-MRI estimates with post-operative bilirubin 
 
 
 
 
 Correlation with post-operative 
bilirubin (umol/L) 
P-value 
Whole Liver estimates 
Liver Volume (ml) 0.1 0.65 
Total Plasma Flow (ml/100ml/min) -0.17 0.44 
Arterial Flow Fraction (%) 0.23 0.35 
Extra Cellular Volume (ml/100ml) -0.17 0.45 
Uptake Rate (ml/100ml/min) -0.43 0.04 
Arterial Plasma Flow (ml/100ml/min) 0.36 0.13 
Venous Plasma Flow (ml/100ml/min) -0.18 0.46 
MTT (secs) 0.01 0.95 
Uptake Fraction (%) -0.2 0.36 
Uptake Function (ml/min) -0.34 0.12 
Plasma Flow (mL/min) -0.097 0.67 
Normalised clearance (mL/min/kg) -0.4 0.056 
FLR estimates 
Volume (ml) -0.34 0.13 
Total Plasma Flow (ml/100ml/min) -0.14 0.54 
Arterial Flow Fraction (%) 0.08 0.74 
Extracellular Volume (ml/100ml) -0.16 0.48 
Uptake Rate (ml/100ml/min) -0.57 0.007 
Arterial Plasma Flow (ml/100ml/min) 0.36 0.15 
Venous Plasma Flow (ml/100ml/min) -0.03 0.91 
MTT (secs) 0.04 0.86 
Uptake Fraction (%) -0.27 0.24 
Uptake Function (ml/min) -0.45 0.04 
Plasma Flow (mL/min) -0.27 0.24 
Normalised clearance (mL/min/kg) -0.53 0.014 
Volume % -0.34 0.09 
Function % -0.41 0.07 
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Table 33: Correlations of patient factors and pre-operative biochemical tests 
 
5.4.5 Secondary outcomes 
5.4.6 Association of FLR volume and function 
There was a strong correlation between the normalised FLR-volume and FLR-function 
%, Pearson correlation = 0.989, R2 = 0.977 and a B value = 1.024 (p=<0.001). This 
demonstrates that in our population FLR-volume and -function are equivalent and FLR-
function testing robust; and would suggest that liver function in this population is 
homogeneous. FLR-function could therefore be considered for assessment of the FLR 
in this population in place of volumetry if reduction of ionising radiation exposure is 
desirable. 
  Correlation with post-operative 
bilirubin (µmol/L) 
P-value 
Pre-operative patient factors 
Weight (kg) 0.13 0.56 
Age 0.39 0.07 
Diabetes status (present vs not) 0.03 0.98 
BMI >30 vs <30  0.46 0.03 
Chemotherapy vs no chemotherapy 0.32 0.14 
Renal Insufficiency (eGFR <90) vs 
eGFR >90 
-0.05 0.83 
Liver steatosis vs normal liver 0.11 0.628 
Pre-operative biochemical tests 
Bilirubin (µmol/L) 0.28 0.21 
ALT (U/L) 0.13 0.58 
Alkaline Phosphatase (U/L) 0.1 0.67 
Albumin (µmol/L) 0.07 0.76 
INR -0.3 0.18 
Prothrombin time (s) -0.2 0.33 
Lactate (mmol/L) 0.14 0.54 
Number of segments 0.29 0.2 
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Figure 19: FLR volume and FLR function 
 
5.4.7 Association of PHLF risk factors with DGE-MRI estimates 
When all risks were examined, there were significant differences for 3 subsets of patients 
for functional parameters: age, steatosis, and extent of resection. All other tested 
variables had non-significant results. 
5.4.8 Function parameters 
Age  
There was a significantly reduced uptake of contrast for the measures of function: uptake 
rate, uptake fraction and uptake function in patients over 75, indicating that older patient’s 
livers may have impaired uptake ability and excretory function.  This was seen in both 
assessment of the uptake of the whole liver and the FLR, which suggests that there is 
global impairment of the older patients’ liver. ROC Analysis showed significant AUC 
values of over 0.75 for each functional parameter, demonstrating each function estimate 
could have a role as a diagnostic test (see table 34).  
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Table 34: Age compared to the Whole Liver functional parameters 
 Age 
<75 
(Mean 
SD) 
n=10 
≥75 
(Mean 
SD) 
n=5 
P 
value 
(T 
test) 
<75 
Median 
(Range) 
≥75 
Median 
P value 
(Mann 
Whitney 
test) 
AUROC P 
value 
Whole Liver Function 
Uptake Rate 
ml/100ml/min 
14 
(3.9) 
8 (4.4) 0.03 14.6 (2-
21) 
6.1 (4-
13) 
0.019 0.84 0.02 
Uptake 
Fraction % 
12 (6) 6 (1.2) 0.002 10 (5-
28) 
5.7 (5-
8) 
0.009 0.88 0.01 
Gadoxetate 
clearance 
ml/min 
225 
(73) 
107 
(69) 
0.013 211 (98-
324) 
78.6 
(45-
200) 
0.012 0.87 0.01 
FLR Function 
Uptake Rate 
ml/100ml/min 
14 (4) 8 (4) 0.05 15 (8-
21) 
5.9 (4-
13) 
0.012 0.87 0.01 
Uptake 
Fraction % 
11.5 
(6) 
6 (1.4) 0.004 9.8 (4-
29) 
6 (5-8) 0.03 0.82 0.03 
Gadoxetate 
clearance 
ml/min 
127 
(74) 
67 
(59) 
0.09 113 (35-
297) 
43 (11-
158) 
0.09 0.76 0.08 
 
Figures 20 and 21 show case examples for a younger vs older patient. demonstrating 
differences in uptake parameters. 
Figure 20: A patient in their 40s undergoing right hepatectomy (T1 axial & coronal) 
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Figure 21: A patient in their 80s undergoing multiple metastatectomy 
 
Background liver steatosis 
The uptake fraction was significantly lower for patients with normal liver parenchyma 
when the whole liver segment was analysed, however although the trend in other uptake 
operators showed lower values, the other functional parameters were non-significant in 
either whole liver or FLR ROIs. It is not clear if this has any meaningful reason for its 
effect. In addition, the extent of steatosis was not confirmed with objective 
immunohistochemical testing, rather based on the reporting pathologist report, therefore 
there is risk of type 1 error due to potential misdiagnosis of extent of steatosis(361). 
Table 35: Background liver and whole liver functional assessment 
 Normal 
liver 
mean 
n=10 
BG Liver 
Steatosis 
mean 
n=13 
P 
value 
(T 
test) 
Normal 
Liver 
median 
Background 
liver median 
P value 
(Mann 
Whitney 
test) 
AUROC P 
value 
Uptake Rate 
ml/100ml/min 
11.5 
(4.4) 
13.9 
(4.9) 
0.24 11.3 (4-
18) 
13.3 (4-21) 0.2 0.67 0.18 
Uptake 
Fraction % 
8 (2.5) 12.6 
(6.7) 
0.04 7.2 (5-
13) 
10.8 (5-28) 0.04 0.75 0.04 
Gadoxetate 
clearance 
ml/min 
165 
(84) 
226 (80) 0.09 163 (45-
309) 
184 (45-324) 0.67 0.73 0.06 
 
Extent of resection 
Patients who required major liver resection for multiple or centrally based tumours had 
significantly lower UF and UR than those who had parenchymal minor liver resection, 
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which was observed, in both whole liver and FLR models. This indicates that patients 
who have larger resection – which indicates either increased cancer burden with 
increased metastasis or larger tumours – seem to have a reduced Gadoxetate uptake 
than those with fewer/smaller metastasis, possibly indicating different cellular function. 
Table 36: Type of resection and functional parameters 
 Minor 
resection 
mean 
n=8 
Major 
resection 
mean 
n=15 
P 
value 
(T 
test) 
Minor 
resection 
median 
Major 
resection 
median 
P value 
(Mann 
Whitney 
test) 
AUROC P 
value 
Whole Liver   
Uptake Rate 
ml/100ml/min 
15 (5.8) 12 (3.8) 0.09 16.4 (4-
21) 
12 (4-18) 0.08 0.73 0.07 
Uptake 
Fraction % 
14 8.5 0.016 12.6 (5-
28) 
7.6 (5-
14) 
0.047 0.75 0.049 
Gadoxetate 
clearance 
ml/min 
246 (98) 174 (70) 0.05 294 (55-
324) 
181 (45-
299) 
0.047 0.76 0.045 
FLR Function   
Uptake rate 
ml/100ml/min 
15 (5.7) 12 (3.8) 0.2 16.6 (4-
21) 
12 (26-
46) 
0.11 0.71 0.1 
Uptake 
fraction % 
14 (8) 8.5 (3.3) 0.03 12 (5-29) 185 (43-
297) 
0.05 0.75 0.05 
Gadoxetate 
clearance 
ml/min 
174 (80) 82.5 (48) 0.003 185 (43-
297) 
75 (11-
179) 
0.008 0.83 0.01 
 
61% of patients under 75 had a major resection and 80% over 75s had major resection; 
there was no significant association between those patients age >75 and major resection 
(ᵪ2 p=0.41).  Both groups can therefore be considered independent of each other, and 
as such there is no evidence of confounding between age and extent of resection. 
Figures 22 and 23 show examples for a major resection vs a more limited resection. 
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Figure 22: A patient having an extended right hepatectomy 
 
Figure 23: A patient having a two-segment resection 
 
PHLF and functional bias 
No perfusion or function parameter was predictive for PHLF when tested and as such no 
individual parameter could be used for this purpose (table 37).  
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Table 37: Key DGE-MRI function parameters with & without PHLF development 
 No PHLF Mean 
(SD) 
PHLF Mean 
(SD) 
P value (T 
Test) 
Whole Liver  
Uptake Function (ml/min)  231.6 (86.9) 188.8 (73.8) 0.22 
Uptake Fraction (%)  11.3 (6.3) 10.2 (5.1) 0.6 
Clearance (mL/min)  203.2 (74) 166.9 (57.1) 0.2 
Normalised clearance (mL/min/kg) 2.6 (0.8) 2.2 (0.6) 0.11 
FLR  
Uptake Function (ml/min)  159.6 (54.1) 99.8 (78.3) 0.06 
Uptake Fraction (%)  11.7 (6.9) 9.8 (5.0) 0.46 
Clearance (mL/min)  139.5(46.1) 88.0 (65.3) 0.055 
Normalised clearance (mL/min/kg)  1.8 (0.6) 1.2 (0.8) 0.06 
 
When the functional bias was tested, there was no difference between the median value 
of no=PHLF compared with cases of PHLF (PHLF=+1 vs no PHLF =+0.2 p=0.74). 
Overall the number of observed cases of clinically significant PHLF (B or C) was low at 
4 cases of PHLF B, therefore too few cases were observed to be able to adequately 
assess for significance of any predictive ability of our method, although FLR clearance 
was found to be near significance(5). 
5.4.9 Perfusion parameters 
There was no significant difference seen in any of the perfusion parameters (plasma 
flow, arterial plasma flow, venous plasma flow, or MTT) with any pre-operative or post-
operative risk factor, suggesting that liver perfusion in isolation cannot detect any 
clinically significant differences. Plasma flow parameters are required to calculate uptake 
fraction % and gadoxetate clearance in our estimates of liver function and therefore are 
still required. 
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5.5 Discussion 
These results demonstrate that DGE-MRI estimates of FLR-function are predictive of 
post-operative function as measured by hyperbilirubinaemia. No currently utilised 
modality such as biochemical biomarkers, clinical parameters or volumetry were 
predictive. This indicates that DGE-MRI could have utility in operative planning in 
combination with currently available investigations.  
The DGE-MRI study was designed to have a pragmatic acquisition methodology which 
could be adapted into a clinically acceptable protocol to both patient and the busy MRI 
department; one with free breathing and requiring no additional acquisition time or 
additional scanning. By adding the DGE-MRI sequence into diagnostic imaging this 
allows flexibility and ease of use in pre-operative planning and could supersede CT 
volumetry when critical FLR values are required; particularly useful to reduce the burden 
of addition scanning to patients.  
5.5.1 Utility of pre-operative FLR-function and post-operative function   
Elevated bilirubin levels are known to be associated with impaired liver function, 
predominantly in parenchymal liver disease(362). When elevated in the post-operative 
period it is an indicator of inadequate liver tissue to handle adequate excretion and it is 
an independent measure of risk of PHLF and mortality(1). It is established that very high 
post-operative bilirubin levels (over 7mg/dL) have high sensitivity and specificity for 
mortality or morbidity(1), both of which are associated with a smaller FLR of <25%(6).  
If it is possible to predict pre-operatively which patients may be at more risk for 
inadequate liver function when FLR is close to 25% (or 0.5% of the total body 
weight(363)), or to be used in the assessment of patients with parenchymal liver disease, 
such as those with hepatocellular carcinomas with background fibrotic or cirrhotic liver, 
it would be beneficial to either offer a more limited, parenchymal resection, or offer a 
hypertrophic liver procedure such as portal vein embolisation or ligation. Such measures 
improves outcome for patients with marginal threshold for FLR(76)(86)(364), or indeed 
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allow patients who would have otherwise been deemed unsuitable to have major 
surgery. 
There was a predictive value of using FLR-function estimates for post-operative 
hyperbilirubinaemia. The only clinical risk factor predictive of functional outcome was 
increased BMI. None of the biochemical markers were predictive of post-operative 
function (table 33).  
Bilirubin was chosen as the primary outcome measure over liver transaminases in the 
post-operative period. Bilirubin and Gadoxetate share a common excretion pathway. 
Impaired hepatocellular excretion would reduce both bilirubin clearance and Gadoxetate 
clearance. FLR-uptake and clearance could prove useful in assessing patients who are 
to undergo major resection (with predicted marginal FLR) to estimate the likelihood of 
post-operative dysfunction.  
Transaminases are commonly used measures of hepatic dysfunction, predominantly in 
parenchymal liver diseases(365), however in a large prospective study of 651 liver 
resections, Boleslawski and colleagues found there was no association with post-
operative transaminases and function(205). As such they have not been investigated 
here. 
5.5.2 Negative results 
DGE-MRI perfusion measurements did not have any predictive capacity, but this 
expected considering no patients enrolled in this study had significant parenchymal, 
macrovascular or microvascular pathology which would impair hepatic perfusion. There 
were no reported cases of CILI. Perfusion is useful when there is parenchymal liver 
pathology and, in this context, its true role requires elucidation. A separate issue that 
may play a role is that perfusion parameters are generally less precisely measurable. To 
some extent that may also reduce the correlations with other markers. 
It is also interesting that FLR volume was not predictive of outcome. CT volumetry is 
commonly used in pre-operative assessment and MRI volumetry has been shown to be 
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equivalent(297)(366). However, volumetry is traditionally only used to assess whether 
resection would reach a critical cut-off point (e.g. FLR < 20% in healthy liver), but not as 
a direct predictor of post-operative function.   
BMI was the only clinical/biochemical marker predictive of outcome though the 
correlations were weaker than for FLR-UR. It is known that patients with increased BMI 
have higher incidence of steatosis and NAFLD(367), and could explain why there was 
alteration in liver function measured; although steatosis itself did not demonstrate 
correlation. Only 4 patients had a BMI of >30 and steatosis and BMI did not correlate 
when tested separately (some patients with normal BMI had steatosis and visa versa). 
Whether BMI is true predictive factor for post-operative function future higher-powered 
study would be required to determine the true relationship. 
Other markers such as pre-operative bilirubin were not predictive of post-operative 
bilirubin, but this may be due to the fact that the population was selected to have healthy 
liver and therefore all bilirubin levels were in or close to the normal range – any patients 
with hyperbilirubinaemia would have been excluded from analysis. 
5.5.3 Benefits of DGE-MRI over other modalities 
Global measures such as ICG (12), have proved useful as a screening tool to risk-stratify 
patients for liver surgery. This test does provide an excellent measure of global liver 
function, mostly used in patients with liver disease as a discriminator for patients with 
already severe liver dysfunction as to whether to even attempt surgery(12)(274). As a 
result, in isolation with a patient with supposed normal functioning liver it would be difficult 
for this to be able to help in risk stratification. DGE-MRI’s strengths until now have been 
for patients with heterogeneous liver function, but these results suggest DGE-MRI could 
prove a more useful function biomarker for patients with homogeneous function 
distribution, and has added benefit as different FLR-ROI can be constructed to assess 
for differences between major or minor resection (for instance the difference in FLR-
function between a 4-segment right hepatectomy or 2-segment right posterior 
sectionectomy). This could help with surgical planning strategies. 
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LiMAx has been demonstrated in a large series by Jara and colleagues that following 
their implementation of LiMAx testing by the above method they reduced their incidence 
of PHLF and mortality – they attribute this to the LiMAx allowing improved patient 
selection for resections(283). LiMAx does provide an excellent stratification of risk for 
surgical candidates and it is much more commonly being used for this purpose. However, 
its role is limited as with the ICG when there is expected to be close to the threshold of 
FLR or in inhomogeneous liver and DGE-MRI will give added benefit of true FLR 
assessment. 
Scintigraphic techniques using radio-labelled Mebrofenin as an albumin bound substrate 
have been developed as predictors of function(288). The drawback with such methods 
is images tend to be low resolution and the quality in detailed anatomy required to 
differentiate segments is difficult. They require combination with CT to obtain a high 
enough resolution for accurate FLR assessment(13).  
CT Volumetry is considered the gold standard for pre-operative planning, however it 
does come with some limitations; variation in tumour size, presence of multiple lesions, 
and atrophic or hypertrophic liver, make CT volumetry an error-sensitive imaging 
technique(348)(199). It involves ionising radiation exposure. This study identified DGE-
MRI as demonstrating good estimates of FLR- function, and it being as efficacious as 
volumetry measurements in a homogeneous liver (chapter 5.4.5). It could be considered 
as an alternative imaging modality over CT. All patients received MRI with Gadoxetate 
as part of their oncological staging, and the DGE-MRI protocol adapted in this study does 
not require an additional examination or hospital visit. It allows diagnostic and function 
assessment in a clinically acceptable timeframe in one scan, avoiding ionizing radiation 
and potentially offering effective assessment. 
DGE-MRI may offer additional benefit when there is inhomogeneous function, such as 
patients with underlying parenchyma disease or hepatic comorbidity. However, this study 
could not examine if this is possible, as this cohort of patients had at most mild steatosis 
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and most had no liver parenchymal disease at all. Further study may be able to fully 
assess DGE-MRI’s utility 
Volumetry was performed on MRI rather than CT, however this should not be an issue 
as CT and MRI volumetry have been shown to be equivocal(297)(366). 
5.5.4 Secondary outcomes 
Age and patients requiring major resection that may have impaired liver cellular function 
for other reasons than fibrotic/cirrhotic diseases. 
5.5.5 Age and function assessment 
The age of 75 was used as a cut-off value to discriminate between younger and older 
patients. This is the age which risk of liver surgery increases(329). This was also the 
determined age cut-off determined in chapter 3. 
Patients in this study who were older tended to have reduced Gadoxetate uptake rate, 
function and fraction observed which may be explained by current understanding of the 
physiology of ageing; essentially older patients may have reduced liver function due to 
age-related physiological changes(332). There seems to be an association between 
ageing and a higher background bilirubin(261), signifying a reduction in liver function, 
and the uptake and excretion of bilirubin in ageing populations, which would follow given 
the shared excretory pathway of both bilirubin and Gadoxetate. Such results to marry up 
with mebrofenin scintigraphy studies by Cieslak and colleagues which demonstrate 
declining uptake as patients age(262), Vallance and colleagues findings of worsening 
outcome with age(333) and the right hepatectomy study found in chapter 3. All this 
suggests older patients have impaired function and this should be taken into 
consideration when planning surgery. 
5.5.6 Background liver steatosis and function assessment 
Uptake function % values were significantly lower in patients with normal liver compared 
to steatotic liver, however this difference was not observed with other functional 
parameters. In fact, from a biological perspective, the expected reduced uptake would 
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be expected to be seen in the reverse situation; that steatotic liver will not uptake contrast 
as well as non-fatty liver. In addition, the degree of steatosis seen in the histological 
resection was very small, always reported as less than 5%, and it is therefore unlikely to 
have such a major effect on the function of the liver itself. As a result, this finding should 
be interpreted with caution as to if it signifies any true biological explanation or is a type 
1 error. A Bonferroni correction (multiplication of the observed p-value by the number of 
performed statistical analyses)(368) would render this value non-significant (p=0.12) 
5.5.7 Extent of resection and function assessment 
These results suggest that patients who needed major resection, viz. those with 
increased tumour burden have reduced functional parameters – the uptake of the 
contrast is diminished and the transfer from molecules from the extra-hepatic space to 
intra-hepatic space is slower.  
The liver is a ‘target organ’ of metastasis(149). Metastatic cells from the colon that enter 
the venous system via haematogenous spread, and so would drain via the portal system 
into the microvascular structure of the liver. Sinusoids allow rapid movement of 
metastatic cells from the intravascular space to beyond the basement membranes(150). 
The microstructure of the liver seems to ‘help’ the metastasis enter tissue(151); as the 
liver’s basement membrane is less well defined as other organs; it seems to disintegrate 
upon exposure and this disintegration leads proliferation of endothelial cells, and 
endothelialisation of tumour – promoting early angiogenesis and hence metastasis 
growth.  
Whether our results reflect something different about such patients’ liver metabolism that 
predisposes patients to increased metastatic disease burden – impaired function leads 
to failure to either destroy metastases or allow implantation into the liver raises a very 
interesting hypothesis about the pathogenesis of CRLM that should be evaluated with a 
larger study. 
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5.5.8 PHLF 
Part of this study aimed to assess if there was any association between DGE-MRI 
parameters, or FLR-function and the development of PHLF. Due to the few cases of 
PHLF observed – no severe, 4 moderate and 8 minor it could not demonstrate any 
parameter was predictive. Indeed, the number recruited was based on a pre-recruitment 
power calculation of 30 major resections based on what was deemed appropriate to test 
the hypothesis of prediction, led to the study being underpowered. 
Our population seldom was close to the critical threshold of 25% at which the risk 
becomes unacceptably high(3), and the total number of major resections was only 15, 
which is only half the number required to achieve adequate power to test this hypothesis. 
Due to the practicalities of the recruitment process and a finite window of one year only 
to recruit study participants, it was not possible to fulfil this obligation, despite the best 
efforts of the authors and the MRI department at St James’s Hospital, Leeds. 
As a result there would not be the expectation of the development of PHLF in this 
population, especially as patients are carefully assessed and any patients felt to be at 
undue risk of PHLF will either be deemed inoperable, have a small parenchymal 
resection or undergo a hypertrophic procedure to reduce PHLF risk, so perhaps this 
population examined was not ever likely to show PHLF, and as such studies on patients 
having major resection with a higher number will have the power to demonstrate if a 
difference exists. 
5.5.9 Limitations 
Background liver disease assessment was assessed by a pathologist with a special 
interest in liver disease, but no immunohistochemical analysis was available which may 
have improved assessment of the extent of steatosis or CILI(361). This could have led 
to confounding results.  
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Liver function is multifactorial, and bilirubin may only represent excretory function, and 
no synthetic or metabolic elements. ICG is a test that does measure liver function 
directly, and future studies should use ICG as primary outcome measure after surgery.  
Our population had homogeneous liver function and generally had resections that 
maintained patients had adequate FLR; the numbers of cases who ultimately underwent 
major liver resection was less than anticipated. Although the intent was to recruit patients 
who required a major liver resection, unforeseen clinical findings led some patients to 
either being inoperable or ultimately undergoing a more minor, parenchymal preserving 
surgery, due to the surgeon’s concern of subjecting patients to undue risk once clinical 
assessment and staging was complete. This means this study was unable to make any 
assessment of patients with established liver disease such as fibrosis or cirrhosis and 
assessing for PHLF risk was not able to be determined in our population. 
Given the nature of this pilot study design and analysis, it is possible there could be a 
familywise type 1 error which could not be controlled. Application of a Bonferroni 
correction (368), would mean many results in this study become non-significant, with 
only comparisons between UF% and age (p=0.006) and both UF% and GC and extent 
of resection (whole liver UF% p=0.048, FLR CG p=0.009) remaining significant. 
Bonferroni correction can reduce type 1 errors, but often overestimates type 2 errors. It 
is most effective if proof of equivalency is required and a type 1 error has to be excluded 
for critical patient treatment decisions. In the case of hypothesis generation studies 
where a large number of tests are carried out, such as this study, it could potentially 
exclude interesting findings from further investigation erroneously(368). This research is 
preliminary and hypothesis generating, and future study such as HEPARIM should 
provide more definitive results.  
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5.5.10 Conclusions 
The data confirm the hypothesis that DGE-MRI based predictions of post-operative liver 
function show potential as a means of informing patient selection and surgery planning. 
This could be particularly relevant in patients with underlying liver disease where 
volumetric estimates are not reliable.  
DGE-MRI function assessment appears to be as effective as volumetry for assessing 
patient’s FLR when undergoing liver resection for CRLM. Older patients and patients 
who underwent major resections had reduced functional parameters measured by our 
model suggesting possible reduced physiological function in such patients.  
A follow-up study (HEPARIM) informed by these data is currently recruiting and will aim 
to confirm this hypothesis in a less selective population, using a more direct 
measurements of post-operative liver function with ICG. 
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Chapter 6 – Discussions and Future projections 
6.1 Inference from studies 
The primary objective of the study described in chapter 3 was to examine the risk of 
increased age on patients having a major resection. It identified being over 75 was an 
independent risk factor for PHLF development. Such new knowledge allows patients 
being considered for major hepatectomy to be risk-assessed for fitness of their resection. 
This may lead to a parenchyma-preserving operation that increases risk of incomplete 
or R1 resection, or for hypertrophic procedures such as PVE, or even ALPPS to be used. 
The study described in Chapter 5 demonstrated there is a significant correlation of FLR-
function and post-operative bilirubin levels, which was improved over FLR-volume 
measurement and biochemical and clinical risk factors. 
The original intent and design of the DGE-MRI study to assess if PHLF could be 
predicted pre-operatively however due to the limited number of patients who actually 
developed a significant degree of PHLF was too low and as such it could not demonstrate 
any difference. However, it did detect a significant difference in age; namely older 
patients had reduced liver function. The findings from both studies do marry up logically 
and do add credence to the idea that age related deterioration of the liver leads to 
reduced function in that sub-group and when exposed to a major physiological insult, 
older patients are therefore more at risk of PHLF development. 
This leads us to question the most appropriate way of optimising older patients do require 
surgery. As discussed, the role of hypertrophic procedures does improve the FLR volume 
and presumed FLR function and can be considered when patients are on the borderline 
of having too small a liver remnant.  
The results show of the role of DGE-MRI derived FLR-function could be useful in patients 
with CRLM, however in patients with parenchymal liver disease who require surgery this 
could prove pivotal in pre-operative assessment of the liver when there may be a 
significant mismatch of volume and function. 
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6.2 Future studies 
6.2.1 Pre-operative PVE study 
The Chapter 3 study raised interesting perspectives for future study.  The influential study 
by Farges and colleagues(79) showed there was no benefit for patients to undergo PVE 
before right hepatectomy, however our results suggest that as older patients have 
increased risk of PHLF, so some kind of intervention is required. Farges’ patient cohort 
was much younger, with the mean age being 53 for those without PVE and 58 for those 
undergoing PVE. Older patients should be considered to be a different patient 
population, and their function may well be impaired, with a mismatch of volume and 
function. The DGE-MRI study does show there may be a difference between the FLR-
volume (which was not correlated with post-operative bilirubin levels) and FLR-function 
(which uptake rate and clearance were correlated with post-operative bilirubin). 
Current cost for PVE is approximately £5,000 per procedure. This analysis shows that 
just on LOS cost that a patient who develops PHLF would cost on average £8,412 more 
than a patient without. If performing PVE on those over-75 years could eliminate PHLF 
then simply performing this on 2 patients could lead to this being cost effective, 
notwithstanding the potential for improved clinical outcomes. There is evidence that PVE 
does induce hypertrophy and therefore increases future liver remnant volume(81)(75). It 
may induce some tumour growth in the contralateral liver in patients, which could render 
disease inoperable(341). As such for this a dedicated prospective randomised controlled 
study should take place to be able to assess both the clinical and the cost-effectiveness 
of PVE in the older population. This study is yet to be fully designed or implemented. 
Table 38: Hypothesis for potential future study 
Population Older Patients undergoing major hepatectomy (4 or more segments)  
Intervention PVE of the contralateral liver prior to surgery 
Comparison Surgery without hypertrophic procedure 
Outcome Incidence of PHLF development 
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6.2.2 HEPARIM study 
DGE-MRI is a potentially useful clinical biomarker for hepatic function, with multiple 
applications beyond the surgical perspective of estimating post-operative function. 
The original intent of this study was to assess if DGE-MRI could have a role in the 
prediction of clinical outcomes, principally the prediction of PHLF. As previously 
discussed, no patients enrolled in the study ultimately really were the patients who would 
run the risk of PHLF; either too minor a resection, or those who had major resection were 
young, with no other comorbid risk factor, and with sufficient FLR remaining that were 
was no predictive capacity. Time and resource limitations limited the opportunity. There 
was only a limited recruitment window and due to the lack of additional funding limited to 
recruitment to no more than 1 patient a week, therefore too few major resections were 
recruited. However the promising results of this pilot study have led to the ‘hepatectomy 
risk-prediction with functional Magnetic Resonance Imaging’ (HEPARIM) study being 
initiated, and recruitment beginning. 
The aims of further study such as HEPARIM should focus on both technical 
improvements and refinement of methods, plus an expanded population base and the 
addition of the comparison of ICG as an improved measure of liver function, over bilirubin 
or clinical scoring systems. 
There was variation in results in many key components for both function and perfusion 
parameters seen depending on complexity of models that was described in chapter 4. It 
is not currently clear what the values should be, or the expected range of data, across 
both a control and disease group of patients, and particularly if more complex models 
are needed to have clinically efficacious results, and a larger population may help define 
the normal range of values. 
DGE-MRI scan methods have undergone significant improvement since the data for this 
study were collected. In particular free-breathing radial imaging sequences have become 
available since these data were collected that promise rapid scanning with high 
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diagnostic quality. This will likely have a major positive impact on the accuracy of DGE-
MRI measurements. It can be expected that this will lead to improved correlations 
compared to this study, which uses scanning sequences that suffer from significant 
motion artefacts and low spatial resolution. Refinement of methodology should improve 
predictive capacity by increased precision and accuracy of data. The methods used in 
this study of analysis were time consuming and potentially error prone, particularly with 
VIF identification – as many patients had poorly imaged or small portal vein that made it 
difficult to identify and draw a consistent ROI that was not overly affected with movement 
artefact - any individual scan could take several hours to draw ROI even with extruding 
ROI in multiple planes, and as such may deter clinical use initially. If improved ROI 
drawing for FLR can be optimised, or even automated, to improve analysis time then it 
would be a more attractive solution to define FLR function. 
Until recently, most studies have assessed patients with liver disease which this study 
did not assess. It was designed pragmatically to fit in with the busy diagnostic scheduling 
of the MRI department, and no additional scans were able to be performed due to time 
and lack of funding for research scans. Patients with parenchymal liver disease have 
clear disparity between functional healthy liver and dysfunction diseased liver. 
Assessment of FLR for such patients that are undergoing resection for primary liver 
cancers would be paramount to ensure lack of complications. DGE-MRI could prove 
most fruitful in this subset of patients, which is planned for future studies. 
ICG is widely recognised for its role in direct measurement of liver function and is 
considered the gold standard measurement. Any future study will require concordance 
with ICG parameters to be truly representative of measurement of liver function as this 
is currently recognised as the gold standard. ICG has seldom been available in the UK 
for use in liver function assessment, despite its common applications routinely in Japan 
and South Korea(319). Approval for concurrent use has been achieved for HEPARIM 
and the utilisation of this with patient having DGE-MRI imaging will hopefully prove fruitful 
in improving assessment of liver diseases and patients requiring liver surgery.  
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HEPARIM’s primary outcome is to compare DGE-MRI functional measurements against 
the results of ICG, which is more robust than using bilirubin as a measurement, which 
levels can vary due to other post-operative factors such as bile leak. ICG is considered 
the gold standard measurement of liver function - to determine if preoperative function 
of the FLR as measured by Gadoxetate Clearance in DGE-MRI is an accurate prediction 
of post-hepatectomy liver function. 
Table 39: Primary outcome of HEPARIM 
Population Patients requiring major hepatectomy for any malignant tumour 
Intervention DGE-MRI prediction of FLR function 
Comparison Change in ICG measurement of liver function from pre- to post-op 
Outcome Strength of correlation 
 
HEPARIM requires around 120 participants to achieve a power of 80% and is currently 
ongoing in recruitment at the University of Leeds and St James’s University Hospital. 
Secondary outcomes of HEPARIM develop on some of the ideas that the study in 
chapter 5, that ultimately required more participants to study. They are to: 
1. determine the measurement uncertainty in DGE-MRI measurements of liver 
function – by refinement of DGE-MRI methodology 
2. determine if preoperative measurement of FLR function can predict severe post-
hepatectomy liver failure, whether FLR function improves the prediction of long-
term outcome compared to a risk assessment that only uses currently available 
predictor variables – to assess fully the impact that the study described in 
chapter 5b aimed to address 
3. to assess if functional measures can play a role is in the selection of a suitable 
time point after PVE/ALPPS to perform the hepatectomy – Hypertrophic 
procedures are being considered more readily to increase the extent of 
resection, and timing after such procedures as to when surgery can be 
considered 
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Essentially, as previously discussed, there was not significant number recruited to be 
able to test some of the original hypotheses related to development of a method to predict 
PHLF, although there is some interesting results that were described in chapter 5, and 
HEPARIM will aim to fully explore the role of DGE-MRI in assessing surgical patients. 
6.3 Conclusions 
The aims of this thesis were to explore risk factors after liver surgery, particularly PHLF, 
and design a novel approach for prediction of surgical outcome using DGE-MRI. A large 
retrospective cohort study found ageing to be an independent risk factor for PHLF, and 
as such patients require careful management and pre-operative optimisation. Utilisation 
of DGE-MRI can estimate post-operative function to a greater extent that volumetry or 
clinical predictions, and as such shows significant promise for pre-operative liver 
assessment; further study is planned for assessing the true role of DGE-MRI in the 
surgical patient across the spectrum of liver resection surgery. 
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Appendix A – Supplemental Clinical Information 
Summary of participants clinical course 
For each of the 29 patients included in the DGE-MRI study below is the following: 
• A brief clinical overview of their pre-operative and post-operative results 
• The MRI report provided for the clinical team, all reported by either a Consultant 
Radiologist or by a Radiology Registrar/Trainee with review and approval by a Consultant 
Radiologist 
• The final pathology report following liver resection, all reported by Consultant Pathologists 
with a special interest in Liver pathology, or by a trainee with Consultant review and 
approval 
Pilot001 
A 64-year-old female who underwent an extended right hepatectomy and segment 3 
metastatectomy (segments 4, 5, 6, 7, 8). She had a 2.6 cm metastasis within segments 7/8, a 2.6 
cm metastasis in the 8/4, a 7-mm metastasis in segment 7, a 1.4 cm metastasis segment 6 and 
a 6-mm metastasis in segment 3. eGFR was 72. She received no pre-operative neoadjuvant 
chemotherapy. Background histology showed mild steatosis. Day 5 post-operative bilirubin was 
28, INR 1.4, Lactate 1.7, indicating mild PHLF. She had post-operative pain management issues 
and was discharged on day 7. 
MRI report 
There is a 2.6 cm metastasis the subcapsular occasion within segments 7/8, a 2.6 cm metastasis 
in the interface between segments eight and four, there is a 7 mm lesion posteriorly within 
segment seven close to the interface with segment six and a 1.4 cm metastasis within segment 
six immediately beneath this. Immediately deep to the anterior capsular surface of segment three 
there is a 6 mm metastasis. The major vascular structures are patent and uncompromised. No 
upper abdominal lymphadenopathy. 
Pathology report 
Macroscopic Description: 
Right liver- Specimen weighs 1097g and 20 x 11 x 9cm. Slicing shows four metastatic deposits 
as follows:  
• Lesion one, segment VII/VIII, 30mm diameter, subcapsular (block B1). 
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• Lesion two, segment VI, 10mm diameter (block B2). 
• Lesion three, segment IV/VIII, 28mm diameter (blocks B3 and B4). 
• Lesion four, segment VI, 15mm diameter (block B5).  
All the deposits are well away from the resection margin, the closest being the lesion in segment 
IV/VIII (lesion three) and this is 20mm from the margin. 
C: Segment III Mets- 25 x 20 x 16mm wedge of liver. Slicing shows a central 12mm lesion, which 
is 5mm from the resection margin.   
Microscopic Description: 
A: Sections show normal gall bladder mucosa and wall with no inflammation or 
neoplasia.  
B & C: Right liver and segment III Mets: 
Summary: 
• Number of tumour(s) present   - Five (right liver and segment III)  
• Maximum diameter   - 30mm 
• Tumour grade   - Moderate  
• Minimum distance from margin- 5mm (segment III lesion) (assessed macro) 
• Vascular invasion   - Yes  
• Response to neoadjuvant therapy - Not known  
• Lymph nodes - None submitted 
• Background liver - Mild steatosis   
Comment: 
It is not known if this patient had pre-op treatment, but there is marked necrosis in the metastasis 
in the right liver while the segment III lesion shows haemorrhagic changes. 
DIAGNOSIS: 
Right liver and segment III resection - Metastatic colorectal adenocarcinoma x 5; all excised.  
Pilot003 
A 41-year-old female who underwent right hepatectomy. She had a 7.2cm solitary liver metastasis 
in segment 7/8 compromising the right hepatic vein and interfacing with the IVC. She received 
pre-operative neoadjuvant chemotherapy. She had an eGFR of >90. Background histology 
demonstrated <1% steatosis.  She had FLR-volume of 44%, and FLR-function of 41%. Day 5 
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postoperative bilirubin was 26, INR 1.5, Lactate 1.6, indicating moderate PHLF. She developed a 
post-operative wound infection requiring antibiotics. She was discharged on day 7. 
MRI report 
There is a solitary liver metastasis which involves segments seven and eight. The maximal 
diameter is 7.2 cm. The lesion compromises the right hepatic vein with intrahepatic collaterals 
from segments five and six draining into the middle hepatic vein. The tumour reaches the cava 
with an interface of less than 90 degrees. There is a simple cyst within the right lobe, but no other 
metastases are identified. 
Pathology report 
Right hemihepatectomy - 70g, 16 x 10 x 8cm.  On slicing, the metastasis is seen with an irregular 
outline, 8.5cm maximum diameter, less than 1mm from the surgical margin. 
Microscopic Description: 
A.  Representative histology from the gall bladder shows mucosa and gall bladder wall within 
normal limits.  No evidence of chronic cholecystitis, dysplasia or malignancy. 
B.  Histology from the metastases shows moderately differentiated adenocarcinoma with a pattern 
consistent with a primary site in the large bowel.  It surrounds the hepatic vein branch, which is 
narrowed by intimal fibrosis but not infiltrated.  It is a minimum of 1.5mm from the surgical margin. 
Background liver tissue shows no evidence of chronic liver disease and less than 1% of 
hepatocyte cholesteatosis. 
Summary: 
• Number of tumour(s) present     1 
• Maximum diameter    -     72mm 
• Tumour grade     -     Moderate 
• Minimum distance from margin     1.5mm (assessed macro/micro combined) 
• Vascular invasion -     Not identified 
• Response to neoadjuvant therapy -     Not identified 
• Lymph nodes    -     None received 
• Background liver   -       Normal 
Right hepatectomy - Metastatic colorectal adenocarcinoma, one lesion, 1.5mm from margin 
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Pilot005 
An 81-year-old female who underwent a right hepatectomy and segment 3 metastatectomy. She 
had 4 metastases; 4 mm metastasis in segment eight, an 8-mm segment 8 close to the right 
hepatic vein, 1.3cm in segment 6, and 4 mm in segment 4/3. She underwent preoperative 
neoadjuvant chemotherapy, and preoperative portal vein embolisation. eGFR was 63. 
Background histology showed effects of the PVE. She had a FLR-volume of 40% and FLR-
function of 45.5%. Day 5 postoperative bilirubin was 11, INR 1.1, Lactate 1.4, with no evidence 
of PHLF. She had a routine postoperative course and was discharged on day 6. 
MRI report 
• Lesion 1 - 4 mm segment eight towards the vertex 4 mm (there is a simple cyst close to 
this lesion). 
• Lesion 2 - segments eight centrally located 8 mm in maximal diameter close to the right 
hepatic vein. 
• Lesion 3 - segment six -1.3 cm in diameter 
• Lesion 4 - segment three 4 mm in diameter close the capsular surface of the inferior 
aspect of the left lobe. 
On the pre-treatment examination there was a further subcapsular lesion high within segment 
two, I cannot identify that on the current examination. 
All lesions are smaller than on the baseline imaging indicating a positive response to 
chemotherapy. There is however abnormality of the signal of the liver parenchyma in keeping 
with chemotherapy related liver injury. 
Pathology report 
Macroscopic Description: 
B: Right hemihepatectomy- 
Piece of liver 120 x 100 x 60mm. The capsular surface has been sliced through and there appears 
to be a subcapsular tumour. Specimen sliced horizontally from superior to inferior. Three definite 
lesions seen; tumour in segment VI has been sampled for research prior to receipt. A further 3mm 
suspicious lesion is seen in the centre of segment VIII (B5). Background liver also sampled (B6).  
Lesion one, upper part segment VIII, subcapsular, 6mm maximum, 20mm from resection margin 
(B1). 
Lesion two, centre segment VIII, 12mm maximum, abutting the margin (B2 and B3). 
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Lesion three, segment VI, subcapsular, 12mm maximum, 40mm from margin (B4).  
C: Liver segment III- Triangular piece of tissue 18 x 11 x 10mm. On slicing, there is an 8mm 
lesion, 2mm from closest margin.  
D: Liver segment II- Piece of tissue 12 x 12 x 10mm. On slicing, there is an 8mm lesion, which 
appears to abut the margin.  
Microscopic Description: 
A: The gallbladder mucosa is near normal with minimal chronic inflammatory infiltrate, and there 
is no fibrosis of the wall to suggest previous chronic cholecystitis.  Within the serosa there are 
multiple foci of foreign body granulomatous reaction to intravascular material - presumably related 
to the previous right portal vein embolisation. This is not associated with any mucosal ulceration 
nor inflammation/fibrosis in the gall bladder wall. 
B-D: All the sampled lesions (three in right lobe, also one each in segments II and III) are deposits 
of metastatic moderately differentiated adenocarcinoma of a pattern in keeping with primary origin 
in the large bowel.  All show some central fibrosis/inflammation, consistent with partial response 
to chemotherapy.  The minimum margin is 0.5mm for lesion 2 in the right lobe and 0.3mm for 
lesion segment II part D.  There is no vascular invasion identified. 
Background liver in part B shows portal vein embolisation, and some atrophy of parenchyma with 
apposition of portal areas and congestion.  There is no steatosis or evidence of other chronic liver 
disease. 
Summary: 
• Number of tumour(s) present          - 5 
• Maximum diameter               - 12mm, 12mm, 8mm, 8mm. 
• Tumour grade                    - Moderate and poorly differentiated 
• Minimum distance from margin     - 0.3mm (assessed macro/micro combined) 
• Vascular invasion               - Not identified 
• Response to neoadjuvant therapy     - Yes incomplete 
• Lymph nodes                    - None received 
• Background liver               - Effects of portal vein embolisation in right liver 
DIAGNOSIS: 
Liver (right hemihepatectomy, metastatectomy segments II and III)   -   5 x metastatic colorectal 
adenocarcinoma, minimum margin 0.3mm. 
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Pilot008 
A 71-year-old male who underwent a resection of segment 5 and 6 of a solitary 1.3cm metastasis 
in 5/6. He had undergone preoperative neoadjuvant chemotherapy. eGFR >90. Background liver 
histology showed mild steatosis and an R1 resection. He had a FLR-volume of 67% and FLR-
function of 65%. Day 5 bilirubin was 25, INR 1.1 Lactate 1.9, indicating mild PHLF. He developed 
a chest infection requiring antibiotics and was discharged on day 13. 
MRI report 
Findings: A solitary 1.3cm lesion is seen peripherally in segment V, best appreciated on delayed 
post contrast imaging. Appearances consistent with metastasis. No further lesions demonstrated 
in the liver. 
Comment: Solitary 1.3cm metastasis in segment V. 
Pathology report 
Macroscopic Description: 
A.  Segment 5 metastasis - A wedge of liver 44g, measures 6 x 3.5 x 3cm.  On slicing, there is a 
single tumour 1.6cm maximum, which extends to one of the lateral resection margins.  It is 
subcapsular.  Background liver appears normal. 
Microscopic Description: 
A.  The tumour is a moderately differentiated adenocarcinoma with morphology characteristic of 
metastatic colorectal cancer.  There are areas of haemorrhagic necrosis within the centre of the 
tumour.  The advancing edge of the tumour has a multinodular configuration and extends focally 
to the tumour margin.  This is in keeping with the macroscopic description (A1).  There is no 
convincing vascular invasion seen (A1 and A2).  The histology of the background liver (A3) shows 
mild steatosis and focally mild portal inflammation without fibrosis.  
Special stains have not been performed. 
Summary: 
• Number of tumour(s) present    - 1 
• Maximum diameter    - 16mm 
• Tumour grade                    - moderate 
• Distance from nearest hepatic resection margin              - Tumour cells at margin - (R1) 
• Vascular invasion               - Not identified 
• Response to neoadjuvant therapy     - n/a 
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• Lymph nodes                    - none received 
• Background liver               - mild Steatosis 
DIAGNOSIS: 
Liver segment 5 - Metastatic adenocarcinoma consistent with colorectal carcinoma. Tumour cells 
at margin (R1). 
Resect001 
A 62-year-old male who underwent a left hepatectomy for a 1.4 cm lesion just above the 
bifurcation of the left portal vein causing obstruction of the segment 2/3 bile ducts. He had pre-
operative bilirubin of 20. eGFR was >90. Background liver histology demonstrated obstructive 
changes. He had an FLR-volume of 57% and a FLR-function of 53%. He had a day 5 bilirubin of 
55, INR 1, Lactate of 1.9, indicating mild PHLF. He had a normal post-operative course and was 
discharged home day 5. 
MRI report 
Appearances within the liver have not significantly changed since the MRI with a 1.4 cm lesion 
just above the bifurcation of the left portal vein causing obstruction of the segment 2/3 bile ducts. 
The degree of dilatation has not changed and there are no newly dilated ducts elsewhere in the 
liver or new liver lesions. Stable appearances of the remaining solid organs. Small stable left 
inguinal lymph nodes. Stable appearances of the thick fibrosis in the presacral space and 
resolution of a previous fluid collection within it. Ileostomy in the right iliac fossa. A few small 
stable retroperitoneal lymph nodes. The lungs are clear. No destructive bony lesion. 
Comment: Stable appearances in the liver. No new sites of disease identified. 
Solitary 1.3cm lesion with characteristics of metastasis 
immediately above left main branch of the portal vein, obstructing segment II and III bile radicals. 
Pathology report 
Macroscopic Description: 
371g measuring 11cm transversely, 11cm in height and 5cm antero-posteriorly. Specimen sliced 
horizontally into 15 slices. The lesion is present in slices 4-6. It is a white lesion with an irregular 
outline, 2cm maximum diameter, which encircles structures entering the liver and has a 
component within the main portal tract in continuity with an intrahepatic component, which is about 
1cm deep. Specimen photographed slices 4-7. The left portal vein is distended by blood. Other 
than this, the liver is macroscopically normal.  
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Microscopic Description: 
A: Representative histology from the gall bladder shows marked cholesterolosis and minimal 
features of inactive chronic cholecystitis. No dysplasia or malignancy.  
B: Histology confirms this is moderately differentiated adenocarcinoma, with a histological pattern 
of central necrosis consistent with a primary site in the large bowel. There is quite extensive 
vascular invasion, including the blood vessels in the connective tissue at the extrahepatic part of 
the left main ducts and vessels. The main portal vein is not thrombosed.  There is also extension 
of the tumour as polypoid growth within the left hepatic duct. There is perineural infiltration. 
Tumour within blood vessels at the porta hepatis is less than 1mm from the surgical margin.  
Immunohistochemistry confirms this is metastatic colorectal adenocarcinoma, being positive for 
CK20 and negative for CK7.  
Representative histology from the background liver shows prominent changes of large bile duct 
obstruction, with atrophy of hepatic parenchyma and apposition of portal areas. There is no 
evidence of other background chronic liver disease. 
Summary: 
• Number of tumour(s) present          - One 
• Maximum diameter               - 20mm 
• Tumour grade                    - Moderate  
• Minimum distance from margin     - 0.8mm from porta hepatis resection margin (assessed 
macro/micro combined) 
• Vascular invasion               - Yes 
• Response to neoadjuvant therapy     - Not identified 
• Lymph nodes                    - None received  
• Background liver               - Large bile duct obstruction  
DIAGNOSIS: 
Left liver resection     - Metastatic colorectal adenocarcinoma, one lesion, 0.8mm from margin.   
PILOT013 
A 69-year-old male who was found to be inoperable when MRI showed liver is studded with 
metastases throughout every segment. 
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MRI report 
Findings: liver is studded with metastases throughout every segment. The largest lesion in the 
segment 2/3 measures 4.6 cm, these range down to tiny sub-centimetre lesions. 
Resect002 
A 64-year-old male who underwent a segment 7 metastatectomy for a solitary metastasis. He had 
preoperative neoadjuvant chemotherapy. He had a BMI >30. eGFR was >90. Background liver 
histology demonstrated mild sinusoidal obstructive syndrome (SOS) and macro-vesicular 
steatosis. He had an FLR-volume of 88.5% and FLR-function of 86%. He had a day 5 bilirubin of 
36, INR 1.1, Lactate 1.8, indicating mild PHF. He had a normal post-operative course and was 
discharged on day 5. 
MRI report 
Findings: In the interim since the baseline CT scan from November 2013 the liver metastases 
have responded well to chemotherapy. The smaller lesion on the posterior surface of segment 7 
is no longer clearly demonstrated although there is some chemotherapy induced SOS around this 
area. The larger lesion on the anterior surface of segment 4 has reduced in size from 3.0 cm to 
1.1 cm. No other metastases demonstrated. There are a few small benign cystic lesions 
elsewhere within the liver. No other significant abnormality demonstrated. 
Conclusion: Residual 11 mm metastasis on the surface of segment 4. The prior segment 7 
metastasis is no longer demonstrable. Minor SOS within the liver. 
Pathology report 
Macroscopic Description: 
Received is a wedge of liver weighing 17.3g and measuring 56 x 38 x 18mm. The capsular surface 
contains a linear defect measuring 22mm. The specimen has been serially sliced to reveal a 
subcapsular tumour measuring up to 15mm in maximum dimension with areas of yellow necrosis. 
The linear defect continues into the tumour and very close to the deep resection margin. The 
tumour appears to abut the resection margin focally.  
Block 1 = tumour closest to resection margin; 2 = small nodule of possible tumour within a 
vessel/duct in the adjacent slice; 3 = background liver.  
Microscopic Description: 
The tumour is a moderately differentiated adenocarcinoma with intraluminal necrosis consistent 
with metastatic colorectal carcinoma. The tumour extends to the surgical margin. he subcapsular 
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part of the tumour shows evidence of regression following chemotherapy. There is no evidence 
of capsular invasion or vascular invasion. A small Von Meyenburg complex is noted within the 
tumour. 
The background liver shows a mild degree of macrovesicular steatosis. There is no evidence of 
chronic liver disease. 
Summary: 
• Site of tumour                    - Segment IV. 
• Number of tumour(s) present          - One.  
• Maximum diameter               - 15mm. 
• Tumour type                    - Adenocarcinoma.  
• Tumour grade                    - Moderately differentiated.  
• Minimum distance from margin     - At margin. (assessed macro/micro combined) 
• Vascular invasion               - Not identified.  
• Response to neoadjuvant therapy     - present  
• Lymph nodes                    - None submitted.  
• Background liver               - Macrovesicular steatosis.  
DIAGNOSIS: 
Liver segment IV - Metastatic colorectal carcinoma, extends to margin.  
Resect003 
A 73-year-old female who had an extended right hepatectomy for 6 metastases in segments 4, 
5, 6, 7 and 8. She had type 2 diabetes. eGFR was 88. She had preoperative neoadjuvant 
chemotherapy. Background liver showed mild steatosis and SOS. She had an FLR-volume of 
25% and FLR-function of 25%. Day 5 bilirubin was 43, INR 1.1, Lactate 1.8, indicating mild PHLF. 
She had a normal post-operative course and was discharged day 5. 
MRI report 
As previously documented, there are multiple metastases within the right lobe segments involving 
segment 8 (2 lesions), segment 7 (2 lesions) and segment 6 (1 lesion) (see Key Images on 
PACS). There is a further sub-centimetre metastasis superiorly within segment 4. Unchanged 
benign cystic lesions are present within the inferior aspect of segment 4 and the left lateral section. 
No other focal liver lesions. There is a large benign cyst within the left kidney. No measurable 
extra-hepatic disease within the volume scanned. 
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Conclusion: 6 metastases within the liver - segments 4, 6, 7 and 8 (see Key Images on PACS). 
Segments 1-3 are clear. 
Pathology report 
Macroscopic Description: 
B: Right lobe of liver- 792g portion of liver measuring 135mm medio-lateral, 180mm supero-
inferior and 68mm antero-posterior. The specimen is sliced into 24 slices from superior to inferior. 
On sectioning, the specimen contains 5 tumours. Segment VIII contains 2 tumours; segment VII 
contains 1 tumour and segment VI contains one. These four tumours match those described in 
the MRI report. A piece of tissue has been previously removed from segment VII and taken for 
research. No obvious residual tumour seen at this site. The background liver appears normal 
(block B6)  
Tumour one, segment VIII, slices 1 -2, 7mm maximum, more than 30mm from the margin (block 
B1). 
Tumour two, segment VIII, slices 6-9, 28mm maximum, 30mm from the margin (block B2). 
Tumour three, segment VII, slices 1-4, 25mm maximum, 40mm from the margin (block B3). 
Tumour four, segment VI, slice 9 and 10, 12mm maximum, 50mm from the margin. (block B5).  
Block 4 = site of previous removal of ? tumour.  Block 6 - background liver.  
Microscopic Description: 
A: Sections from the gallbladder show features of mild chronic cholecystitis. 
B: All the four tumours in the right hepatectomy show features of moderately differentiated 
metastatic colorectal adenocarcinoma. The second lesion in segment VII was taken for research 
(block four described in macroscopic description) and no residual tumour identified at this site 
macroscopically or microscopically. 
The background liver shows mild steatosis and a microscopic focus of metastatic 
adenocarcinoma measuring 0.4mm. There are features of sinusoidal obstruction syndrome which 
is likely chemotherapy effect.  There is no evidence of chronic liver disease. All the tumours are 
more than 30mm from the resection margin. 
Summary: 
• Number of tumour(s) present          - 4 
• Maximum diameter               - 28mm 
• Tumour grade                    - Moderately differentiated 
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• Minimum distance from margin     - 30mm (Assessed macro) 
• Vascular invasion               - Absent 
• Response to neoadjuvant therapy     - Not known 
• Lymph nodes                    - Not submitted 
• Background liver               - Mild steatosis, Sinusoidal obstruction syndrome. 
DIAGNOSIS: 
Right lobe of liver:   Metastatic colorectal adenocarcinoma x 4 
Resect004 
A 68-year-old male who had a large central (4/8) metastasis, and metastasis in the left lobe. He 
was deemed unsuitable for surgery due to extrahepatic disease and lymphadenopathy in the right 
para-cardiac and posterior mediastinal regions. 
MRI report 
Unfortunately, several of the sequences are degraded by breathing artefact which significantly 
reduces the quality of the study. The large central metastasis seen on the recent CT involving 
segments four and eight has increased in size and now measures at least 10.2 cm in longest axis 
(previously 8 cm in May 2015). This abuts the portal bifurcation and contacts the proximal left 
portal vein and more extensive contact with the right portal vein and its anterior branch. There is 
a peripheral metastasis within segment two of the liver measuring approximately 4.1 cm diameter. 
In addition, there are small foci of tumour within the medial aspect of segment two abutting the 
falciform ligament which are in close proximity with the central metastasis and likely to represent 
further tumour foci. In addition, there are enlarged right para-cardiac lymph nodes and a further 
node in the posterior mediastinum on the right which show restricted diffusion and these raise 
concern for extra-hepatic disease (see Key Images on PACS). 
Conclusion: Poor quality study due to difficulty with breath holding. Interim enlargement of the 
large central metastasis which abuts the portal bifurcation. Smaller volume metastatic disease 
within the left lateral segment. Probable nodal disease in the right para-cardiac and posterior 
mediastinal regions. 
Resect005 
A 49-year-old Male who was deemed inoperable after MRI demonstrated multiple bilobar liver 
Metastases, and widespread residual small volume metastases which were scattered throughout 
every segment within the liver. 
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MRI report 
MRI Diffusion weighted: There has been a good partial response to chemotherapy within the 
multiple bilobar liver metastases demonstrated on previous imaging. Unfortunately, there are 
however widespread residual small volume metastases which are scattered throughout every 
segment within the liver apart from the caudate lobe (see Key Images on PACS). These include 
a number of small awkwardly placed lesions deep within segments 4 and 8. There is background 
fatty infiltration within the liver which is likely to be related to chemotherapy. No other significant 
abnormality demonstrated. 
Conclusion: Partial response to chemotherapy but residual widespread small volume liver 
metastases throughout the liver (see Key Images on PACS). 
Resect006 
A 49-year-old female underwent a bisegmentectomy 5 and 6, metastatectomy of 7 and segment 
1 for 2 metastases in segment 5 and 6 and what proved to be peribiliary gland hamartomas in 6 
and 1. She had preoperative neoadjuvant chemotherapy. eGFR was >90. Background liver 
appeared normal. FLR-volume was 57%, FLR-function 60%. Day 5 bilirubin was 5, INR 1, lactate 
1.2, so no evidence of PHLF. She had no postoperative complication and was discharged home 
day 5. 
MRI report 
Findings: There are 2 lesions in segment 5 - one 8 mm and one 4 mm - these have not changed 
significantly in size since the initial CT from 8/11/14 and whilst the imaging characteristics are 
more in keeping with metastases, the stability is surprising and introduces an element of doubt. 
There is a questionable tiny lesion involving the tip of the caudate lobe. 
(If a watch and wait strategy is adopted Gadolinium rather than Primovist may be of value). 
Pathology report 
Macroscopic Description: 
A: Segment V/VI-   5g, capsular surface 27 x 20mm with underlying tissue 20mm. On slicing there 
is one lesion 10mm in diameter at the deep resection margin.  
B: Segment V-  2g, capsular surface 17 x 15mm with underlying tissue 17mm. There is an 
indistinct 3mm lesion seen at the deepest aspect, adjacent to the resection margin. 
C: Segment VII- 0.3g, 10 x 9 x 7mm, sliced and all embedded. There is 2mm subcapsular lesion.  
D: Segment II- 0.1g, 10 x 6 x 4mm, sliced and all embedded. 2mm lesion seen.  
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E: Segment I-  0.2g, 11 x 9 x 7mm irregular liver tissue. 2mm subcapsular lesion. All embedded. 
Microscopic Description: 
A: This is a small focus of metastatic adenocarcinoma, moderately differentiated with a pattern 
consistent with a primary site in the large bowel. The tumour is about 7mm in diameter and is 
surrounded by a capsule of fibrosis and inflammatory tissue. There is about 0.2mm of fibrosis 
separating the adenocarcinoma from the deep surgical resection margin.  
Tissue from the background liver shows a normal architecture with no fatty change or evidence 
of chronic liver disease. There are very minor equivocal features that may represent sinusoidal 
obstruction syndrome, but insufficient for a confident diagnosis.  
B: The second segment V lesion is a focus of adenocarcinoma at the deep resection margin. This 
is again surrounded by dense fibrosis and the adenocarcinoma measures about 3mm in diameter. 
It is separated from the deep resection margin by about 0.4mm of fibrous capsule.  
C-E: All three lesions from segments VII, II and I are peribiliary gland hamartomas and there is 
no evidence of metastatic carcinoma in any of these specimens. 
Summary: 
• Number of tumour(s) present          - Two  
• Maximum diameter               - 10mm, 3mm 
• Tumour grade                    - Moderate  
• Minimum distance from margin     - 0.2mm (assessed macro/micro combined) 
• Vascular invasion               - Not identified  
• Response to neoadjuvant therapy     - Not identified  
• Lymph nodes                    - None received  
• Background liver               - Normal   
DIAGNOSIS: 
Liver metastatectomy specimens      - 2 x metastatic carcinoma in segment V - 3 x peribiliary 
gland hamartomas.  
Resect007 
A 79-year-old female underwent a right posterior segmentectomy (6/7) and segment 3 resections 
for a 4-cm lesion in segment seven, a 3-cm lesion at the interface between segments six/seven. 
a 2.1 cm segment metastasis. eGFR was >90. She had preoperative neoadjuvant chemotherapy. 
The background liver was unremarkable.  Her FLR-volume was 60%, FLR-function was 63%. Day 
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5 bilirubin was 25, INR 1.1, Lactate 1.6, so no evidence of PHLF. She developed a postoperative 
chest infection requiring antibiotics and was discharged day 8. 
MRI report 
Findings: Three lesions with characteristics of liver metastases demonstrated, all well way from 
major vascular structures: - 
1.  there is a 4 cm lesion in segment seven,   
2. a 3 cm lesion at the interface between segments six/seven 
3. a 2.1 cm metastasis inferiorly within segment three.   
No additional lesions demonstrated. 
Pathology report 
Macroscopic Description: 
A: Segment III liver - Specimen measures 65 x 65 x 30mm. It weighs 75g. Slicing reveals a tumour 
measuring 20 x 22 x 15mm. It abuts the capsular surface and lies 14mm from the resection 
margin.  
B: Segment VI/VII liver - Specimen measures 70 x 65 x 10 mm. It weighs 265g. Slicing reveals 
two lesions, the first in segment VI measuring 35 x 22 x 22mm. It lies 24mm from the resection 
margin. The 2nd lesion is in segment VII and measures 45 x 40 x 33mm. It lies 13mm from the 
resection margin. The background liver is unremarkable.  
Blocks B1 and B2 = first lesion; B3 and B4 = second lesion.  
Microscopic Description: 
A&B) All three lesions show features of metastatic moderately differentiated adenocarcinoma with 
areas of dirty necrosis, mucin lakes and fibrosis. The appearances are consistent with colorectal 
origin. All the lesions are excised. 
Summary: 
• Number of tumour(s) present          - Three. 
• Maximum diameter               - 22, 35, 45 mm. 
• Tumour grade                    - Moderately differentiated. 
• Minimum distance from margin     - 5,10,12mm. (assessed combined) 
• Vascular invasion               - yes. 
• Response to neoadjuvant therapy     - Unknown.  
• Lymph nodes                    - None submitted. 
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• Background liver               - Unremarkable. 
DIAGNOSIS: 
A) Liver resection, segment III     - Metastatic colorectal adenocarcinoma x 1. 
B) Liver resection, segment VI/VII     - Metastatic colorectal adenocarcinoma x 2. 
Resect008 
A 54-year-old male who had a segment 7 and 8 resections for a 2.1cm segment 7 metastasis and 
a resolved segment 8 lesion. He had preoperative neoadjuvant chemotherapy. eGFR was >90. 
He had mild steatosis and portal inflammation. The segment 8 lesion was an R1 resection. His 
FLR-volume was 69% and FLR-function was 71%. Day 5 bilirubin was 9, INR 1, Lactate 1.3, 
indicating no evidence of PHLF. He had no postoperative complications and was discharged day 
5. 
MRI report 
Previously demonstrated segment VI metastasis has decreased in size and now measures 21 
mm (previously 44 mm). Previously demonstrated smaller 8mm lesion in segment 8 is not 
appreciable in today’s examination it was peripheral - see previous SJUH MR index lesion. No 
new focal liver lesions.  
There is evidence of chemotherapy related liver injury (mild- in the right lobe). 
Pathology report 
Macroscopic Description: 
A: Segment VIII- Liver tissue measuring 19 x 14 x 16mm. Resection margin inked black. 
Specimen serially sliced. On slicing a white ill-defined nodule is identified 9mm maximum, which 
appears to abut the resection margin in one of the sections. All embedded in 3 blocks.  
B: Segment VII- Segment of liver measuring 90 x 63 x 45mm. Two sections have been cut out of 
the capsular surface. At the edge of where one of these sections has been taken, there appears 
to be a tumour abutting the capsular margin. The section that has been taken of tumour appears 
to be 19 x 28 x 22mm and the section of background liver taken measures 12 x 26 x 19mm. Prior 
to slicing the maximum dimension of the tumour visible appears to be 29mm. The resection 
margin is inked black. Segment sliced into 18 slices and tumour is seen within slices 7-16. On 
slicing, the maximum tumour dimension seems to be 38mm however this is difficult to estimate 
due to the previous tissue taken. The tumour is clear of the resection margin by 13mm.  
Microscopic Description: 
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A: Segment VIII- 
This specimen comprises liver infiltrated by atypical epithelial cells forming glandular structures 
with central necrosis. The appearance is consistent with a metastatic colorectal adenocarcinoma.  
The tumour reaches the resection margin. There is no evidence of regression effect.  
Summary: 
• Number of tumour(s) present          - 1 
• Maximum diameter               - 9mm 
• Tumour grade                    - moderately-differentiated 
• Minimum distance from margin     - reaches resection margin (assessed macro/micro 
combined) 
• Vascular invasion               - Yes 
• Response to neoadjuvant therapy     - No 
• Lymph nodes                    - None submitted 
• Background liver               - Mild steatosis  
B: Segment VII- This comprises liver infiltrated by metastatic adenocarcinoma with areas of 
necrosis. It shows the same morphology as specimen A. The tumour lies 10mm from the resection 
margin. There is fibrosis and dystrophic calcification suggesting regression effect. Background 
liver shows mild steatosis and mild portal tract inflammation.   
Summary: 
• Number of tumour(s) present          - 1 
• Maximum diameter               - 38mm 
• Tumour grade                    - moderately-differentiated 
• Minimum distance from margin     - 10mm (assessed macro/micro combined) 
• Vascular invasion               - no 
• Response to neoadjuvant therapy     - Yes 
• Lymph nodes                    - None submitted 
• Background liver               - Mild portal inflammation 
DIAGNOSIS: 
Liver Segment VIII: Metastatic Colorectal Adenocarcinoma, involved resection 
margin 
Liver Segment VII: Metastatic Colorectal Adenocarcinoma, fully excised 
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Resect009 
A 65-year-old female who had segment 6 resection and segment 2 metastatectomy for a 3cm 
metastasis in 6 and an indeterminate lesion in segment 2, that was FNH. She had no preoperative 
chemotherapy. eGFR was >90. Her background liver was normal and had an R1 resection, Her 
FLR-volume was 69% and FLR-function was 71%. Day 5 bilirubin was 5, INR 1 Lactate 1, and so 
showed no evidence of PHLF. Her post-operative course was uneventful and was discharged day 
3. 
MRI report 
As previously there are multiple benign cystic lesions in both lobes of the liver. 
The concerning lesion segment 5/6 at the inferior tip of the liver measures 30mm which 
demonstrate signal characteristics of metastatic deposit. This has increased in size from previous 
study (17mm previously). Further 7mm lesion in segment 2, this is irregular in contour and does 
not have the high signal of a simple cyst and is more intermediate in signal intensity, this appears 
unchanged in size and character compared to the MRI dated 04/02/15, it is indeterminate in 
character, I think it more likely to represent benign malformation than a metastasis. If left in situ it 
will need to be followed. A subcapsular haemangioma is noted in segment seven.  The lesions 
are away from the major vascular structures.  
Pathology report 
Macroscopic Description: 
Metastatectomy specimen 65g and measures 85 x 55 x 35mm. Specimen received disrupted, 
previously incised - no description of tumour sampling. This incision goes into the surgical margin. 
Sliced at right angles to plane of resection, there is a single solid yellowish tumour with 
macroscopic characteristics of metastatic colorectal carcinoma, 35mm maximum diameter and 
generally greater than 10mm from the surgical plane, although previous incision makes this 
difficult to assess. 
Microscopic Description: 
Histology confirms this is metastatic adenocarcinoma, which is moderately differentiated and with 
a pattern characteristic of metastatic colorectal adenocarcinoma. The specimen has split on the 
resection margin, but elsewhere adjacent to this, the adenocarcinoma is seen at a minimum of 
0.3mm from the surgical margin. No vascular invasion is identified.  
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The background liver shows no steatosis and no evidence of chronic liver disease. It does show 
"glycogenic islands" - a physiological change in hepatocyte cytoplasm, which is not of pathological 
significance.  
Summary: 
• Number of tumour(s) present          - One 
• Maximum diameter               - 35mm 
• Tumour grade                    - Moderate  
• Minimum distance from margin - 0.3mm (R1) (assessed macro/micro combined) 
• Vascular invasion               - Not identified 
• Response to neoadjuvant therapy     - Not identified 
• Lymph nodes                    - None received  
• Background liver               - Normal    
DIAGNOSIS: 
Liver (segment VI resection) - Metastatic colorectal adenocarcinoma, extends to 0.3mm from 
margin.  
Resect010 
A 59-year-old Male who had a bisegemental resection of 5 and 6 for a solitary metastasis in 5/6. 
He did not receive any preoperative chemotherapy. eGFR was >90. He had normal background 
liver. His FLR-volume was 71% and FLR was 73%. Day 5 bilirubin was 6, INR 1, Lactate 1.1, and 
so showed no evidence of PHLF. His postoperative was uneventful and was discharged on day 
3. 
MRI report 
As demonstrated on previous MRI scan dated 17/04/2015, there is a solitary metastasis in the 
segment V/ VI which has increased in size and now measures 29 mm (18 mm previously). This 
lesion is well from the major vascular structures although there is a local perfusion effect. No 
further new concerning lesions are demonstrated in the rest of the liver. 
The periportal lymph nodes are a little enlarged. 
Pathology report 
Macroscopic Description: 
Specimen weighs 311g and measures 13 x 9 x 7cm. Slicing shows a single tumour deposit 25mm 
in maximum diameter and it is 10mm from the margin.  
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Microscopic Description: 
Summary: 
• Number of tumour(s) present          - One 
• Maximum diameter               - 24mm 
• Tumour grade                    - Poorly differentiated  
• Minimum distance from margin     - 10mm (assessed macro) 
• Vascular invasion               - Yes 
• Response to neoadjuvant therapy     - Not known 
• Lymph nodes                    - None submitted 
• Background liver               - Unremarkable    
DIAGNOSIS: 
Liver segments V and VI - Metastatic poorly differentiated colorectal adenocarcinoma. - Excised.  
Resect011 
A 63-year-old female who was found to be inoperable due to Liver metastases within segment 
two and eight and probable new metastasis within the right adrenal gland. 
MRI report 
MRI Diffusion weighted: As demonstrated on the recent CT there is a central metastasis within 
segment eight which measures 2.8 cm in dimension and abuts the right portal and hepatic veins. 
There is a further small metastasis measuring 9 mm within the superior aspect of segment two. 
In addition, there is a nodule arising from the body of the right adrenal gland which has developed 
since the baseline CT in March 2015 and shows diffusion restriction which is concerning for a 
further site of metastatic disease. There are unchanged part calcified nodules within the right 
lower lobe which may be benign. No other new features demonstrated. 
Conclusion: Liver metastases within segment two and eight and probable new metastasis within 
the right adrenal gland. 
Resect012 
A 60-year-old male underwent a left lateral retinectomy and segment 6 resections. He received 
pre-operative chemotherapy He had a 2.7cm metastasis in the left lateral tip and a 9mm segment 
2 metastases. He also had a metastasis on the right lateral margin in segment 6. eGFR was >90. 
FLR-volume was 61% and FLR-function 56%. This was for a moderately differentiated 
adenocarcinoma. Background liver showed mild stenosis with no other evidence of chronic liver 
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disease. Day 5 bilirubin was 6 and INR was 1.2, and so had no evidence of PHF. He developed 
a post-operative chest infection and was discharged after 7 days. 
MRI report 
Findings: there are multiple benign lesions of varying sizes throughout the remnant liver and 
artefact from the surgical clips. Three metastases are demonstrated, a 2.7 cm metastasis at the 
left lateral tip, a 9 mm lesion within segment two abutting the anterior capsular surface, and within 
the right lateral margin of what I take to be residual segment four there is 2.9 cm metastasis. The 
lesions well way from major vascular structures. No upper abdominal lymphadenopathy of 
pathological dimensions. 
Pathology report 
Macroscopic Description: 
A: Segment IV tumour- 
31g capsular surface 65 x 45mm with underlying tissue up to 27mm deep. Wedge shaped portions 
of tumour and background liver previously taken. The capsular surface is covered by adhesions. 
On slicing, there is a residual tumour about 
25mm diameter, which is 5mm from the surgical margin.  
Block A1 = tumour; A2 = background liver. 
B: Segment III lesion- 
9.5g capsular surface 30 x 22mm covered by adhesions, underlying tissue 25mm deep. There is 
a subcapsular tumour 11mm in diameter, 2mm from the nearest resection margin. 
C: Segment II lesion- 
30g tissue with capsule over two surfaces and associated adhesions. The specimen is 55 x 40 x 
29mm. On slicing, there is a single subcapsular tumour 29mm maximum diameter, 10mm from 
the surgical margin.  
Microscopic Description: 
A-C: Histology from all three tumours confirms these are metastatic moderately differentiated 
adenocarcinomas, with a morphology consistent with a primary site in the large bowel. The lesion 
in part A extends into the surgical resection margin. The lesion in part B is suggestive of invasion 
through the capsule into adherent connective tissue, although does not breach the margin of this. 
The lesion in part C is also subcapsular, but the capsule is not invaded.  
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Representative histology of background liver in part A shows normal architecture, mild steatosis 
and no evidence of other chronic liver disease.  
Summary: 
• Number of tumour(s) present          - Three 
• Maximum diameter               - 29mm, 25mm and 11mm  
• Tumour grade                    - Moderate  
• Minimum distance from margin     - Tumour cells at margin (segment IV tumour) 
(assessed macro/micro combined) 
• Vascular invasion               - Not identified  
• Response to neoadjuvant therapy     - Not identified 
• Lymph nodes                    - None received  
• Background liver               - Mild steatosis   
DIAGNOSIS: 
Liver metastatectomy x 3 (segments IV, III and II) - Metastatic adenocarcinoma x 3, margin 
positive in segment IV lesion.  
Resect013 
A 47-year-old female underwent a segment 3 resections for a metastasis. 2 other lesions in 
segment 6 and 7 appeared benign. She didn’t receive any chemotherapy. eGFR was >90. She 
had mild steatosis in her liver. Her FLR-volume was 90% and FLR-function was 91%. Day 5 
bilirubin was 6, INR 1, Lactate 1.1 and so showed no evidence of PHLF. She had a normal post-
operative course and was discharged day 3. 
MRI report 
Two well defined lesions are identified. 
Lesion 1: 9mm lesion in segment 3 (mild high T2, restricted diffusion and does not concentrate 
Primovist) - Metastatic 
deposit. This is well away from the major vascular structures. 
Lesion 2: 6mm lesion in segment 7 (high T2 with shine through and does not concentrate 
Primovist) – Benign lesion. 
A wedge-shaped area in segment 6 which extends from the subcapsular surface with reduced 
uptake on Primovist on delayed phase imaging and has altered diffusion on DWI. No sinister 
lesion identified in relation to this, it is likely to represent a perfusion effect. 
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Pathology report 
Macroscopic Description: 
Wedge of liver measuring 65 x 50 x 25mm. The excision margin measures 60 x 25mm. An area 
of puckering is identified on both anterior and posterior capsular surfaces measuring 10 x 10mm. 
On slicing, a well circumscribed lesion is identified, which appears fibrotic at the periphery and 
necrotic in the centre. This measures 7mm in maximum dimension and lies at 16mm from the 
resection margin. 
Microscopic Description: 
Sections of the tumour show a moderately differentiated adenocarcinoma with morphology in 
keeping with colonic primary. The lesion contains a fibrotic and necrotic centre together with 
marked indrawing of the capsule, indicating there has been significant partial response to 
chemotherapy.  
The background liver shows atrophic changes beyond the tumour.  Elsewhere there is very mild 
steatosis.  There is no sinusoidal obstruction syndrome or evidence of chronic liver disease.   
Summary: 
• Number of tumour(s) present - 1 
• Maximum diameter - 7mm 
• Tumour grade - Moderately differentiated 
• Minimum distance from margin - 16mm (assessed macro/micro combined) 
• Vascular invasion - Not present 
• Response to neoadjuvant therapy - Yes. Incomplete. 
• Lymph nodes - N/A 
• Background liver - Mild steatosis 
DIAGNOSIS: 
Liver segment III - Moderately differentiated metastatic colorectal adenocarcinoma. Excised. Mild 
steatosis.  
Resect014 
A 60-year-old male who was deemed inoperable for liver disease progression involving all 
segments apart from segment 1 
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MRI report 
Comparison is made with serial examinations dating back to the CT of the 24/11/2014 
Unfortunately the majority of the lesions within the liver have increased in size, for example the 
lesion in segment four close to the interface with segment two measures 11 mm compared to 9 
mm on the prior study of 16/3/15 and the lesion within the medial aspect of segment 5/6 measures 
1.5 cm compared to 1.1 cm. The implication being that they are metastases. The lesions are 
widespread involving all segments apart from segment one. 
Resect015 
A 68-year-old male who underwent a segment 8 resections for a 2.7cm lesion in segment 8. He 
didn’t receive any preoperative chemotherapy. He had mild background liver steatosis. eGFR was 
83. His FLR-volume was 91% and FLR-function was 92%. Day 5 bilirubin was 7, INR 1, Lactate 
1.7 so had no evidence of PHLF. He had an uneventful postoperative course and was discharged 
day 3. 
MRI report 
A solitary metastatic deposit is demonstrated in segment eight of the liver measuring 27 mm which 
is marginally larger than the previous examination (25 mm previously). This lesion is well away 
from the major vascular structures. Small lesions with benign characteristics are present in 
segment 1 and 5. No other concerning lesions demonstrated rest of the liver. 
Pathology report  
Macroscopic Description: 134g of liver measuring 80 x 70 x 35mm. Slicing shows a subcapsular 
tumour deposit, maximum 36mm diameter and it is 20mm from the resection margin.  
Microscopic Description: 
Summary: 
• Number of tumour(s) present - One 
• Maximum diameter - 36mm 
• Tumour grade - Moderately differentiated  
• Minimum distance from margin - 20mm (assessed macro) 
• Vascular invasion - Yes 
• Response to neoadjuvant therapy - Pre-op treatment not stated 
• Lymph nodes - None submitted 
• Background liver - Steatosis   
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DIAGNOSIS: 
Liver segment VIII - Metastatic colorectal adenocarcinoma; excised.  
Resect016 
A 57-year-old female who had resection of segments 5, 6 and 7 for a metastasis in each. She 
had preoperative neoadjuvant chemotherapy. eGFR was >90. She had mild background steatosis 
and had an R1 resection. Her FLR-volume was 59% and FLR-function was 57%. Day 5 bilirubin 
was 50, INR 1, Lactate 1.7 indicating mild PHLF. She developed a postoperative chest infection 
requiring antibiotics and was discharged day 8. 
MRI report 
As previously demonstrated, two discrete lesions in segment VII which have signal characteristics 
of metastatic deposits. 
Lesion 1: The larger lesion measures 19mm and is marginally smaller (21mm previously). 
Lesion 2: Subcapsular lesion measures 12mm and is unchanged. 
Both these lesions are well away from the major vascular structures. No new concerning lesions 
in the rest of the liver. 
Pathology report 
A: Mesenteric lymph node. 
B: Segment VI liver metastatectomy. 
C: Segment V lesion.  
Macroscopic Description: 
A: Mesenteric lymph node- 
Fibrofatty tissue 11 x 7 x 3mm. Possible lymph node 5mm maximum identified. All embedded.  
B: Segment VI liver metastatectomy- Portion of liver weighing 125g and measuring 75 x 65 x 
30mm. There is an ill-defined whitish area protruding on the capsular surface measuring 10 x 
8mm. The specimen has been serially sliced into 9 slices. On slicing two lesions are revealed. 
The larger measures 19 x 22 x 20mm and appears to abut the deep margin. The smaller lesion 
measures 10 x 10 x10mm and lies at about 22mm from the deep and 11mm from the peripheral 
margin. The background parenchyma appears unremarkable. 
C: Segment V lesion- Fragment of liver weighing 1.2g and measuring 17 x 14 x 8mm. This is 
covered in part by capsule. There is a well circumscribed whitish area identified on the capsular 
surface measuring 4mm in maximum dimension. The specimen was serially sliced into 6 slices. 
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On slicing an ill-defined white lesion is identified, corresponding to the area noted on the capsular 
surface. This measures 6mm in maximum dimension and appears to be excised at a clearance 
of 2mm at the deep margin and at least 3mm at the peripheral margin.  
Microscopic Description: 
A. Histology reveals fibrofatty tissue with a central area of fat necrosis and associated 
inflammation. There is no evidence of lymphoid tissue. There is no evidence of neoplasia. 
B. Sections from both lesions reveal moderately differentiated colorectal adenocarcinomas, the 
smaller of which is mucin producing. The larger lesion extends to <1mm from the deep resection 
margin.  
C. Sections reveal a small subcapsular deposit of moderately differentiated metastatic colorectal 
adenocarcinoma, which shows no signs of regression. The tumour appears to be excised at a 
clearance of 1.8mm. 
The background parenchyma shows mild steatosis without features of steatohepatitis. The portal 
tracts are normal. There is no fibrosis or inflammation. The bile ducts are unremarkable and in 
appropriate numbers.  
Summary: 
• Number of tumour(s) present          - 3 
• Maximum diameter               - 22mm, 10mm, 6mm 
• Tumour grade                    - Moderately differentiated 
• Minimum distance from margin     - R1 (largest lesion, segment VI <1mm from margin), 
(assessed macro/micro combined) 
• Vascular invasion               - not identified 
• Response to neoadjuvant therapy     - not identified 
• Lymph nodes                    - N/A 
• Background liver               - Steatosis 
DIAGNOSIS: 
A. Mesenteric lymph node - Fat necrosis. No evidence of lymphoid tissue. 
B. Segment VI liver metastatectomy - Metastatic, moderately differentiated colorectal 
adenocarcinomas X 2. The largest at the resection margin  
C. Segment V liver lesion - Metastatic moderately differentiated colorectal adenocarcinoma. 
Excised. 
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Resect017 
An 83-year-old male who had 6 separate metastatectomy resections of 4, 5, 6 and 7 for individual 
lesions. He had preoperative neoadjuvant chemotherapy. eGFR was 78. He had minimal 
background liver changes. FLR-volume was 45% and FLR-function was 42%. Day 5 bilirubin was 
93, INR 1, Lactate 2. This indicated moderate PHLF. He developed a post-operative wound 
infection requiring antibiotics. He was discharged on day 9. 
MRI report 
Findings: there are two lesions with characteristics of metastases demonstrated in segment 7, 
one 5 mm in diameter of the other 1 cm. There is a subcapsular lesion high within segment four 
4 mm in diameter, a subcapsular metastasis in segment five 1.6 cm in diameter. A more equivocal 
lesion which is likely to represent metastasis is present adjacent to the gallbladder at the interface 
between segments five and four. No other lesions identified. The lesions are well way from major 
vascular structures. The background liver parenchyma appears normal. 
Pathology report 
Subcapsular lesion high within segment 4, 4mm in diameter, subcapsular metastasis segment 5, 
1.6cm.  More equivocal lesion likely to represent metastasis is present adjacent to the gallbladder 
at the interface between segments 5 and 4. 
Macroscopic Description: 
B: Liver, segment 7 A disc shaped sample of liver (30 x 20 x 20mm, weight 7.5g) with capsule on 
one side and resection margin on the other three. 
On sectioning there is a yellow coloured tumour, maximum 18mm which is free of the resection 
margin by 2mm grossly.  Sampled in one cassette (B1). 
C: Liver, segment 4 A disc of liver (10 x 10 x 5mm) with capsule on one side and resection margin 
on the others.  On serial sectioning there is an indistinct yellow-white tumour approximately 6mm 
in maximum dimension.  All embedded in one cassette (C1). 
D: Liver, segment 4/5 A specimen of liver (30 x 20 x 15mm weight 5.8g).  The specimen has a 
groove on the inferior surface consistent with the lobulation between segments 4/5.  On sectioning 
there is a single yellow-white tumour approximately 8mm in maximum dimension which is free of 
the resection margin by 2mm grossly.  Sampled in one cassette (D1). 
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E: Liver, segment 6. A wedge of liver tissue (40 x 40 x 20mm, weight 20.1g) with capsule on two 
sides and resection margin on the other.  The capsule is wrinkled and roughened, and a 
bosselated tumour is seen on the surface.  On serial slicing there is a single whitish tumour 
(maximum dimension 20mm) which is free of the resection margin by 8mm. 
F: Liver, segment 7: A wedge of liver tissue (22 x 15 x 10mm) with capsule on one side and 
resection margin on the others.  On serial slicing there is a single small yellowish tumour 6mm in 
maximum dimension which is 3mm from the resection margin.  Sampled in one cassette (F1). 
G: Liver, segment 6: A wedge of liver (20 x 20 x 14mm).  On slicing there is a single yellowish 
tumour 9mm in maximum size which is free of the resection margin by 7mm.  Sampled in one 
cassette (G1). 
Microscopic Description: 
B.-G. Liver, multiple metastatectomies, see macroscopy  
Within these 6 metastatectomy specimens, 5 of the lesions found grossly show similar histological 
features. They comprise mostly necrotic lobulated lesions with focal calcification. They are 
surrounded by fibrosis and evidence of old haemorrhage. There is focal foreign body giant cell 
reaction, and non-specific chronic inflammation. They show no viable carcinoma. Only the lesion 
in specimen G shows evidence of residual viable adenocarcinoma, with one area approximately 
6 mm in size. 
Otherwise the background liver shows mild non-specific portal inflammation and minimal degree 
of macro vesicular steatosis. 
These histological appearances are of one viable metastasis, in keeping with colorectal 
carcinoma (specimen G), and 5 necrotic lesions in keeping with a complete response to therapy. 
Summary: 
• Number of tumour(s) present           1 
• Maximum diameter               -     6mm (microscopically) 
• Tumour grade                    -     Moderate 
• Minimum distance from margin     -     7mm (grossly) (assessed macro/micro combined) 
• Vascular invasion               -     No 
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• Response to neoadjuvant therapy     -     Significant, see above 
• Lymph nodes                    -     None 
• Background liver               -       Minimal changes 
DIAGNOSIS: 
B.-G. Liver, multiple metastatectomies, see macroscopy a single viable metastasis, 5 showing 
complete response to therapy/regression, see above 
Resect018 
A 60-year-old male who had a left hepatectomy and segment 6/7 metastatectomy for multiple 
metastasis: 11 mm metastasis within segment two, a 1.4 cm and 4 mm metastasis in segment 
three, a 2.1 cm and a 2.6cm metastasis in segment 7, a 3.5 cm metastasis just above the left 
main branch of the portal vein in segment four extending into segment two, a 2.3 cm metastasis 
in segment 1 abutting the IVC. He had no preoperative chemotherapy. eGFR was >90. His 
background liver was unremarkable. FLR-volume was 40% and FLR-function 41%. Day 5 bilirubin 
was 25 INR 1.5, lactate 1.7. This indicated moderate PHLF He developed a post-operative chest 
infection requiring antibiotics and was discharged on day 7. 
MRI report 
Findings: the left lobe extends into the left sub phrenic space. There is 11 mm metastasis high 
within segment two. Within segment seven there is a 2.1 cm metastasis. Within segment four 
extending into segment two just above the left main branch of the portal vein there is a 3.5 cm 
metastasis. Within the caudate lobe there is a 2.3 cm metastasis abutting the IVC. In segment 
three immediately adjacent to the anterior capsular surface there is a 1.4 cm and 4 mm 
metastasis. Posteriorly within segment seven in a subcapsular location there is a 2.6 cm 
metastasis. No other lesions identified. 
Pathology report 
Macroscopic Description: 
A: Liver segment 6 - Wedge shaped liver fragment measuring 6.5cm (superior to inferior) x 3.5cm 
(anterior to posterior) x 3.8cm (medial to lateral). A subcapsular, ill-defined white lesion is 
identified at the posterior aspect of specimen. Resection margin inked black. On slicing the lesion 
appears white and soft with central necrosis and measures 3.5 x 2.8 x 2.4cm (presumably 
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representing radiological lesion 7). The lesion appears to be very close to the presumed superior 
margin and appears to abut the presumed lateral margin. 
B: Tumour on caudate lobe Wedge of liver measuring 3.6 x 2.8 x 3cm. Resection margin has 
been inked black. A subcapsular, ill-defined white lesion measuring 3 x1.5 x2.5cm is identified 
(presumably representing radiological lesion 4). On slicing the lesion appears to abut the 
resection margin. 
C: Left lobe of liver 
Left hemihepatectomy measuring 21cm superior to inferior x 10cm medial to lateral x 6cm anterior 
to posterior.  Ligamentum teres is attached measuring 5 x 3.5 x 1.5cm.  On the anteroinferior 
aspect of the specimen an incision is identified measuring 7.8cm in length.  The cut surface 
reveals tumour and adjacent hepatic parenchyma sampling for research prior to receipt in the lab. 
as stated on the request form.  Two subcapsular white lesions are noted within segment 3. The 
larger measures 1.2 x 1.3cm and the smaller measures 0.6 x 0.6cm.  Excision margin measures 
12 x 6cm and shows an area of incision measuring approximately 5cm in length and 1.5cm in 
depth.  Area of incision inked orange and resection margin inked black.  Specimen serially sliced 
from superior to inferior in 32 slices. 
On slicing, three whitish, firm lesions are identified. The largest is in segments 2-4 (radiological 
lesion 3), measures 3.8 x 3.5 x 2.7cm and appears to abut the resection margin. The remaining 
two lesions are located in segment 3. The largest has been previously sampled as mentioned 
above and measures 1 x 1 x1 cm (presumably radiological lesion 5). The smallest measures 0.8 
x 0.6 cm (radiological lesion 6). Both lesions are well far from the resection margin. 
Radiological lesion 1 was not visualised on initial sectioning, so segment 2 has been sliced after 
further fixation into 0.2cm intervals and three potential lesions are noted. Proceeding from 
superior to inferior, a subcapsular, multiloculated cystic lesion (pathological lesion 7) is identified 
measuring 0.8cm in maximum dimension, an area of portal tract fibrosis (pathological lesion 8), 
measuring 0.7cm and an area of dilated ductal formations (pathological lesion 9) measuring 
0.9cm, are identified. All lesions in segment 2 are embedded in their entirety. 
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C1= small lesion segment 3  radiological lesion 6; C2= large and small lesion segment 3  
radiological lesions 5 and 6; C3= large lesion segment 3  radiological lesion 5; C4-5-6= lesion 
segments 2-4 and resection margin  radiological lesion 3; C7=cystic lesion segment 2 
(pathological lesion 7); C8=portal tract thickening segment 2 (pathological lesion 8); C9-10= 
"ductal" lesion segment 2 (pathological lesion 9).   
D: Liver, segment 7 metastasis Irregular fragment of liver measuring 3.8 x 2.3 x 2.3cm, partially 
covered by capsule. Resection margin is inked black. On slicing, a subcapsular, whitish ill-defined 
lesion with central necrosis is identified (presumably representing radiological lesion 2). This 
measures 2.5 x 2 x 2cm and appears to abut both capsule and resection margin. 
Microscopic Description: 
On sections six metastatic, moderately to poorly differentiated, partially necrotic, colorectal 
adenocarcinomas are identified as follows: 
Pathological lesion 1: radiological lesion 7, segment 6, maximum dimension: 3.5cm, subcapsular, 
extends up to the lateral resection margin.  
Pathological lesion 2: radiological lesion 4, segment 1, maximum dimension: 3cm, subcapsular, 
extends up to the resection margin. 
Pathological. lesion 3: radiological lesion 3, segments 2-4, maximum dimension 3.8cm, extends 
up to the resection margin. Adjacent to the tumour a big blood vessel, most likely hepatic vein 
branch, with the lumen occluded by fibrous tissue is identified (block C6). No tumour involving the 
lumen, or the wall is identified.   
Pathological. lesion 4: radiological lesion 5, segment 3, maximum dimension 1cm, excised  
Pathological. lesion 5: radiological lesion 6, segment 3, maximum dimension 0.8cm, excised 
Pathological. lesion 6: radiological lesion 7, segment 7, maximum dimension 3.8cm, extends up 
to the resection margin.  
Pathological lesion 7 in segment 2 shows Von Meyenburg complex with a cystically dilated duct 
in keeping with simple biliary cyst.  This is presumably radiological lesion 1. 
Pathological lesion 8 in segment 2 show an expanded portal tract only. 
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Pathological lesion 9 in segment 2 shows dilated lymphatic vessels. 
Summary: 
• Number of tumour(s) present 6 
• Maximum diameter 3.8cm 
• Tumour grade -                               moderately to poorly differentiated 
• Minimum distance from margin -                     At the margin (pathological lesion 1/segment 
6, pathological lesion 2/segment 4, pathological lesion 3/segments 2-4) 
• Vascular invasion -                               not seen 
• Response to neoadjuvant therapy -                     not applicable 
• Lymph nodes -                               not submitted 
• Background liver -                               unremarkable  
DIAGNOSIS: 
Liver segments 6, 7, caudate lobe and left lobe, resection  - Metastatic colorectal carcinoma x 6 
Resect019 
An 80-year-old male who had a left lateral sectionectomy for a segment 3 metastases. He 
received no preoperative chemotherapy. eGFR was 88. He had mild steatosis in his background 
liver. His FLR-volume was 82% and FLR-function was 82%. Day 5 bilirubin was 32, INR 1.1, 
Lactate 1.2, indicating mild PHLF. He had a normal post-operative course and was discharged 
day 5. 
MRI report 
Findings: there is a solitary metastasis in segment three with a maximal diameter of the 2.8 cm. 
This extends to the falciform ligament and the anterior aspect of the left main branch the portal 
vein, there is dilatation of the ducts in segment four suggesting that there is infiltration at the level 
of the falciform ligament. The rest of the liver appears unremarkable. 
Pathology report 
Macroscopic Description: 
Specimen weighing 249.9g comprising segments II and III and a small area of segment IV. It 
measures 140 x 80 x 60mm.  The falciform ligament is present measuring 40 x 20 x 10mm.  
215 
 
 
 
In segment III there is a tumour with a maximal diameter of 35mm. The closest distance to the 
tumour is 15mm. The tumour appears to have grown in structures ?bile duct and bears a satellite 
lesion approximately 15mm from the main tumour (1). In lower segment III close to the falciform 
ligament there is a small subcapsular whitish nodule measuring 5mm maximum and is 15mm 
from the closest resection margin (3). 
Block 2 = liver to capsule including small satellite lesion above the tumour; 4 = background liver.   
Microscopic Description: 
The liver contains three lesions of moderately differentiated adenocarcinoma in keeping with 
metastases from a colorectal origin. The tumours show some central necrosis, haemorrhagic 
areas and fibrosis. The advancing edge of the tumour is diffusely infiltrating; the liver capsule is 
intact over the tumour.  The nearest surgical resection margin is 14mm. The tumour grows in 
biliary ducts (1) and has two satellite lesions (1 and 3). The histology of the background liver (4) 
shows a normal architecture and some mild steatosis, but no evidence of chronic liver disease. 
Special stains have not been performed.  
Summary: 
• Number of tumour(s) present          - Three 
• Maximum diameter               - 35mm 
• Tumour grade                    - Moderate  
• Minimum distance from margin     - 14mm (assessed macro/micro combined) 
• Vascular invasion               - Not identified  
• Response to neoadjuvant therapy     - N/A 
• Lymph nodes                    - None received  
• Background liver               - Mild steatosis  
DIAGNOSIS: 
Left lobe of liver - Metastatic adenocarcinoma consistent with colorectal origin, margin 15mm.  
Resect020 
A 78-year-old male who had a left lateral sectionectomy for an 11mm segment 2 resection. He 
received no preoperative chemotherapy. eGFR was 82. He had type 2 diabetes. He had mild 
steatosis in his background liver. His FLR-volume was 82 and FLR-function was 80%. Day 5 
bilirubin was 14, INR 1, Lactate 1.2, with no evidence of PHLF. He had a normal post-operative 
course and was discharged day 3. 
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MRI report 
Findings: Solitary 11 mm lesion in segment two away from major vascular structures 11 mm from 
the anterior capsules surface. The lesion is very bright on T2 with T2 shine through on diffusion. 
This is atypical for a "conventional" colorectal metastasis however I understand that the patient 
has had a mucinous primary and has had chemotherapy, this could account for this appearance. 
It also appears to have increased in size on earlier serial CTs. Following gadolinium, the 
enhancement pattern is against that of a haemangioma. 
Pathology report 
Macroscopic Description: 
Left lobe of liver weighing 168g and measuring 13 x 7 x 4.5cm. Slicing shows one lesion 11mm 
diameter and it is 8mm from the resection margin. The lesion has a haemorrhagic periphery and 
some viable tumour in the middle.  
Microscopic Description: 
Summary: 
• Number of tumour(s) present          - One 
• Maximum diameter               - 11mm 
• Tumour grade                    - Moderately differentiated mucinous  
• Minimum distance from margin     - 8mm (assessed macro) 
• Vascular invasion               - No 
• Response to neoadjuvant therapy     - Yes, partial  
• Lymph nodes                    - None submitted 
• Background liver               - Mild steatosis 
Comment: 
The metastatic colorectal adenocarcinoma is moderately differentiated, present in a pool of 
extracellular mucin and is fairly circumscribed. The pool of extracellular mucin, which in many 
areas has no viable cells, will explain the radiological appearances described.   
DIAGNOSIS: Left liver lobe - Metastatic mucinous colorectal adenocarcinoma.  - Excised.  
Resect021 
A 64-year-old male who was found to be inoperable due extrahepatic disease on a repeat staging 
CT. 
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MRI report 
Findings: There is a solitary 1.4 cm metastasis within segment eight extending just under the 
middle hepatic vein into segment four. The lesion is very close to the segment eight biliary radicle 
in addition to the middle hepatic vein. No other metastases demonstrated 
Resect022 
A 62-year-old female who underwent resection of segment 2, 6 and 4a for 3 metastases. She had 
undergone preoperative neoadjuvant chemotherapy. eGFR was >90. She had normal 
background liver. Her FLR-volume was 65.5% and FLR-function was 65.5%. Day 5 Bilirubin was 
12, INR 1, Lactate 1.3, so had no evidence of PHLF. She had a normal post-operative course and 
as discharged home day 5. 
MRI report 
There are were multiple ring enhancing lesions on the CT of 5.7.13, the majority of there have 
disappeared with no residuum visible - a rare event. 
The unequivocal the metastasis within segment four crossing into segment eight measuring 3.9 
cm in diameter. There is a satellite metastasis inferior to this in relatively peripheral location. There 
are multiple lesions with benign characteristics elsewhere. A more indeterminate but probable 
benign lesion is present high within segment 8, this measures 4 mm in diameter and is well way 
from major vascular structures. 
Pathology report 
Macroscopic Description: 
A: Liver segment 4a.  A specimen of liver weighing 127g and measures 85mm medial to later, 
85mm superior to inferior and 40mm anterior to posterior.  Falciform ligament can be identified 
on the anterior aspect.  The anterior of the liver shows a puckered lesion with depression of the 
surface measuring 22mm in maximum dimension.  The resection margin inked black.  Slicing 
reveals possible two foci of tumour, the first focus measures approximately 4cm from superior to 
inferior and 4cm medial to lateral.  It has irregular boundaries and shows areas of haemorrhage 
and necrosis.  A second focus is present in the inferior aspect which measures 15mm in maximum 
dimension.  It is 2cm from away from the resection margin.  Tumour 1 present at the capsular 
margin and is close to or present at resection margin in one of the other slices.  There is no 
obvious vascular invasion in any of the sections examined. 
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B: Liver segment 2 metastasis.  A small fragment of liver which measures 10 x 6 x 3mm.  No 
obvious lesion is identified.  It is painted black. 
C: Liver segment 6 metastasis.  A small fragment of liver measuring 7 x 6 x 2mm.  It contains a 
circular white lesion in the middle which measures approximately 3mm in maximum dimension.  
Inked black. 
Microscopic Description: 
• Number of tumour(s) present          - 2 
• Maximum diameter               - 40 mm 
• Tumour grade                    - Moderately to focally poorly differentiated in keeping with 
metastatic colorectal carcinoma 
• Minimum distance from margin     - Less than 1mm, tumour 1 (assessed macro/micro 
combined) 
• Vascular invasion               - Yes 
• Response to neoadjuvant therapy     - None 
• Lymph nodes                    - No 
• Background liver               -normal 
B and C.  These are pieces of liver tissue, each of which demonstrating an area of fibrosis within 
a septal portal tract.  There is no evidence of viable metastatic carcinoma, and definitive 
histological features are not present in either lesion. Lesion 1 is most likely a small metastasis 
which has undergone complete response to therapy. Lesion 2 could represent a sclerosed 
haemangioma/solitary sclerotic nodule.  
DIAGNOSIS: 
A. Liver segment 4a, metastatectomy     -      Metastatic adenocarcinoma.   
B. Liver segment 2, metastatectomy     -      Fibrosis; no evidence of viable metastatic carcinoma.   
C. Liver segment 6, metastatectomy     -      Fibrosis; no evidence of viable metastatic carcinoma.   
Resect023 
A 60-year-old man who underwent a left hepatectomy and caudate metastatectomy. He did not 
receive any chemotherapy prior to liver surgery. eGFR was >90. He had an 11mm metastasis in 
segment 2, a 3.5cm segment 4/2 metastasis just above the left portal vein, a 2.3cm metastasis in 
the caudate lobe. His FLR-volume was 54% and FLR-function was 56%. Background liver was 
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unremarkable. Day 5 bilirubin was 21, INR was 1.7. This indicates Moderate PHLF. He developed 
a post-operative chest infection requiring antibiotics. He was discharged 8 days’ post-surgery.  
MRI report 
Lesion 1: Segment 3 posteriorly- unchanged from previous and measures 14mm. 
Lesion 2: Segment 8 - smaller in size and measures 12mm (16mm previously). 
Lesion 3 & 4: Two adjacent lesions in Segment 8 – reduced in size and now measures 15mm (23 
mm previously). 
Lesion 5: There is a new lesion in segment 2 anteriorly measuring 11mm which was not present 
on previous CT or MRI. 
There are two small peripheral wedge-shaped areas of reduced Primovist concentration in 
segment 7 (present previously) and medially in segment 6. These are unlikely to represent 
metastases. No intrahepatic biliary duct dilatation. Normal adrenal glands. 
Comment: Mixed response with interval improvement in segment 8 lesions but segment 3 lesion 
unchanged with new lesion in 
segment 2. 
Pathology report 
Macroscopic Description: 
A: Gall bladder- Distended 100 x 40 x 40mm gall bladder with a short 10mm length of cystic duct. 
The serosa is smooth, the wall is 2mm thick and the mucosa is velvety with no focal lesions. One 
7mm gallstone seen.   
B: Segment V- 158g segment of liver 75mm supero-inferior, 65mm antero-posterior and 75mm 
medio-lateral. The lower anterior surface in continuity with the posterior surface inferiorly is 
covered by capsule. Three ?surgical defects are noted anteriorly largest 12mm. Margins inked, 
and specimen serially sliced into 19 slices. Two nodules are identified: 
Lesion one, slices 1-4, 20mm maximum, at surgical margin, distant from capsule (blocks B1 and 
B2). Lesion two, slices 8-13, 24mm maximum, firm and cream-coloured, 11mm from capsule, 
15mm from nearest margin (block B3). 
C: Segment II- 9.9g disc of liver with capsule on one side 40 x 32 x 12mm. The capsule is 
puckered by an underlying cream-coloured lesion. Serially sliced into 10 slices. Tumour nodule is 
seen in slices 2-9, 26 x 18 x 22mm. It has a firm cut surface and extends to the capsular surface 
and surgical margin (slices3-6).  
220 
 
 
 
D: Segment III- 1.7g disc of liver measuring 7mm with smooth glistening capsule on one surface. 
Inked with silver nitrate and serially sliced into 5 slices. Pale nodule is identified in slices 2-5 
measuring 9 x 9 x 10mm, reaching the margin in slices 2 and 3, and within 1mm of the capsule. 
E: Segment IIb- 11.4g cuboid piece of liver 30 x 27 x 25mm with capsule on one surface bearing 
a 2mm area of puckering. Serially sliced into 6 to reveal a firm cream-coloured tumour in slices 
3-6, 14 x 14 x 16mm. The capsule puckering is unrelated to the tumour. The tumour lies at the 
surgical margin (slices 4 and 6). 
Block E1 = slice 4, tumour to margin; E2 = slice 6, tumour to margin.  
Microscopic Description: 
A. The gall bladder shows unremarkable epithelium with a mild chronic inflammatory cell infiltrate 
in the lamina propria. There is no evidence of dysplasia or malignancy. The features are those of 
mild chronic cholecystitis.  
B-E.  Sections of liver resections confirm five tumour deposits with features consistent with 
moderately- to poorly differentiated metastatic colorectal adenocarcinoma. The tumour shows 
central necrosis and fibrosis in areas and there is a peripheral cuff of lymphoplasma cells at the 
outer edges. 
Three of the deposits in segments II, III and IIb (parts C-E) show tumour at the resection margins. 
In Part B, one of the two deposits in segment V ('Lesion 1') lies within 0.1mm of the inked resection 
margin and 'Lesion 2' lies 9mm from the resection margin.  No definite bile duct or vascular space 
invasion are identified. 
The background liver shows occasional macrovesicular steatosis in less than 2% of hepatocytes. 
The portal tracts show no significant pathology.  
Summary: 
• Number of tumour(s) present          - Five  
• Maximum diameter               - 20mm, 24mm, 26mm;  
• Tumour grade                    - poorly differentiated 
• Minimum distance from margin     - 0mm (assessed combined)         
• Vascular invasion               - Not identified 
• Response to neoadjuvant therapy     - cannot comment 
• Lymph nodes                    - None submitted 
• Background liver               - steatosis  
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DIAGNOSIS: 
Liver segments V, II, III, IIB     - Metastatic colorectal adenocarcinoma x5   - three at the resection 
margins 
Resect024 
A 63-year-old male who underwent a right hepatectomy for a 5.6 cm metastasis within segment 
7/8, a peripheral 2.3 cm metastasis high in segment eight and a 1.8cm metastasis posteriorly in 
the sub capsular location in segment six. He did not receive any preoperative chemotherapy. He 
had type 2 diabetes. eGFR was 73. His background liver was normal. His FLR-volume was 49% 
and FLR-function was 49%. His day 5 bilirubin was 18, INR 1.7, Lactate 2.5. This indicates mild 
PHLF. He developed a post-operative chest infection requiring antibiotics and was discharged on 
day 5. 
MRI report 
Findings: there is a 5.6 cm metastasis within segment 7/8, a peripheral 2.3 cm metastasis high in 
segment eight and a 1.8 cm metastasis posteriorly in the subcapsular location in segment six. 
The previously noted lesion within the left lobe has benign features. 
Features of chronic pancreatitis with dilated PD noted. 
Pathology report 
Macroscopic Description: 
Liver, right hemihepatectomy 
A right hemihepatectomy specimen (140mm anterior to posterior x 90mm medial to lateral x 
170mm superior to inferior, weight 1068g).  A large incision has been made on the anterior surface 
of the specimen prior to receipt in the laboratory (140mm) from which samples of tumour and 
normal tissue have been sampled (approximately 15mm each in size). 
Externally the liver has a smooth contour.  On sectioning 3 tumours are identified in keeping with 
the MRI appearances as follows: 
Tumour 1, segment 7, size 80 x 60 x 60mm, free of resection margin by 30mm, block B1. 
Tumour 2, anterior part of segment 8, size 30 x 20 x 20mm.  Free of resection margin by 15mm.  
Sampled in block B2. 
Tumour 3, posteriorly in segment 6, size 30 x 30 x 10mm. Free of margin. Sampled in block B3. 
The background liver appears unremarkable grossly and sampled in block B4. 
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Microscopic Description: 
Liver, right hemihepatectomy 
All 3 of the tumours sampled show similar histological features of metastatic moderate to poorly 
differentiated adenocarcinoma in keeping with a colorectal primary. There is a moderate amount 
of tumour necrosis. Focal lymphovascular 
invasion is seen in tumour 1. Tumour 1 also surrounds and destroys a large vessel, which looks 
like a large branch of the hepatic vein. 
The background liver shows a mild degree of steatosis occupying approximately 2% of the liver. 
There is no evidence of significant progressive chronic liver disease or fibrosis. 
Summary: 
• Number of tumour(s) present          3 
• Maximum diameter - 80 
• Tumour grade - moderate/poor 
• Minimum distance from margin     15mm (assessed macro/micro combined) 
• Vascular invasion -   Focal 
• Background liver - Unremarkable  
DIAGNOSIS: 
Liver, right hemihepatectomy, metastatic adenocarcinoma x3, see report 
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00 
28.4 9.3 89.9 0.0 17.
2 
9.4 138.
1 
RESEC
T/010 
190
2 
171.1 14.6
3 
52.5 16.2 25.0 146.1 16.
8 
8.7 308.
7 
RESEC
T/012 
181
5 
101.4 36.4
5 
40.7 16.5 37.0 64.5 20.
7 
14.0 299.
2 
RESEC
T/013 
151
7 
159.0 16.1
4 
33.8 16.6 25.7 133.4 11.
5 
9.5 252.
2 
RESEC
T/015 
146
7 
53.2 51.2
4 
31.0 20.7 27.2 25.9 25.
2 
28.0 303.
1 
RESEC
T/016 
124
4 
86.7 N/A 29.6 10.5 N/A N/A 18.
3 
10.8 130.
4 
RESEC
T/017 
129
6 
101.0 N/A 29.8 6.1 N/A N/A 16.
7 
5.7 78.6 
RESEC
T/018 
165
1 
70.0 N/A 30.4 10.6 N/A N/A 22.
6 
13.1 174.
5 
RESEC
T/019 
150
0 
151.6 4.30 38.4 13.3 6.5 145.1 14.
0 
8.1 199.
9 
RESEC
T/020 
140
0 
71.5 3.95 12.2 3.9 2.8 68.7 9.7 5.2 54.8 
RESEC
T/022 
966 185.1 5.94 31.5 10.1 11.0 174.1 9.7 5.2 98.0 
RESEC
T/023 
145
1 
144.1 11.8
2 
40.4 12.5 17.0 127.1 15.
5 
8.0 181.
0 
RESEC
T/024 
158
5 
241.8 17.2
4 
38.3 18.4 41.7 200.1 8.8 7.1 292.
3 
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Results of FLR DGE-MRI output dependant variables 
 
Patient 
referenc
e 
FLR 
Volu
me 
(ml) 
FLR 
Total 
Plasma 
Flow 
(ml/100
ml/min) 
FLR 
Arter
ial 
Flow 
Frac
tion 
(%) 
FLR 
Extra 
Cellul
ar 
Volum
e 
(ml/10
0ml) 
FLR 
Uptake 
Rate 
(ml/100
ml/min) 
FLR 
Arterial 
Plasma 
Flow 
(ml/100
ml/min) 
FLR 
Venous 
Plasma 
Flow 
(ml/100
ml/min) 
FL
R 
MT
T 
(se
cs) 
FLR 
Upta
ke 
Frac
tion 
(%) 
FLR 
Upta
ke 
Func
tion 
(ml/
min) 
PILOT/0
01 
397 199.8 18.8 31.16
286 
9.74146
5 
37.5437 162.2 8.9 4.6 39 
PILOT/0
03 
336 132.1 13.4 30.68
444 
14.5528
5 
17.7048 114.4 12.
6 
9.9 49 
PILOT/0
05 
189 71.3 54.4 39.79
971 
5.907 38.8065 32.5 30.
9 
7.6 11 
PILOT/0
08 
102
6 
64.2 64.5 31.05
426 
17.1427
1 
41.3595 22.8 22.
9 
21.1 176 
RESEC
T/001 
101
8 
176.1 57.7 48.61
431 
8.17489
4 
101.608 74.5 15.
8 
4.4 83 
RESEC
T/002 
139
3 
117.6 14.2 32.69
485 
21.2972
7 
16.7024 100.9 14.
1 
15.3 297 
RESEC
T/003 
254 99.1 44.7 36.74
374 
13.7647
7 
44.3065 54.8 19.
5 
12.2 35 
RESEC
T/006 
703 123.2 34.6 33.25
7 
17.2790
7 
42.621 80.6 14.
2 
12.3 122 
RESEC
T/007 
819 234.3 8.9 35.27
952 
11.5782
6 
20.8599 213.4 8.6 4.7 95 
RESEC
T/008 
951 93.0 43.2 54.65
135 
15.9192
3 
40.2168 52.8 30.
1 
14.6 151 
RESEC
T/009 
102
7 
92.5 94.1 27.42
064 
8.70372
1 
86.9595 5.5 16.
3 
8.6 89 
RESEC
T/010 
117
8 
181.7 11.7 53.06
105 
16.4495
6 
21.2751 160.5 16.
1 
8.3 194 
RESEC
T/012 
116
3 
89.7 40.4 38.52
246 
15.3851
7 
36.2731 53.5 22.
0 
14.6 179 
RESEC
T/013 
140
2 
157.8 16.6 34.10
796 
16.7260
1 
26.1631 131.7 11.
7 
9.6 235 
RESEC
T/015 
107
5 
47.2 56.7 29.55
027 
19.3613
5 
26.7253 20.4 26.
7 
29.1 208 
RESEC
T/016 
677 91.8 N/A 26.75
846 
9.81929 N/A N/A 15.
8 
9.7 66 
RESEC
T/017 
517 85.3 N/A 26.10
864 
5.62805
9 
N/A N/A 17.
2 
6.2 29 
RESEC
T/018 
658 73.3 N/A 32.43
474 
11.4335
7 
N/A N/A 23.
0 
13.5 75 
RESEC
T/019 
122
5 
146.7 4.4 36.70
581 
12.9090
5 
6.43183 140.3 13.
8 
8.1 158 
RESEC
T/020 
111
8 
71.7 6.6 12.47
333 
3.85918
8 
4.77013 67.0 9.9 5.1 43 
RESEC
T/022 
665 180.4 9.9 31.36
166 
9.70314
1 
17.7854 162.6 9.9 5.1 65 
RESEC
T/023 
973 155.0 8.4 41.73
778 
12.9736
2 
13.0655 142.0 14.
9 
7.7 126 
RESEC
T/024 
564 243.5 12.1 38.17
356 
18.7932
1 
29.3634 214.1 8.7 7.2 106 
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FLR function, Volume and Functional bias 
Patient 
reference 
FLR 
volume % 
FLR 
Function % 
functional 
bias (%) 
Mean FLR 
Function & 
Volume (%) 
PILOT/001 18.6 16.4 2.21 17.5 
PILOT/003 25.3 29.4 -4.16 27.4 
PILOT/005 18.1 25.1 -6.95 21.6 
PILOT/008 58.3 54.3 4.04 56.3 
RESECT/001 43.5 45.6 -2.10 44.6 
RESECT/002 92.2 95.7 -3.50 93.9 
RESECT/003 18.3 18.9 -0.62 18.6 
RESECT/006 60.2 65.5 -5.21 62.8 
RESECT/007 61.1 58.8 2.25 59.9 
RESECT/008 53.4 53.2 0.20 53.3 
RESECT/009 69.1 64.7 4.36 66.9 
RESECT/010 61.9 62.8 -0.83 62.3 
RESECT/012 64.1 59.8 4.26 62.0 
RESECT/013 92.4 93.0 -0.59 92.7 
RESECT/015 73.3 68.6 4.61 71.0 
RESECT/016 54.4 50.9 3.46 52.7 
RESECT/017 39.9 37.0 2.91 38.4 
RESECT/018 39.9 43.1 -3.26 41.5 
RESECT/019 81.7 79.1 2.57 80.4 
RESECT/020 79.8 78.6 1.19 79.2 
RESECT/022 68.9 65.9 3.00 67.4 
RESECT/023 67.1 69.7 -2.68 68.4 
RESECT/024 35.6 36.3 -0.68 35.9 
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1.0 RESEARCH SUMMARY 
 
General Information 
Title: Pilot study for determining the best method of acquisition of Dynamic Contrast-Enhanced Liver 
MRI  
Principal investigator: David Longbotham  
Version:    1.7, 26/3/14 
Co-ordinating Centre: St James’s University Hospital (SJUH), HPB and Transplantation Unit 
Sponsor: R&D Department, Leeds Teaching Hospitals 
 
Study Information 
Type:     Pilot Study 
Indication: To determine the most appropriate data acquisition protocol for Dynamic Contrast MRI 
Design: Prospective, single centre, randomised 
Primary Objectives: Comparison of three MRI protocols on quality of data to determine which is the most suitable to 
be used in the clinical setting. 
 
Study Timelines 
Expected Start Date:  May 2014 
Subject Enrolment Phase:  May-August 2014 
End of Study:    August 2014 
Expected Completion Date: September 2014 
 
Study Subject Information 
Number of trial subjects: ~15 
Age group of study subjects: 18 years and above 
Inclusion criteria: Patients undergoing MRI for investigation into Colorectal Liver Metastasis 
Exclusion criteria: Current Pregnancy, Allergy/intolerance to Gadolinium based contrast agents, Inability to 
undergo MRI (see appendix for list) 
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2.0 INTRODUCTION 
 
2.1 Background  
 
Colorectal Liver Metastases (CRLM) is a common and potentially fatal disease. There are around 
40,000 new cases of colorectal cancer diagnosed a year1. A third of patients of all patients 
diagnosed with Colorectal Cancer will have metastatic liver disease at time of presentation. 
 
Surgical Resection of CRLM remains the only curative option for this group of patients2. Due to 
advances in surgical, radiological and oncological techniques and technology, increasingly radical 
liver resections are being considered. Due to the large volume of liver that is being considered for 
resection it is vitally important to know pre-operatively that the remnant liver volume (RLV) will be 
sufficient to be compatible with life.  
 
In current practice, 75% of total liver volume (TLV) can be safely resected (or to leave a remnant 
weighing 0.5% of total body weight) in patients with apparently healthy liver. The percentage of 
TLV resectable reduces to 70% in patients with known liver disease or having received 
chemotherapy pre-operatively, and 65% in patients with established cirrhosis3. Those patients 
requiring larger resections would need to be considered for techniques to induce liver hypertrophy 
(such as portal vein embolisation or two-stage hepatectomy) or to be deemed unresectable. 
 
Dynamic Contrast MRI (DCE-MRI) of the Liver is a new technique using Gadoxetic Acid (Primovist 
tm) – a liver specific contrast agent. Rapidly acquired images at short interval can calculate rate 
of flow of contrast into hepatic arterial architectures, portal venous flow and diffusion into 
hepatocytes. Diseased, fibrotic liver tissue will have altered blood flow and diffusion rates from 
normal healthy tissue. A region of interest (ROI) within each liver segment can be identified and 
the data derived provides a limited number of parameters that characterise the physiological state 
of the tissue. Calculation of the function of each segment can be used as a numerator over the 
total calculated liver function as its denominator4-7.    
Previous studies8 have shown good levels of correlation of DCE-MRI against global measures of 
hepatic function Indocyanine Green (ICG) testing and nuclear medicine Galactosyl Serum 
Albumin scintigraphy (GSA). 
However, there is little concordance about the method of acquisition for DCE-MRI in the literature. 
Previous studies have involved times that require over an hour to obtain the necessary data: 
impractical for routine clinical work. This means its current use is only limited to research.  
 
2.2 Rationale for Study 
 
Using three different designed acquisition protocols that use differing sequences that can be 
incorporated into a pre-existing protocol for Liver MRI, a shortening of the acquisition time could 
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be obtained. If the quality of the images obtained is adequate in providing the necessary data that 
is needed to complete the DCE-MRI, then these shorter MRI scans may be able to be both more 
tolerable to patients and potentially suitable for clinical practice. 
 
For those patients who are undergoing a staging Liver MRI, their acquisition protocol can be 
amended to include the DCE-MRI sequences as the only delayed phase of the MRI acquisition is 
necessary for radiological staging, and the initial phases (arterial and portovenous phase) are not 
required. As a result, could be altered to obtain dynamic data without changing the required 
radiological images in these patients to stage these patients accurately. 
 
Continuous data over a set period of time can be acquired, collecting ‘semi-quantitative’ and 
quantitative data.  
Semi-quantitative: This is the information includes: The maximal signal intensity (SMAX), the time 
to reach SMAX (TMAX), the half-life (T1/2) and the area under the curve for the data6. This can be 
directly compared with comparative signal in other organs (e.g. Heart, Spleen) for a calculated 
fraction of contrast within the liver at that given time. This would allow corrections for deviations 
in timing of the data acquisitions.  
Quantitative measurements calculate the hepatic extraction fraction (HEF), input-relative blood 
flow (irBF) and mean transit time (MTT) of the segments as method of assessing hepatic function5, 
6. This estimates the slope of the arterial perfusion divided by the sum of the slope of the arterial 
and portal perfusions7. These values could correlate with liver function.  
 
This study will analyse 3 different methods on adequacy of images prior to a subsequent study 
that aims to determine its effectiveness in obtaining the following values: SMAX, TMAX, T1/2, AUC, 
HEF, irBF, MTT, and RLE. The ability to accurately calculate these values with narrow confidence 
ranges shall demonstrate which of the 3 protocols is the most appropriate to be used in a clinical 
trial. 
• Standard 3D Sequence obtaining images every 2 seconds with normal breathing - this is the type 
of sequence used currently in St James’ University Hospital 
• TWIST 3D Sequence obtaining images every second with normal breathing, in a method used in 
other studies6,8 into Liver MRI 
• Pre-bolus 2D slice sequence with a multi-slice 2D sequence every 6 seconds with normal 
breathing - used in DCE-MRI of kidneys.18,19 
2.3 Hypothesis – One of the three acquisition methods will provide good quality data and images 
to be used in clinical practice to be utilised in further planned studies. 
 
3.0 STUDY OBJECTIVES AND AIMS 
 
3.1 Primary objective 
3.1.1 To assess 3 separate DCE-MRI acquisition protocols to determine which would be the most 
suitable for shortening the sequence with no compromise on the quantitative result.  
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3.1.2 The following values shall be calculated: 
SMAX, TMAX, T1/2, HEF, irBF, MTT, and RLE 
Reproducibility of results and accuracy will be calculated 
3.1.3 Image quality and artefacts will be qualitatively assessed 
 
 
4.0 STUDY DESIGN 
 
4.1 Randomised, non-blinded 
4.2 Single centre 
4.3 Prospective data collection: 
4.3.1 Patient characteristics (such as age, medical history, BMI, alcohol intake (units/week), 
medications and any known liver/biliary disease) will be collected 
4.3.2 Diagnosis of Colorectal Liver Metastases will be confirmed from the St James Specialist 
hepatobiliary Multi-disciplinary Meeting (MDT) 
 
4.4 Dynamic Contrast Enhanced MRI 
4.4.1 Patients will be randomised to one of the three pre designed DCE-MRI protocols 
4.4.2 5 patients in each group. 
4.4.3 Use of MRI in St James’ University Hospital Radiology department. 
4.4.4 Brief Explanation of how MRI works 
4.4.4.1 Utilises paramagnetic qualities of water molecules within tissue to demonstrate liver anatomy and 
pathology 
4.4.4.2 Utilises intravenous liver specific contrast agent (Gadoxetic Acid) to demonstrate blood flow and 
diffusion in the liver 
4.4.4.3 This agent is taken up by hepatocytes via organic anion transporting polypeptide OATP and 
excreted into bile canaliculi via multidrug resistant protein (MRP) system 
4.4.4.4 This acquisition will be added onto the participants routine MRI scan for staging of their CRLM – 
no additional MRI will need to be requested 
4.4.4.5 A study8 has shown strong correlation of DCE-MRI with validated methods of global hepatic 
function ICG and GSA 
4.4.4.6 Acquisition will be taken dynamically during the arterial and portovenous phases (first 5 minutes). 
4.4.5 This phase is not utilised on a routine MRI scan and 3 acquisition protocols written by Dr Dan 
Wilson and Dr Steven Sourbron will be used 
4.4.5.1 Standard 3D Sequence obtaining images every 2 seconds with normal breathing 
4.4.5.2 TWIST 3D Sequence obtaining images every second with normal breathing 
4.4.5.3 Pre-bolus 2D slice sequence with a multi-slice 2D sequence every 6 seconds with normal 
breathing 
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4.4.5.4 In addition 3 extra breath hold sequences shall be obtained to provide a comparison against 
movement artefacts. 
4.4.6 Analysis of the DCE-MRI data will take place in in-house computer system at University of Leeds 
MRI Physics Department by Steven Sourbron and DL. 
4.4.7 The interpreting consultant radiologist will be blinded to the results of the DCE-MRI phase to 
prevent this data being used in their reporting of patients MRI 
 
5.0 STUDY SUBJECT SELECTION 
 
5.1 Patient List: 
5.1.1 Patients will be identified from the hepatobiliary outpatient clinic from tertiary referrals for patients 
with potentially resectable liver metastases 
5.1.2 Information regarding the study will be provided to potential participants at this stage via post 
 
5.2 Eligibility criteria 
5.2.1 Inclusion criteria 
5.2.1.1 Confirmed diagnosis of Colorectal Liver Metastasis: 
5.2.1.1.1.1 Histological confirmation of adenocarcinoma of the large bowel 
5.2.1.1.1.2 Radiologically diagnosed CRLM at time of diagnosis of Large bowel tumour or subsequent time 
5.2.1.1.3 Needing a staging Liver MRI 
5.2.1.1.2 Able and willing to provide informed consent 
 
 
5.2.2 Exclusion criteria 
5.2.2.1 Current pregnancy 
5.2.2.2 Allergy/intolerance to Gadolinium based intravenous contrast agents 
5.2.2.3 Intolerance to MRI 
5.2.2.4 Unable to undergo MRI due to safety concerns (see appendix for complete listing) 
5.3 Sample Size 
5.3.1 Approximately 160-180 patients undergo resection of their CRLM a year in St James’ University 
Hospital (as per local prospectively maintained databases) 
5.3.2 Due to availability of obtaining MRI to allow DCE-MRI to be performed the anticipated recruitment 
shall be ~1-2 patients per week 
5.3.3 The aim of recruiting ~15 patients that will allow the study to be completed and analysed within 3 
months 
5.4 Recruitment 
Potential participants will be identified at the Hepatobiliary Specialist MDT as potentially needing 
a liver resection. They must have plan for a Liver MRI in Leeds to stage their metastasis. 
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A Patient Information Sheet and letter of invitation (see appendix) will be posted out to patients 
prior to their attendance at their outpatient MRI appointment explaining the study and need to 
adapt their MRI to one of the 3 acquisition protocols. 
 They will be invited to attend their appointment 15 minutes early, and approached on the day of 
their MRI to consent them into the study, at which time they will be randomised to one of the 3 
acquisition protocols. 
This process will be clearly documented onto PPM (patient pathway manager) – hospital 
database with patient information and clinic letters that can be printed out easily and also kept in 
their medical case notes.   
 
5.5 Consent  
Informed written consent will be obtained when patients attend their outpatient Liver MRI 
appointment. The right of the patient to refuse consent without giving reasons will be respected. 
Furthermore, the patient will remain free to withdraw from the study at any time without giving 
reasons. The rights and welfare of the patients will be protected by emphasising to them that the 
quality of medical care will not be adversely affected if they decline to participate in this study. A 
copy of the consent will be given to the patient, the original filed in the Trial Master File (TMF), 
and one filed in the hospital notes. The written consent will be taken by a clinician, who has signed 
/ dated the staff authorisation / delegation log.  The process of obtaining written consent will be 
clearly documented in the patient’s medical notes. 
The participant’s General Practitioner (GP) will also receive confirmation of the patient’s inclusion 
into the trial.  
6.0 STUDY SCHEDULE  
 
6.1 Patients identified from Hepatobiliary clinic referrals from Colorectal Surgery/Oncology as 
to possible resectability of CRLM 
 
6.2 Recruitment of patients over 3 months: 
6.2.1 Initial identification of needing staging Liver MRI for Colorectal Liver Metastasis 
6.2.2 Letter posted to patient containing information sheet and consent form 
6.2.3 Highlighted patients as potential participants will be logged onto prospectively maintained 
database as a potential and their date of MRI will be obtained 
6.2.4 Potential participants will have their MRI requested as per radiology department guidelines for 
including patients in research 
6.2.5 Once written informed consent has been obtained, participants will have their sequence modified 
as per their randomly allocated MRI protocol 
6.2.6 Participants will be randomised but not blinded to one of the 3 DCE-MRI protocols 
 
6.3 Analysis of data over 1 months 
6.4 Write up of results over 1 months 
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7.0 DATA COLLECTION, SOURCE DATA AND CONFIDENTIALITY 
 
7.1 General 
7.1.1 All information collected during the course of the trial will be kept strictly confidential.   
7.1.2 Information will be held securely on paper and electronically on secure university and hospital 
servers.  
7.1.3 A database of all information will be anonymised with patients allocated to a study number. 
Identification of the patients to their number will be kept on a separate password protected file on 
secure servers accessible only to the principal investigator. 
7.1.4 The HPB and Transplant Unit, SJUH will comply with all aspects of the Data Protection Act 1998, 
International Conference on Harmonization (ICH) of Good Clinical Practice (GCP) guidelines and 
Declaration of Helsinki (2008). Operationally this will include: 
 
7.1.4.1 Consent from patients to record personal details including name, date of birth, address and 
telephone number, NHS ID, hospital ID, GP name and address.  
7.1.4.2 Appropriate storage, restricted access and disposal arrangements for patient personal and clinical 
details.  
7.1.4.3 Consent from patients for access to their medical records by responsible individuals from the 
research staff, the sponsor or from regulatory authorities, where it is relevant to trial participation 
that have received ICH GCP training and are thus aware of the importance of patient 
confidentiality. 
7.1.4.4 Consent from patients for the data collected for the trial to be used to evaluate safety and develop 
new research. 
 
7.2 Archiving 
In line with the principles of ICH-GCP / UK Clinical trial Regulations guidelines, at the end of the 
trial, data will be securely archived at each participating centre for a minimum of 10 years.  
Arrangements for confidential destruction will then be made. If a patient withdraws consent for 
their data to be used, it will be confidentially destroyed immediately.  
8.0 DATA ANALYSIS 
 
8.1 Patient characteristics 
 
8.2 Statistical Analysis 
8.2.1 The pilot study is aiming for 15 patients over 7-8 weeks 
8.2.2 There shall be 3 arms of the research DCE-MRI protocol (information in Appendix 
8.2.3 Each protocol will calculate the following values: SMAX, TMAX, T1/2, HEF, irBF, MTT, and RLE 
8.2.4 The reproducibility of the data will be assessed for its variance as to maintaining narrow 
confidence intervals of the spread of the data 
8.2.5 Image quality and artefacts will be assessed qualitatively by SS, DW, AG and DL 
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8.2.6 Comparison on each ability to produce reproducible data will be compared  
 
8.3 Randomisation of patients as per radiology research methods – an in house computer 
program will allocate patients to protocol 1, 2 or 3. 5 patients will be allocated to each 
protocol. 
 
 
9.0  DATA MONITORING & QUALITY ASSURANCE 
 
The nature of the proposed study aims to primarily assess which DCE-MRI protocol gives the 
most reproducible data and can be used for a further clinical trial. 
The scientific and academic quality of the proposal has been reviewed by all of the clinical and 
academic supervisors for the study.  
 
The components of the study will involve and be led by members of the research team with the 
appropriate experience. Interpretation of MRI images will be performed by Dan Wilson and Steven 
Sourbron. Statistical analysis will be overseen by Mr David Longbotham with help from Helene H 
Thygesen (Leeds Cancer Research UK Centre Statistician).  
 
This study is being used as part of a research degree for DL. Routine Regular research meetings 
will be held every 4 weeks from an academic point of view and clinical meetings will be held every 
4 weeks. This will ensure good lines of communication between the different aspects of the study 
with regular review of progress.  
 
10.0 ETHICAL CONSIDERATIONS 
 
There are no risks for participants taking part in the study as there shall be no difference between 
planned MRI. The three MRI acquisition protocols are designed to obtain the planned necessary 
data required for accurate Liver MRI staging as planned. They shall last for around 10 minutes 
longer than a standard liver MRI.  
The study will be performed in accordance with the recommendations guiding ethical research 
involving human subjects adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964, 
amended at the 48th General Assembly, Somerset West Republic of South Africa; October 1996. 
All participants will be volunteers. Informed written consent will be obtained from the patients prior 
to registration into the study.  
 The right of a patient to refuse participation without giving reasons must be respected.   
The patient must remain free to withdraw at any time from the study without giving reasons and 
without prejudicing his/her further treatment.  
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The study will be submitted to and approved by a main Research Ethics Committee (REC) and 
the appropriate REC for the participating centre prior to entering patients into the study.  
 
11.0 PUBLICATION POLICY  
 
We reserve the right to present and publish the results of our study. At the end of the study, the 
results will form part of an MD degree thesis. We will also disseminate the results in peer reviewed 
medical and scientific journals. No individual patient information will be identified in any 
publications or documents.  
 
12.0 TABLE OF DEFINITIONS AND ABBRIVIATION 
 
 
Acronym Full name Definition 
MRI Magnetic Resonance 
Imaging 
 
DCE-MRI Dynamic Contrast 
Enhanced Magnetic 
Resonance Imaging 
 
CRLM Colorectal Liver 
Metastasis 
 
TLV Total Liver Volume The volume(cm3) of the liver before any surgery 
RLV Remnant Liver Volume The volume (cm3) of the liver after surgery 
TLF Total Liver Function The function of the liver calculated by the result of the 
DCE-MRI before surgery 
RLF Remnant Liver Function The function of the liver calculated by the result of the 
DCE-MRI after surgery 
ICG Indocyanine Green Test A measure of global liver function 
GSA Galactosyl Serum Albumin 
scintigraphy 
 
RLE % Relative Liver 
Enhancement 
=((SIhp-SIun)/SIun) x 100  
SI is signal intensity, hp is hepatobiliary 
Phase, un is unenhanced. 
SMAX,  maximal signal intensity  
TMAX time to reach SMAX  
T1/2 Half life  
AUC Area under curve  
HEF hepatic extraction fraction  
irBF input-relative blood flow  
MTT mean transit time  
GCP Good Clinical Practice  
 
13.0 FUNDING APPLICATION 
 
An application to the Pelican Foundation has been undertaken for up to £20,000 for the cost of 
running this study. The outcome is pending at this time.  
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Pilot Patient Information Sheet 
 
Pilot study for determining the best method of acquisition of 
Dynamic Contrast-Enhanced Liver MRI 
Can a new way of taking MRI pictures of the Liver tell us how well the Liver is working? 
 
 
PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT DOCUMENT 
HELPING YOU DECIDE WHETHER OR NOT TO JOIN OUR STUDY 
• Before you decide whether to take part, it is important for you to understand why the research is being done 
and what it will involve. 
• Please take time to read the following information carefully. Discuss it with friends and relatives if you wish. 
Take time to decide whether or not you wish to take part. 
• You are free to decide whether or not to take part in this research study. If you choose not to take part, this 
will not affect the care you receive from your own doctors. 
• Ask us if there is anything that is not clear or if you would like more information. 
• Thank you for reading this information. If you decide to take part you will be given a copy of this information 
sheet and your signed consent form. 
Important things that you need to know 
• You are to undergo an MRI scan of your Liver to investigate the lesions found in your Liver 
• We would like to know more about a new way of getting of MRI scan data. We feel it may provide more 
information to accurately assess the how the liver is functioning. 
• The care you receive will be the same if you take part in the study or not. 
• You can stop taking part in the study at any time, without giving a reason. Your treatment and care will not 
be affected in any way. 
• This is an initial (also known as a pilot) study done at St James’ University Hospital looking to provide 
information about a new type of MRI scan works.  
• It has yet to be shown if the information gained from this type of scan can be used in care of patients, this is 
what this study aims to assess. 
• We aim to recruit 15 patients into this study. 
Contents 
1 Why we are doing this study 
2 Why am I being asked to take part? 
3 What will happen to me if I take part? 
4 Are there any drawbacks of taking part? 
5 Benefits of taking part 
6 What happens with my data? 
7 Who has reviewed the project? 
8 More information about taking part 
9 Contact for further information 
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How to contact us 
Our researcher, Mr David Longbotham, would be available to answer any questions that you may have. He can be contacted via 0113 
20XXXXX. 
1 Why we are doing this study 
Your Consultant needs detailed pictures from a Liver MRI to plan further treatment for the lesions found in the liver. We would like to know 
whether the pictures that a new technique called Dynamic Contrast Enhanced MRI (DCE-MRI) could be used to tell us how well the liver is 
working as a whole. We feel that knowing how well the liver is functioning may be helpful for us to plan treatment in the future. 
2 Why am I being asked to take part? 
You have been asked to take part in this study because your consultant has asked us to perform an MRI of the liver to provide us more 
information of the lesion/s in your to plan further treatment. We would like to adapt your MRI scan to provide us with extra information.  
3 What will happen to me if I take part?  
The care of your condition will not be any different whether you decide to take part in the study or not. If you wish to take part, the MRI scan you 
have will be adapted in a way that the information we need to plan your treatment is entirely unaffected.  
Your scan will be altered to take lots of different pictures in addition to the ones that we would normally take of your Liver. You will notice no 
difference in the MRI – it will not differ from the experience of any other person undergoing a Liver MRI. The scan itself may take 10 minutes 
longer than a routine scan. At times you may be asked to hold your breath for up to 20 seconds. This is standard practice that is often asked in 
MRI scans and is nothing to be concerned about. 
After the scan we will have all the information and pictures to allow your consultant to make decisions on your care as normal, in addition there 
will be the extra pictures that will be used for this research study. 
Following the scan you will be seen in the outpatient clinic of your consultant. They will be able to make the decision on your care based on the 
MRI results as normal.  
There is no need for you to attend any extra clinics or scan appointments if you wish to take part in this study. 
 
Are there any drugs or additional tests involved? 
You will be given a contrast agent into a needle (also known as a cannula) placed in a vein in your arm. This is part of routine liver scanning 
and will happen whether your take part in the study or not. There are no other drugs or contrast agents given.  You will not need any extra 
scans as part of this study, although the time of your MRI may take around 10 minutes longer than the routine scan. 
Will I be paid for taking part? 
You will not be paid for taking part in this study. 
 
Informing your General Practitioner 
Your GP will be aware that you have been invited to take part in the study as they will be copied into all the invitations. Results of the scan will 
also be relayed to your GP so they have a complete record of your health. 
 
4 Are there any drawbacks of taking part? 
There are no drawbacks to taking part in this study. The care of your liver condition will not change and you will be followed up as planned as 
any other patient. There is no risk to your health from taking part in this study.  
5 What are the advantages of taking part? 
There will be no direct benefit to you from this research study. However the information obtained from the study will potentially help people in 
the future who have the same disease as you. Once all the data has been analysed it is hoped that we will be able to understand better how 
this type of MRI works. We are hopeful that it will be able to help guide our treatment of these liver lesions. 
244 
 
 
 
6 What happens with my data? 
Will my taking part be kept confidential? 
All information collected about you during the course of this research will be kept strictly confidential.  Your information will be entered into a 
computer database on a password-protected computer at St James’ University Hospital.  This information will be unavailable to anyone outside 
the research team.  You will be allocated a unique study identifier on entry into the study and your name will be removed from the study images. 
Will the researchers have access to my clinical data? 
As part of the study protocol we will need to gather clinical information relating to your treatment which may require access to your medical 
notes. We will only access your notes if it is absolutely essential. Case notes will only be accessed by the following members of the research 
team.  Any information will be entered in a password protected computer as described above. As you will be allocated a study number we will 
not keep any personal identifiable information on the computer. 
What will happen to the results of the research study? 
The results of the study will be published in peer reviewed journals and presented at scientific meetings nationally and internationally. All data 
will be fully anonymised. 
 
7 Who has reviewed the study? 
All research in the NHS is looked at by independent research ethics committee to protect your safety, rights and dignity.  
 
8 More information about taking part 
Who is organising the research? 
The study is being organised by Mr Raj Prasad, Consultant Hepatobiliary and Transplant Surgeon in collaboration with Mr David Longbotham, 
Clinical Research Fellow, Mr Ernest Hidalgo - Consultant Hepatobiliary and Transplant Surgeons and Dr Ashley Guthrie, Consultant Radiologist 
at St James University Hospital. The study has been reviewed by an NRES approved Ethics Committee and the Research and Development 
Department situated in Leeds Teaching Hospitals NHS Trust.  
 
What will happen to the data I have provided? 
In line with Good Clinical Practice guidelines, at the end of the study, your data will be securely archived. For the purpose of this study, data 
will be archived for a minimum of 10 years after which arrangements for confidential destruction will be made 
Your data will not be used for commercial purposes. 
Additional research 
Your data may also be stored, and may provide a resource for future surgical research. If any information from this study is used to develop new 
research, data protection regulations will be observed and strict confidentiality maintained; your data will have your personal details removed, 
but will be coded so it may be linked back to your details. This would also be with your consent. You will not be identified in the results of future 
studies. Ethical approval will be obtained for any future studies involving your data or samples. 
 
9 Contacts for further information 
If you would like any further information about this study, please contact: 
Mr David Longbotham on 0113 20XXXXX 
You will be given copies of this information sheet and your signed consent form to keep 
 
Thank you for taking the time to read the information sheet and for considering taking part in this study. 
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Pilot Consent 
Research Study: Pilot study for determining the best method of acquisition of Dynamic Contrast-Enhanced Liver MRI 
(Consent Form; Version 1.7; 26th March 2014) 
 
Participant ID:  
 
Initials:  
 
Date of Birth:  
 
NHS/Hospital Number:  
 
Principal Investigator: 
Mr David Longbotham 
Clinical Research Fellow – HPB and 
Transplant 
Supervising Clinician: 
Mr Raj  Prasad 
Consultant in HPB and Transplant Surgery 
 
Participant consent form for research study 
 
1. I confirm that I have read and understand the information sheet (Version 1.7, 26th March 2014) for the above study and have had the opportunity to 
ask questions.  
 
 
2. I understand that my participation in this study is voluntary and that I am free to withdraw at any time without my medical care or legal rights being 
affected. I understand that even if I withdraw from the above study, the data and samples collected from me will be used in analysing the results of 
the study. 
 
 
3. I understand that my healthcare records may be looked at by authorised individuals from the study team, regulatory bodies, funder or Sponsor in 
order to check that the study is being carried out correctly.  
 
4. I agree to allow any information or results arising from this study to be used for healthcare and/or further medical research upon the understanding 
that my identity will remain anonymous.  
 
5. I agree to my General Practitioner being contacted by letter about my inclusion in this study.  
 
 
6. I agree to take part in the study.  
 
Participant: 
Signature……………………………………………………………………………………. 
 
 
Date………………………………………………….………………………………………. 
 
Investigator: 
I have explained the study to the above named participant and he/she has indicated his/her willingness to participate. 
 
Signature…………………………………………..……………………………………… 
(1 copy for participant; 1 to be kept in medical notes and original stored in Investigator Site File) 
 
 
 
 
 
Please initial each box 
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Pilot GP information sheet 
GP Letter; Version 1.7; 26th March 2014 
 
Re: Patient Mr David Longbotham 
Clinical Research Fellow 
3th Floor, Bexley Wing Building 
St James’s University teaching Hospital 
Beckett Street 
LS9 7TF 
Email: david.longbotham@leedsth.nhs.uk 
 
29th July 2014 
Dear General Practitioner 
 
Information regarding recruitment of patient to Participate in Dynamic Contrast Enhanced MRI of the Liver and predicting liver 
dysfunction study 
 
I am writing to inform you that your patient has agreed to take part in a research study by the Leeds Teaching Hospitals Trust. This study has 
been approved by the above institutions and by the National Research Ethics Service ethics committee. 
 
Our aim is to determine if a new type of Dynamic Contrast Enhanced MRI scan can be used to predict Quantitative Segmental Liver function is 
able to help us work out before surgery the residual function. Their routine staging MRI scan has been modified into one of 3 acquisition protocols 
that we hoe. This scan will be slightly adapted to obtain more information that the scan would normally take, however it stil l get the same 
information that is necessary to plan your surgery in the best way 
 
We have included the patient information sheet for you. It explains the study and tells you why we are doing it, how you can help and how we 
will carry out the research. Please contact me if there is anything that is not clear, if you need help or have any queries or if you would like more 
information.  
 
Yours sincerely 
 
 
 
David Longbotham (Principal Investigator) 
MBBS MRCS 
Clinical Research Fellow 
For Mr Hidalgo, Consultant HPB and Transplant Surgeon and  
Mr Prasad, Consultant HPB and Transplant Surgeon and Chief Investigator 
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Appendix C: Resection Study Ethics Application 
REC Approval 
Part of the research infrastructure for Wales funded by the National Institute for Social Care and Health Research, Welsh Government. 
Yn rhan o seilwaith ymchwil Cymru a ariannir gan y Sefydliad Cenedlaethol ar gyfer Ymchwil Gofal Cymdeithasol ac Iechyd, Llywodraeth Cymru 
 
 
 
 
Wales REC 6 
Floor 8 
36 Orchard Street 
Swansea 
SA1 5AQ 
 
Telephone : 01792 607416 
Fax : 01792 607533 
E-mail : penny.beresford@wales.nhs.uk 
Website : www.nres.nhs.uk 
 
09 September 2014 
 
Mr David 
Longbotham 
Research Fellow 
Leeds Teaching Hospitals NHS 
Trust Level 3 Bexley Wing 
St James' University 
Hospital Leeds 
LS9 7TF 
 
 
Dear Mr Longbotham 
 
Study title: Can use of Dynamic contrast Enhanced MRI (DCE-MRI) of the 
Liver accurately predict Quantitative Segmental Function to 
determine post operative remnant liver function after major 
resection for Colorectal Liver Metastasis? 
REC reference: 14/WA/1141 
IRAS project ID: 146183 
 
Thank you for responding to the Proportionate Review Sub-Committee’s request for 
changes to the documentation for the above study. 
 
The revised documentation has been reviewed and approved by the sub-committee. 
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We plan to publish your research summary wording for the above study on the NRES 
website, together with your contact details, unless you expressly withhold permission to do 
so. Publication will be no earlier than three months from the date of this favourable opinion 
letter. Should you wish to provide a substitute contact point, require further information, or 
wish to withhold permission to publish, please contact the REC Manager Ms Penny 
Beresford, penny.beresford@wales.nhs.uk. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations involved in the 
study in accordance with NHS research governance arrangements. 
 
 
Cynhelir Cydweithrediad Gwyddor Iechyd Academaidd y Sefydliad Cenedlaethol ar 
gyfer Ymchwil Gofal Cymdeithasol ac Iechyd gan Fwrdd Addysgu Iechyd Powys 
 
The National Institute for Social Care and Health Research Academic Health Science 
Collaboration is hosted by Powys Teaching Health Board 
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Guidance on applying for NHS permission for research is available in the Integrated Research Application 
System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought from the R&D 
office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and 
publication trees). 
 
There is no requirement to separately notify the REC but you should do so at the earliest opportunity 
e.g. when submitting an amendment. We will audit the registration details as part of the 
annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its 
initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion” above). 
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Approved documents 
 
The documents reviewed and approved by the Committee are: 
 
Document Version Date 
GP/consultant information sheets or letters [Resection GP letter] V1.7 23 July 2014 
IRAS Checklist XML [Checklist_08092014]  08 September 2014 
Letter from statistician [Helene Thygesen Letter]  12 March 2014 
Letters of invitation to participant [Resection study Invitation letter] V1.8 05 September 2014 
Participant consent form [Resection Consent form] V1.7 23 July 2014 
Participant information sheet (PIS) [Resection Patient Information 
Sheet] 
V1.8 05 September 2014 
REC Application Form [REC_Form_28082014]  28 August 2014 
Research protocol or project proposal [Resection study protocol] V1.7 23 July 2014 
Response to Request for Further Information   
Summary CV for Chief Investigator (CI) [CI CV David Longbotham]  14 April 2014 
Summary CV for student [Mr Prasad CV - included here as could 
not upload 2 files for supervisor CV section. CI CV is same as 
students] 
 11 November 2013 
Summary CV for supervisor (student research) [Dr Sourbron CV]  11 February 2014 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
Notifying substantial 
amendments Adding new sites 
and investigators 
Notification of serious breaches of the 
protocol Progress and safety reports 
Notifying the end of the study 
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The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality- assurance 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
pp 
Roy L. Evans Chair 
 
Email: penny.beresford@wales.nhs.uk 
 
Enclosures: “After ethical review – guidance for researchers” [SL-AR2] 
 
Copy to: Dr Derek Norfolk, Leeds Teaching Hospitals NHS Trust 
Anne Gowing, Research and Development Leeds Teaching Hospitals NHS 
Trust 
14/WA/1141 Please quote this number on all correspondence 
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Resection Protocol 
                                                                                                                                                                                                       
 
St James’s University Hospital: HPB and Transplantation 
 
 
 
RESEARCH PROTOCOL 
 
 
 
Version 1.7 
 23rd July 2014 
 
                                                                                                                                                                                                                                                                                                                                              
 
 
Study Full Title:  Can use of Dynamic contrast Enhanced MRI (DCE-MRI) of the Liver accurately predict Quantitative Segmental 
Function to determine post-operative remnant liver function? 
Protocol Number:   1.7 
 
 
Principal Investigator: David Longbotham 
    Clinical Research Fellow 
    HPB and Transplantation Unit 
St James University Hospital 
    Bexley Wing, 3rd Floor  
Beckett Street 
Leeds 
LS9 7TF 
Tel:   
Email:  david.longbotham@leedsth.nhs.uk 
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23. STATISTICAL CONSIDERATION 
 
24. DATA MONITORING & QUALITY ASSURANCE 
 
25. ETHICAL CONSIDERATIONS 
 
26. PUBLICATION POLICY 
 
27. REFERENCES 
 
28. APPENDICES  
 
29. Abbreviations and acronyms used 
 
30. Funding 
 
TEAM CONTACT 
 
Principal Investigator: Mr David Longbotham 
 
Primary Supervisor:  Mr Raj Prasad 
    HPB and Transplant Consultant 
    3rd Floor, Bexley Wing  
St James’s University Hospital 
    Beckett Street 
    Leeds 
    LS9 7TF 
 
    Dr Steven Sourbron 
    Lecturer in MRI Physics 
Leeds Institute of Genetics, Health and Therapeutics (LIGHT) 
University of Leeds 
 
    Dr Ashley Guthrie 
    Consultant Radiologist 
    3rd Floor, Bexley Wing  
St James’s University Hospital 
    Beckett Street 
    Leeds 
    LS9 7TF 
1.0 RESEARCH SUMMARY 
 
General Information 
Title 
Principal investigator: David Longbotham  
Version:    1.7, 23/7/14 
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Co-ordinating Centre: St James’s University Hospital (SJUH), HPB and Transplantation Unit 
Sponsor: University of Leeds, Faculty Graduate School, 
Faculty of Medicine and Health 
 
Study Information 
Type:     Prospective Correlation/Prediction Study 
Indication: To investigate if a new form of Liver MRI can lead to accurate predictions of liver function after major liver resection 
for patients with Colorectal Liver Metastasis 
Design: Prospective, single centre, non-randomised 
Primary Objectives: Comparison and correlation of results of DCE-MRI based predicted liver quantitative segmental function compared 
with clinical scoring systems of post-operative hepatic dysfunction 
Secondary Objectives: Comparison and correlation of results of DCE-MRI based predicted liver quantitative segmental function compared 
with general post-operative complications, length of stay, morbidity and mortality 
 
Study Timelines 
Expected Start Date:  November 2014 
Subject Enrolment Phase:  November 2014 
End of Study:    July 2015 
Expected Completion Date: Oct 2015 
 
Study Subject Information 
Number of trial subjects: ~32 
Age group of study subjects: 18 years to no upper limit 
Inclusion criteria: For major liver resection (defined as >3 liver segments) for Colorectal Liver Metastasis with curative intent 
Exclusion criteria: Current Pregnancy, Allergy/intolerance to Gadolinium based contrast agents, Inability to undergo MRI (see 
appendix for list), Concurrent enrolment in other research trial 
 
2.0 INTRODUCTION 
 
2.1 Background  
 
Colorectal Liver Metastases (CRLM) is a common and potentially fatal disease. There are around 40,000 new cases 
of colorectal cancer diagnosed a year1. A third of patients diagnosed with Colorectal Cancer will have metastatic liver 
disease at time of presentation. 
 
Surgical Resection of CRLM remains the only curative option for this group of patients2. Due to advances in surgical, 
radiological and oncological techniques and technology, increasingly radical liver resections are being considered. 
Due to the large volume of liver that is being considered for resection it is vitally important to know pre-operatively 
that the remnant liver volume (RLV) will be sufficient to be compatible with life.  
 
In current practice, 75% of total liver volume (TLV) can be safely resected3,18 (or to leave a remnant weighing 0.5% 
of total body weight19) in patients with apparently healthy liver. The percentage of TLV resectable reduces to 70% in 
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patients with known liver disease or having received chemotherapy pre-operatively, and for patients with established 
cirrhosis there is need to be extremely selective3. Those patients potentially requiring larger resections would need 
to be considered for techniques to induce liver hypertrophy (such as portal vein embolisation or two-stage 
hepatectomy) or to be deemed unresectable. 
 
Dynamic Contrast MRI (DCE-MRI) of the Liver is a new technique using Gadoxetic Acid (PrimovistTM) – a liver specific 
contrast agent. Rapidly acquired images at short interval can calculate rate of flow of contrast into hepatic arterial 
architectures, portal venous flow and diffusion into hepatocytes. Diseased, fibrotic liver tissue will have altered blood 
flow and diffusion rates from normal healthy tissue. A region of interest (ROI) within each liver segment can be 
identified and the data derived provides a limited number of parameters that characterise the physiological state of 
the tissue. Calculation function of each segment can be used as a numerator over the total calculated liver function 
as its denominator4-7.    
Previous studies8 have shown good levels of correlation of DCE-MRI against global measures of hepatic function 
Indocyanine Green (ICG) testing and nuclear medicine Galactosyl serum albumin scintigraphy (GSA). 
Other methods based on DCE-MRI such as relative liver enhancement (RLE) have recently shown that a lower RLE 
has a relationship with an increased risk of liver failure post hepatectomy15, 20. 
 
In order to objectively define Liver dysfunction following resection, many different clinical scoring systems have 
been developed. The 3 most commonly used scoring systems are the International Study Group of Liver Surgery 
(ISGLS) definition and grading system9, the Edinburgh Hepatic Dysfunction score10, and Balzan’s 50/50 criteria 
definition11. 
 
2.2 Rationale for Study 
 
Currently, preoperative assessment of RLV is mainly done by CT Volumetry – which gives detailed anatomical and 
volumetric data. In Japan, ICG testing is used; however this is not licensed in the UK. However this seems to 
underestimate the risk of post resection insufficiency by 11% even when compared to an estimated value from the 
patient’s weight12. This indicates that the volume of liver does not equate to function; therefore a more accurate 
assessment is required. It is conceivable that many patients have a degree of subclinical hepatic dysfunction that we 
are currently underestimating in purely volumetric analysis. 
 
Post Hepatectomy Liver Failure (PHLF) is a serious complication with significant morbidity and mortality associated13. 
There is need to identify more accurate assessments of function of the liver in operative planning to reduce its 
incidence. 
Recent studies have been published looking at steatosis preoperatively14 and different static MRI techniques15 in 
patients who undergo liver resection; however the role of DCE-MRI in this setting has not been established. 
 
2.3 Hypothesis  
 
DCE-MRI can predict quantitative segmental function and hence predict risk of PHLF. 
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3.0 STUDY OBJECTIVES AND AIMS 
 
3.2 Primary objective 
3.2.1 To calculate participants quantitative segmental hepatic function, and thus predict the remnant liver function (RLF). 
Correlation will be calculated against Edinburgh hepatic dysfunction score (see section 4.4.1), ISGLS classification 
of hepatic dysfunction (section 4.4.2) and Balzan’s 50/50 criteria (section 4.4.3).  
 
3.3 Secondary objectives 
3.3.1 To calculate a comparison in clinical outcomes between the calculated result of quantitative segmental function of 
DCE-MRI against the result of Relative Liver Enhancement (RLE) 
3.3.2 To calculate participants quantitative segmental hepatic function, and predict the remnant hepatic function (RHF). 
Correlation will be calculated against general surgical complications (Clavien classification17 - see section 4.6) length 
of stay, readmission to critical care, mortality 
3.3.3 Cost effectiveness of use of DCE-MRI in assessment of CRLM. 
4.0 STUDY DESIGN 
4.5 Non randomised 
4.6 Single centre 
4.7 Prospective 
4.7.1 Patient characteristics (such as age, medical history, BMI, alcohol intake (units/week), medications and any known 
liver/biliary disease) will be collected 
4.7.2 Baseline calculations of the 3 clinical hepatic dysfunction scores. The following investigations will need to be 
collected: Bilirubin, Prothrombin Time, Lactate (can be taken from venous or arterial sample), U&Es, Encephalopathy 
grade (as per West Haven Criteria) 
4.8 Clinical Scoring System 
 
4.8.1                    Edinburgh hepatic dysfunction score  
Score 0 1 2 
 
Bilirubin  
(mmol/L) 
<20 21-60 >60 
PT (seconds above 
normal 
<4 4-6 >6 
Lactate <1.5 1.6-3.5 >3.5 
Encephalopathy 0 1-2 3-4 
 
 
Severity (the four values above are added together to give a sum value – this then 
stratifies patients into 4 groups range is 0 to 8) 
 
None Mild Moderate Severe 
0 1-2 3-4 >4 
 
This is based on patients without chronic liver diseases. Based on the findings of the original authors of this system 
total dysfunction occurred in 74.1% of cases. Mild dysfunction occurred in 40.4%, moderate in 21.2%, and severe 
hepatic dysfunction was evident in 12.5% of patients. 
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4.4.2 ISGLS classification 
 
Grade Definition  
A PHLF resulting in abnormal laboratory parameters but requiring no change in the 
clinical management of the patient 
 
B PHLF resulting in a deviation from the regular clinical management but manageable 
without invasive treatment 
 
C PHLF resulting in a deviation from the regular clinical management  
 
4.4.2.1 A patient’s PHLF is graded by the worst identified criteria (i.e., by fulfilling at least 1 criterion of non-invasive or 
invasive intervention, patients are classified to have PHLF grade B and C, respectively). 
 
 Grade A Grade B Grade C 
Specific treatment Nil Required any of the 
following: FFP, HAS, NIV, 
Level 2 Care related to 
hepatic insufficiency 
Required any of the 
following: 
Inotropes/vasopressor 
use, Glucose infusion, 
I&V, Extracorporeal liver 
support, rescue 
hepatectomy/transplant 
Hepatic function INR <1.5 
No encephalopathy 
INR  ≥1.5 but <2 
Mild encephalopathy 
INR >2 
Encephalopathy 
Renal Function Ur <8.3mmol/L 
UO > 0.5ml/kg/hr 
Ur <8.3mmol/L 
OU ≤0.5ml/kg/hr 
Ur ≥8.3mmol/L 
Renal Replacement 
Therapy 
Respiratory function O2 >90% (can be given 
via nasal/mask) 
O2 <90% via nasal/mask ≤85% on high O2 
Additional info n/a Unplanned Abdo USS/CT, 
CXR, cultures, Head CT 
ICP monitoring 
Slightly modified from Rahbari – converted into units used in UK 
 
Using ISGLS classification, 11% of liver resections meet the criteria to diagnose PHLF. Of these 8% were 
diagnosed with grade A PHLF. 72% had grade B PHLF, because they required a change in their clinical 
management without need for invasive therapy. Grade C PHLF was diagnosed in 13 patients (20%). The 
perioperative mortality of patients with PHLF grades A, B, and C was 0%, 12%, and 54% respectively. 
 
4.8.2 Balzan’s 50/50 criteria - prothrombin time ratio less than 50% (this corresponds to an INR of 1.7) and serum bilirubin 
greater than 50μmol/L at postoperative day 5 is defined as post-operative Liver failure 
4.8.2.1.1 In the original study 5.5% of patients undergoing resection fulfil the criteria of both raised INR >1.7 and Bilirubin 
>50, 9.8% have a raised INR >1.7 on day 5, and 21.5% have a raised bilirubin >50 on day 5. 
4.8.2.1.2 Mortality was 59% in the population with both raised INR and bilirubin, 33% in those with raised INR only, and 15% 
in raised bilirubin, compared to mortality of 1.5% in those with neither. 
4.4.4 West Haven Criteria16 
 Grade 1 - Trivial lack of awareness; euphoria or anxiety; shortened attention  span; impaired 
performance of addition or subtraction  
 Grade 2 - Lethargy or apathy; minimal disorientation for time or place; subtle  personality change; 
inappropriate behavior  
 Grade 3 - Somnolence to semi stupor, but responsive to verbal stimuli;  confusion; gross disorientation  
 Grade 4 - Coma (unresponsive to verbal or noxious stimuli)  
 
4.9 Dynamic Contrast Enhanced MRI 
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4.9.1 Part of the study that calculates predicted RLF. 
4.9.2 Use of MRI in St James’ University Hospital Radiology department. 
4.9.2.1 Utilises paramagnetic qualities of water molecules within tissue to demonstrate liver anatomy and pathology 
4.9.2.1.1 Utilises intravenous liver specific contrast agent (Gadoxetic Acid) to demonstrate blood flow and diffusion in the liver 
4.9.2.1.2 This agent is taken up by hepatocytes via organic anion transporting polypeptide OATP and excreted into bile 
canaliculi via multidrug resistant protein (MRP) system – the same uptake and excretion as bilirubin. 
4.9.2.2 This acquisition will be added onto the participants routine MRI scan for staging of their CRLM – no additional MRI 
will need to be requested 
4.9.2.3 A study has shown strong correlation 8 of DCE-MRI with validated methods of global hepatic function ICG and GSA 
4.9.2.4 Acquisition will be taken dynamically during the arterial and portovenous phases (first 5 minutes). 
4.9.2.5 This phase is not utilised on a routine MRI scan and an acquisition protocol written by Dr Dan Wilson and Dr Steven 
Sourbron will be used 
4.9.2.6 Delayed contrast data for the hepatobiliary phase (30-40 minutes) using relative liver enhancement (RLE) techniques 
4.9.2.6.1 RLE 15, 20 calculated as the ratio of signal intensity (SI) measurements of the liver parenchyma before (SI DCE) 
and 20 minutes after intravenous administration of gadoxetic acid. 
4.9.2.6.2 RLE (%) = (SI DCE-SI/SI) *100 
4.9.2.7 Analysis of the DCE-MRI data will take place on an In-House computer system at University of Leeds MRI Physics 
Department by Steven Sourbron and David Longbotham 
4.9.3 All research team will be blinded to patients’ baseline scoring results to reduce observer bias in analysis 
4.9.4 The interpreting radiologist will be blinded to the results of the DCE-MRI phase to prevent this data being used in 
their reporting of patients MRI 
 
4.6 Clavien Classification17 
Grade Definition 
I Deviation from normal postoperative course without need for intervention (although including 
antiemetics, antipyretics, analgesics, diuretics, IV fluid, Physio, local wound management 
II Pharmacological intervention 
III Surgical/Endoscopic/Radiological intervention 
   a No GA 
   b GA 
IV Life-threatening complications needing ICU management 
   a Single organ dysfunction 
   b Multiorgan dysfunction  
V Death 
Suffix d Prolonged disability after discharge (e.g. cardiac insufficiency post MI, faecal incontinence post 
injury of nerves, stroke etc 
 
5.0 STUDY SUBJECT SELECTION 
 
5.6 Patient List: 
5.6.1 Patients will be identified from the hepatobiliary outpatient clinic from tertiary referrals for patients with potentially 
resectable liver metastases 
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5.6.2 Baseline characteristics such as age, sex, alcohol intake, medication history, prior liver disease, chemotherapy status 
(type, time scale and duration 
5.6.3 Information regarding the study will be provided to potential participants at this stage 
 
5.7 Eligibility criteria 
5.7.1 Inclusion criteria 
5.7.1.1 Confirmed diagnosis of Colorectal Liver Metastasis: 
5.7.1.1.1.1 Histological confirmation of adenocarcinoma of the large bowel 
5.7.1.1.1.2 Radiologically diagnosed CRLM at time of diagnosis of Large bowel tumour or subsequent time 
5.7.1.1.2 Confirmed potential resectability of liver that involves at least 3 or more liver segments  
5.7.1.1.3 Able and willing to provide informed consent 
 
 
 
5.7.2 Exclusion criteria 
5.7.2.1 Current pregnancy 
5.7.2.2 Unresectable CRLM 
5.7.2.3 Extra-hepatic colorectal metastases that are unresectable 
5.7.2.4 Other concurrent malignancy of any kind 
5.7.2.5 Allergy/intolerance to Gadolinium based intravenous contrast agents 
5.7.2.6 Intolerance to MRI 
5.7.2.7 Unable to undergo MRI due to safety concerns (see appendix) 
5.7.2.8 Inclusion in other clinical trials related to liver disease or surgical intervention running concurrently 
 
5.8 Sample Size 
5.8.1 Approximately 250 patients undergo resection of their CRLM a year in St James’ University Hospital 
5.8.2 Approximately 130 patients will have a major liver resection  
5.8.3 Due to availability of obtaining MRI to allow DCE-MRI to be performed the anticipated recruitment shall be ~1 patient 
per week 
5.8.4 The aim of recruiting ~32 patients that will allow the study to be completed and analysed within a year  
 
 
5.9 Recruitment 
Potential participants will be identified form the Specialist Hepatobiliary Multi-disciplinary team (MDT) meeting and 
information regarding participation will be mailed. 
A Patient Information Sheet and letter of invitation will be provided by the authorised trial clinician for the patient to 
consider participation (appendix). Following information provision, patients will have at least 24 hours to consider 
participation and will be given the opportunity to discuss the trial with their family and healthcare professionals before 
they are asked whether they would be willing to take part in the trial. This process will be clearly documented onto 
PPM (patient pathway manager) – hospital database with patient information and clinic letters that can be printed out 
easily and also kept in their medical case notes.  Clarification to potential participants that the DCE-MRI will have no 
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implications of the standard of care they will receive. They will be contacted by to confirm understanding of the study, 
ask any immediate questions and confirm acceptance onto study. 
 
5.10 Consent  
Informed written consent will be obtained when patients attend their MRI appointment. A copy of the consent will be 
given to the patient, the original filed in the Trial Master File (TMF), and one filed in the hospital notes. The written 
consent will be taken by a clinician, who has signed / dated the staff authorisation / delegation log.  The process of 
obtaining written consent will be clearly documented in the patient’s medical notes. 
All members for the research team are Good Clinical Practice (CGP) Trained 
The participant’s General Practitioner (GP) will also receive confirmation of the patient’s inclusion into the trial.  
7.0 STUDY SCHEDULE  
 
6.5 Patients identified from Hepatobiliary clinic referrals from Colorectal Surgery/Oncology as to possible 
resectability of CRL 
6.6 Recruitment of patients over 12 months: 
6.6.1 Initial contact after discussion in MDT - patients who have yet to undergo a diagnosis staging MRI in St James’ 
Hospital 
6.6.2 Informed consent for inclusion into the trial 
6.6.3 Once written informed consent has been obtained, patients will be listed for their MRI using specific radiology 
department approved Lilac forms. 
6.6.4 Their DCE-MRI will occur <8 weeks and >1 day before their surgery 
6.6.5 On the day of their DCE-MRI scan they will have their Edinburgh Hepatic Dysfunction Score, ISGLS score and 
Balzan’s 50/50 score calculated, including lactate, oxygen saturations (non-invasive) – to ensure there is no obvious 
preoperative hepatic dysfunction.  
6.6.6 At time of Surgery data will be obtained – time of operation, intra-operative complication, unexpected procedures, 
use of Pringle Manoeuvre, Blood loss, need for transfusion, use of Inotropes 
6.6.7 Post-operative, daily calculations of the 3 hepatic dysfunction scores will be obtained for up to 7 days and/or 
discharge 
6.6.8 This will include blood tests as defined as above, Oxygen use, lactate levels, Critical care input, blood and blood 
products (FFP, platelets, Cryoprecipitate), non-routine radiology requests, unanticipated pharmacological use (e.g. 
Antibiotics), urine output, need for renal replacement therapy, any observed medical complication (e.g. myocardial 
infarction, pulmonary embolus) need for input from other specialists (e.g. cardiology, respiratory) 
6.6.9 Other information, length of patient stay, mortality 
6.6.10 Post-operative histology reports on the resected live 
6.7 Analysis of data over 2 months 
7.0 DATA COLLECTION, SOURCE DATA AND CONFIDENTIALITY 
 
7.3 General 
7.3.1 All information collected during the course of the trial will be kept strictly confidential.   
7.3.2 Information will be held securely on paper and electronically on secure university and hospital servers.  
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7.3.3 A database of all information will be anonymised with patients allocated to a study number. Identification of the 
patients to their number will be kept on a separate password protected file on secure servers accessible only to the 
research team members as listed above. 
7.3.4 The HPB and Transplant Unit, SJUH complies with all aspects of the Data Protection Act 1998, International 
Conference on Harmonization (ICH) of Good Clinical Practice (GCP) guidelines and Declaration of Helsinki (2008). 
Operationally this will include: 
 
7.3.4.1 Consent from patients to record personal details including name, date of birth, address and telephone number, NHS 
ID, hospital ID, GP name and address.  
7.3.4.2 Appropriate storage, restricted access and disposal arrangements for patient personal and clinical details.  
7.3.4.3 Consent from patients for access to their medical records by responsible individuals from the research staff, the 
sponsor or from regulatory authorities, where it is relevant to trial participation that have received ICH GCP training 
and are thus aware of the importance of patient confidentiality. 
7.3.4.4 Consent from patients for the data collected for the trial to be used to evaluate safety and develop new research. 
 
7.1.5 Data will be stored in a locked filing cabinet behind a keypad access only door in the John Goligher Academic 
Unit 
 
7.4 Archiving 
In line with the principles of ICH-GCP / UK Clinical trial Regulations guidelines, at the end of the trial, data will be 
securely archived at each participating centre for a minimum of 10 years.  Arrangements for confidential destruction 
will then be made. If a patient withdraws consent for their data to be used, it will be confidentially destroyed 
immediately.  
 
8.0 DATA ANALYSIS 
 
8.2 Patient characteristics 
 
8.4 Statistical Analysis 
8.4.1 The pilot study is aiming to recruit ~32 patients over 15-30 weeks  
8.4.2 Outcome data will be presented as correlation between predicted function of the remnant liver (RLF) given as a 
percentage (%) as calculated by the Liver DCE-MRI (Provided as a percentage of overall function) versus each of 
the 3 validated clinical post hepatectomy hepatic dysfunction scoring systems 
8.4.2.1 Balzan’s 50/50 Criteria (raised INR to 1.7 and bilirubin >50mmol/L on post-operative day 5) will be presented as a 
either being: no rise in either, raised bilirubin >50 but no rise in INR above 1.7, raised INR above 1.7 but no raise in 
bilirubin, or both elevated.  
8.4.2.2 In analysis of this test, patients will have their RLF compared to their result of their 50/50 criteria 
8.4.2.2.1 In the original study 5.5% of patients undergoing resection fulfil the criteria of both raised INR >1.7 and Bilirubin 
>50, 9.8% have a raised INR >1.7 on day 5, and 21.5% have a raised bilirubin >50 on day 5. 
8.4.2.3 ISGLS classification will be represented as 3 results – group A, B and C 
8.4.2.3.1 Total hepatic dysfunction scores A, B or C are expected in 11% of cases of liver resection, ~1% fell into Group A, 
8% into group B and 2% in Group C 
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8.4.2.4 Edinburgh Hepatic Dysfunction score shall be 4 results – no dysfunction, mild, moderate and severe 
8.4.2.5 Based on the findings of the original authors of this system total dysfunction occurred in 74.1% of cases. Mild 
dysfunction occurred in 40.4%, moderate in 21.2%, and severe hepatic dysfunction was evident in 12.5% of patients. 
8.4.3 Any significant differences in proportions will be demonstrated by correlation – Spearman’s Rank Coefficient 
8.4.4 Each group will be compared against the RLF as calculated by the DCE-MRI 
8.5 RLE values will also be calculated and analysed against each of the 3 clinical scoring systems as similar study to 
Wibmer and collegues15 that will allow a comparison between RLE and DCE-MRI 
 
For 32 participants: 
Assuming that the overall risk of moderate to severe liver dysfunction is 33.7% 10, and assuming that the MRI results 
are dichotomized as (above median, below median), risks of moderate or severe liver dysfunction of 53.4% in the 
high-MRI group versus 14.0% in the low-MRI group, can be detected with 80% power at 95% confidence (two-sided 
Fisher test). This corresponds to a relative risk of 3.8 or an odds ratio of 7.0. Applying a Spearman Rank correlation 
test will make the power slightly better than this. 
 
The power calculations were carried out with the statmod package for R (version 3.0.2 for OS/X). 
 
9.0  DATA MONITORING & QUALITY ASSURANCE 
 
The nature of the proposed study aims to primarily assess if DCE-MRI can be used to predict post-operative hepatic 
dysfunction 
The scientific and academic quality of the proposal has been reviewed by two clinical and academic supervisors for 
the study.  
 
The components of the study will involve and be led by members of the research team with the appropriate 
experience. Interpretation of MRI images will be performed by Dan Wilson and Steven Sourbron. Statistical analysis 
will be overseen by Mr David Longbotham with help from Helene H Thygesen (Leeds Cancer Research UK Centre 
Statistician).  
 
Regular research meetings will be held every 4 weeks from an academic point of view and clinical meetings will be 
held every 2 weeks and informally during weekly liver surgery clinics. This will ensure good lines of communication 
between the different aspects of the study with regular review of progress.  
 
15.0 ETHICAL CONSIDERATIONS 
 
There are minimal risks for participants taking part in the study as there shall be no difference between planned MRI 
and blood investigations. The MRI acquisition protocol is designed to obtain the planned necessary data required for 
effective clinical decision making as is currently performed.  
This study is not interventional in nature - no change to patients’ care will be undertaken. It is using the information 
from participants MRI in a novel way only. 
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The study will be performed in accordance with the recommendations guiding ethical research involving human 
subjects adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964, amended at the 48th General 
Assembly, Somerset West Republic of South Africa; October 1996. All participants will be volunteers. Informed 
written consent will be obtained from the patients prior to registration into the study.  
 The right of a patient to refuse participation without giving reasons must be respected.   
The patient must remain free to withdraw at any time from the study without giving reasons and without prejudicing 
his/her further treatment.  
The study will be submitted to and approved by a main Research Ethics Committee (REC) and the appropriate REC 
for the participating centre prior to entering patients into the study.  
Table of terminology used 
Acronym Full name Definition 
MRI Magnetic Resonance Imaging  
DCE-MRI Dynamic Contrast Enhanced Magnetic 
Resonance Imaging 
 
CRLM Colorectal Liver Metastasis  
TLV Total Liver Volume  
RLV Remnant Liver Volume  
TLF Total Liver Function  
RLF Remnant Liver Function  
ICG Indocyanine Green Test  
GSA G  
RLE % Relative Liver Enhancement =((SIhp-SIun)/SIun) x 100  
SI is signal intensity, hp is hepatobiliary 
phase, un is unenhanced. 
ISGLS International Study Group 
of Liver Surgery 
 
PHLF Post Hepatectomy Liver Failure  
INR International normalised ratio  
FFP Fresh Frozen Plasma  
HAS Human Albumin Solution  
NIV Non-invasive Ventilation  
Study funding 
There is no external funding available for this study 
16.0 PUBLICATION POLICY  
 
We reserve the right to present and publish the results of our study. At the end of the study, the results will form part 
of an MD degree thesis. We will also disseminate the results in peer reviewed medical and scientific journals. No 
individual patient information will be identified in any publications or documents.  
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Resection Patient Information Sheet 
 
Can use of Dynamic contrast Enhanced MRI (DCE-MRI) of the Liver 
accurately predict Quantitative Segmental Function to determine post-
operative remnant liver function? 
 Can a new way of taking MRI pictures of the liver tell us how well the Liver is working?  
 
PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT DOCUMENT 
HELPING YOU DECIDE WHETHER OR NOT TO JOIN OUR STUDY 
• Before you decide whether to take part, it is important for you to understand why the research is being done and what it will 
involve. 
• Please take time to read the following information carefully. Discuss it with friends and relatives if you wish. Take time to decide 
whether or not you wish to take part. 
• You are free to decide whether or not to take part in this research study. If you choose not to take part, this will not affect the care 
you receive from your own doctors. 
• Ask us if there is anything that is not clear or if you would like more information. 
• Thank you for reading this information. If you decide to take part, you will be given a copy of this information sheet and your signed 
consent form. 
Important things that you need to know 
• You are to undergo an MRI scan of your Liver to investigate your Liver condition. 
• We would like to know more about a new way of getting of MRI scan data. We feel it may provide more information to accurately 
assess the how the liver is functioning. 
• We will work out how your liver is working on the day of your MRI in the form of routine blood and memory tests. If you require an 
operation for your condition, we would look at your blood and memory tests every day for your hospital stay 
• You will not require any extra tests or investigations as part of this study. 
• The care you receive will be the same if you take part in the study or not. 
• You can stop taking part in the study at any time, without giving a reason. Your treatment and care will not be affected in any way. 
• This is an initial (also known as a pilot) study done at St James’ University Hospital looking to provide information about a new 
type of MRI scan works.  
• It has yet to be shown if the information gained from this type of scan can be used in care of patients, this is what this study aims 
to assess. 
• The results of this study form part of a higher research degree (MD). 
• We aim to recruit 32 patients into this study. 
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How to contact us 
Our researcher, Mr David Longbotham, would be available to answer any questions that you may have. He can be 
contacted via 0113 20XXXXX 
10 Why we are doing this study 
Your Consultant needs detailed pictures from a Liver MRI to plan further treatment for the lesions found in the liver. 
We would like to know whether the pictures that a new technique called Dynamic Contrast Enhanced MRI (DCE-
MRI) could be used to tell us how well the liver is working as a whole. We feel that knowing how well the liver is 
functioning may be helpful for us to plan treatment in the future. 
11 Why am I being asked to take part? 
You have been asked to take part in this study because your consultant has asked us to perform an MRI of the 
liver to provide us more information of the lesion/s in your to plan further treatment. We would like to adapt your 
MRI scan to provide us with extra information.  
12 What will happen to me if I take part?  
The care of your condition will not be any different whether you decide to take part in the study or not.  
If you wish to take part, the MRI scan you have will be adapted in a way that the information we need to plan your 
treatment is entirely unaffected. We will take some routine blood tests on the day of your scan. People having an 
MRI of their liver routinely have a plastic needle (cannula) inserted for the scan and bloods can be taken at this 
time. In addition we will perform an assessment of your liver function that involves a simple test of your memory. 
Your scan will be altered to take lots of different pictures in addition to the ones that we would normally take of your 
Liver. You will notice no difference in the MRI – it will not differ from the experience of any other person undergoing 
a Liver MRI. The scan itself may take 10 minutes longer than a routine scan. At times you may be asked to hold 
your breath for up to 20 seconds. This is standard practice that is often asked in MRI scans and is nothing to be 
concerned about. 
After the scan we will have all the information and pictures to allow your consultant to make decisions on your care 
as normal, in addition there will be the extra pictures that will be used for this research study. 
Following the scan you will be seen in the outpatient clinic of your consultant. They will be able to make the decision 
on your care based on the MRI results as normal.  
If the findings of the scan show that your consultant can offer an operation for your condition then we would follow 
your progress in your first week after surgery, looking at your routine blood results and to retest your memory 
scoring as was done on the day of your MRI. You won’t have to have any extra tests as part of this study. 
There is no need for you to attend any extra clinics or scan appointments if you wish to take part in this study. 
Will I be paid for taking part? 
You will not be paid for taking part in this study. 
 
Will any genetic tests be done? 
No.  
Informing your General Practitioner 
Your GP will be aware that you have been invited to take part in the study as they will be copied into all the 
invitations. Results of the scan will also be relayed to your GP so they have a complete record of your health. 
 
13 Are there any drawbacks of taking part? 
There are no drawbacks to taking part in this study. The management of your liver lesions will not change and you 
will be followed up as normal.  If there are any changes to the liver these will be discussed in detail during routine 
follow up. There is no risk to your health from taking part in this study.  
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14 What are the advantages of taking part? 
There will be no direct benefit to you from this research study. However the information obtained from the study 
will potentially help people in the future who have the same disease as you. Once all the data has been analysed 
it is hoped that we will be able to understand better how this type of MRI works. We are hopeful that it will be able 
to make surgery even safer in the future. 
15 What happens with my data? 
Will my taking part be kept confidential? 
If you decide to participate in study, the information collected about you will be handled strictly in accordance with 
the consent that you have given and also the 1998 Data Protection Act.  
Information will be collected from your hospital notes on your past medical history and diagnostic tests you may 
have had previously. This information will be stored in a password protected University and hospital computers.  
You will be allocated a unique study number, which will be used along with your date of birth as a code to identify 
you on all paper forms. Only the research team will be able to identify you from this study number. With your 
permission, your relevant medical records may be inspected by authorised individuals from the research team or 
the University of Leeds (the study Sponsor). They may also be looked at by the relevant regulatory authorities and 
by authorised people from the Trust or other NHS bodies to check that the study is being carried out correctly. This 
data will have your name removed so that you cannot be identified from the information.  
The information collected about you may be shared with other research teams to answer new research questions 
in the future. Information will be anonymised (for example, your full name will not be disclosed with this information). 
These records will be stored for a minimum of 10 years and after which they will be securely removed. Within this 
period, your medical records may also be looked at, if required, by the researcher or a member of your clinical care 
team under the direction of Mr Prasad, Consultant Hepatobiliary and Transplant Surgeon. 
What will happen if I don’t want to carry on with the study? 
You can decide to leave the study at any time. You do not need to give a reason. This will not have any effect on 
any subsequent treatment you receive. 
If you decide to leave the study after your liver has been scanned then your data collected up until that time will 
remain on file and will be included in the final study analysis and follow up information will continue to be collected 
from your medical records.  
If you decide to leave the study and do not wish for any further data to be collected about you, you should inform 
your clinical care team of this in order that no further follow up information is collected from your medical records. 
What will happen to the results of the research study? 
When the study is complete the results will be published in a medical journal, but no individual participants will be 
identified. If you would like to obtain a copy of the published results, please ask your doctor. 
What will happen if I lose mental capacity during the study period? 
This is expected to be a very rare occurrence. It could however happen to any patient whether or not they are a 
participant in this study, for example due to an entirely separate event (e.g. a head injury). If this did occur before 
your liver scan we would withdraw you from the study. However, if it occurs after the liver scan, we would like to 
continue to use the data we have collected for the study and would like you to let us know on the consent form if 
you would be happy for us to do so.  
What if something goes wrong in the study? 
In the very unlikely event that something does go wrong and you are harmed during the research and this 
is due to someone’s negligence then you may have grounds for a legal action for compensation against 
The Leeds Teaching Hospitals Trust but you may have to pay your legal costs. The normal National Health 
Services complaints mechanism and Patient Advice and Liaison Service (PALS) will still be available to 
you (if appropriate).  
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16 Who has reviewed the study? 
All research in the NHS is looked at by an independent research ethics committee to protect your safety, rights and 
dignity.  
The study has been reviewed by an NRES approved Ethics Committee, Wales REC 6, and the Research 
and Development Department situated at Leeds Teaching Hospitals NHS Trust. 
The study has been independently peer reviewed by Professor JPA Lodge for its scientific merit. He is a 
Professor of Surgery at the University of Leeds and St James’ University Hospital. 
 
17 More information about taking part 
Who is organising the research? 
The study is being organised by Mr David Longbotham in collaboration with Mr Raj Prasad, Mr Ernest Hidalgo - 
Consultant Hepatobiliary and Transplant Surgeons, Dr Ashley Guthrie, Consultant Radiologist at St James 
University Hospital.   
What will happen to the data I have provided? 
In line with Good Clinical Practice guidelines, at the end of the study, your data will be securely archived. For the 
purpose of this study, data will be archived for a minimum of 10 years after which arrangements for confidential 
destruction will be made 
Your data will not be used for commercial purposes. 
Additional research 
Your data may also be stored, and may provide a resource for future surgical research. If any information from this 
study is used to develop new research, data protection regulations will be observed and strict confidentiality 
maintained; your data will have your personal details removed, but will be coded so it may be linked back to your 
details. This would also be with your consent. You will not be identified in the results of future studies. Ethical 
approval will be obtained for any future studies involving your data or samples. 
18 Contacts for further information 
If you would like any further information about this study, please contact: 
Mr David Longbotham on 0113 20XXXXX 
 
Thank you for taking the time to consider taking part in this study. 
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Resection Consent 
 
Research Study: Can use of Dynamic contrast Enhanced MRI (DCE-MRI) of the Liver accurately 
predict Quantitative Segmental Function to determine post-operative remnant liver function? 
(Consent Form; Version 1.7; 23rd July 2014) 
 
Participant ID:  
 
Initials:  
 
Date of Birth:  
 
NHS/Hospital Number:  
 
Principal Investigator: 
Mr David Longbotham 
Clinical Research Fellow – HPB and 
Transplant 
Supervising Clinician: 
Mr Raj  Prasad 
Consultant in HPB and Transplant Surgery 
 
Participant consent form for research study 
 
 
1. I confirm that I have read and understand the information sheet (Version 1.7, 23rd July 2014) for the above study and 
have had the opportunity to ask questions.  
 
2. I understand that my participation in this study is voluntary and that I am free to withdraw at any time without my medical 
care or legal rights being affected. I understand that even if I withdraw from the above study, the data and samples 
collected from me will be used in analysing the results of the study. 
 
3. I understand that my healthcare records may be looked at by authorised individuals from the study team, regulatory 
bodies, funder or Sponsor in order to check that the study is being carried out correctly.  
 
 
 
4. I agree to allow any information or results arising from this study to be used for healthcare and/or further medical 
research upon the understanding that my identity will remain anonymous wherever possible.  
 
5. I agree to my General Practitioner being contacted by letter about my inclusion in this study.  
 
 
6.  I agree to take part in the study.  
 
 
Participant: 
Signature……………………………………………………………………………………. 
 
Name (block capitals)……………………………………………….…………………… 
 
Date………………………………………………….………………………………………. 
 
Investigator: 
I have explained the study to the above named participant and he/she has indicated his/her willingness to 
participate. 
 
Signature…………………………………………..……………………………………… 
 
 
 
(1 copy for participant; 1 to be kept in medical notes and original stored in Investigator Site File;) 
 
 
 
 
 
Please initial each box 
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Resection GP Information Sheet 
GP Letter; Version 1.7; 23th July 2014 
 
Re:  
 
Mr David Longbotham 
Clinical Research Fellow 
3th Floor, Bexley Wing Building 
St James’s University teaching Hospital 
Beckett Street 
LS9 7TF 
Email: david.longbotham@leedsth.nhs.uk 
 
Date 
Dear General Practitioner 
 
Information regarding recruitment of patient to Participate in Dynamic Contrast Enhanced MRI of the 
Liver and predicting liver dysfunction study 
 
I am writing to inform you that your patient has agreed to take part in a research study by the Leeds Teaching 
Hospitals Trust. This study has been approved by the above institutions and by the National Research Ethics 
Service ethics committee. 
 
Our aim is to determine if a new type of Dynamic Contrast Enhanced MRI scan can be used to predict Quantitative 
Segmental Liver function is able to help us work out before surgery the residual function. Their routine staging MRI 
scan has been modified into a different acquisition protocol that we hope shall correlate to their clinical post-
operative function. 
 
We have included the patient information sheet for you. It explains the study and tells you why we are doing it, how 
you can help and how we will carry out the research. Please contact me if there is anything that is not clear, if you 
need help or have any queries or if you would like more information.  
 
Yours sincerely 
 
 
 
David Longbotham (Principal Investigator) 
MBBS MRCS 
Clinical Research Fellow 
For Mr Hidalgo, Consultant HPB and Transplant Surgeon and  
Mr Prasad, Consultant HPB and Transplant Surgeon and Chief Investigator 
 
 
 
